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Abstract 
Brain metastases are associated with a very poor prognosis and frequently occur in patients suffering 
from breast or colorectal cancer. During the process of metastatic colonization, successfully 
disseminated cancer cells settle in the brain and progress into macro-metastases. In this context, we 
recently summarized significant morphological differences at the macro-metastases/organ 
parenchyma interface (MMPI) with a strong influence on prognosis in several studies. While displacing 
metastases usually displayed a more favorable prognosis, infiltrative metastases had an unfavorable 
disease progression.  
Since diffuse and epithelial infiltrative cells differed in their pathophysiology, the aim of this study was 
to investigate the potentially responsible mechanisms underlying this difference. In our lab, we 
previously established a variety of brain metastasis mouse models that allow the detailed 
characterization of the MMPI on a morphological and molecular basis. Interestingly, diffuse and 
epithelial infiltrative models showed differences in their innate expression levels of the cell adhesion 
receptor E-cadherin across species and entities. However, we hypothesized that E-cadherin is not only 
a marker for the type of infiltration, but also plays a critical functional role.  
Thus, we performed specific opposing genetic modifications of E-cadherin in the corresponding cell 
lines of our brain metastasis mouse models representing the different infiltrative MMPI patterns to 
investigate the impact on the infiltration pattern and the metastatic microenvironment. Although both 
genetic approaches provoked profound phenotypic changes, they had no influence on the original 
characteristic of the cell. Nevertheless, the gain of E-cadherin decreased migratory and invasive 
capacity in vitro, while the artificial loss made cells more invasive across entities. This was reflected in 
the animal model with less aggressive metastases and prolonged survival after the overexpression of 
E-cadherin and increased aggressiveness and shortened survival in the knockdown cohorts. The switch 
of the infiltration pattern due to the E-cadherin modification in the metastatic outgrowth models, from 
diffuse to epithelial-like infiltrative after the gain of E-cadherin and the other way around after its loss, 
further resulted in an altered immune reaction of the metastatic microenvironment. In general, diffuse 
infiltrative patterns were associated with an increased immune response at the MMPI. Furthermore, 
we could establish a gene expression signature that clearly differentiated diffuse and epithelial 
infiltrative mouse models based on their metastatic cell character and even had a prognostic impact 
in murine and human metastases.  
In conclusion, these data emphasize the essential role of the MMPI during metastatic colonization of 
the brain and might contribute to MMPI pattern-based therapeutic decisions for cancer patients in the 
future. The identified gene targets could represent a prognostic tool to classify the outcome of patients 
with metastases based on the analysis of their tumor gene expression signature. 
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1. Introduction 
1.1. Metastatic colonization 
At a certain point during disease progression, many cancer cells spread from a primary tumor to the 
brain and attack the central nervous system (CNS). This usually has far-reaching consequences for the 
patient. CNS metastases are found in 8–10% of all cancer patients and 40% of patients with metastatic 
cancer and normally imply a decline in quality of life as they are generally associated with a very poor 
prognosis and have the worst survival rates compared to other sites (Chamberlain et al., 2017; S. G. 
Wu et al., 2017). While isolated soft tissue metastases have a median survival of 50 months (Tampellini 
et al., 1997) and bone metastases around 48 months (Sherry et al., 1986), cerebral metastases confer 
a much worse prognosis with a median survival of only 4 months after diagnosis (Nussbaum et al., 
1996). The number of patients with brain metastases even seems to increase nowadays. The most 
likely reasons are prolonged patient survival due to more effective systemic therapies for the primary 
cancer and earlier detection due to advanced imaging systems (Chamberlain et al., 2017).  
Apart from lung cancer and melanoma, breast and colorectal cancer account for the highest risk of 
brain metastases formation (Neagu et al., 2015). One of the major problems in their effective 
treatment is the fact that metastatic infiltration differs enormously from primary tumor invasion. 
While classical therapy methods such as surgery (removing the visible tumor tissue with a gross total 
resection (GTR)) or radiotherapy usually are used successfully for primary tumors, they often have only 
moderate effects in metastatic disease and can not completely remove the metastatic tissue in most 
cases (Chamberlain et al., 2017). However, systemic therapies targeting specific molecules appear as 
effective treatment options in a growing number of studies (Chamberlain et al., 2017). 
1.1.1. Steps of metastatic colonization 
The metastatic cascade consists of several steps. Initially, the primary tumor forms, starts growing and 
during progression single tumor cells seed into the surrounding tissue. Via intravasation, the tumor 
cells enter the circulatory systems and are spread through the whole body until they reach a distant 
organ site (for example, the CNS), where they leave the circulation again and form micro-metastases. 
Meanwhile the primary tumor continues to grow and at some point, the first diagnosis is made. 
However, at this time the initial seeding of disseminated cancer cells has already taken place in many 
cases and can not be prevented (Hosseini et al., 2016). The treatment of the primary tumor is thus only 
half the battle. With the currently available diagnostic tools, it is not possible to recognize this first 
step early enough to represent a feasible therapeutic approach. This leaves only one possible 
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targetable step to interfere, which is the colonization of the target organ, when the micro-metastases 
grow and form clinically detectable macro-metastases. 
At least, metastatic colonization is a highly inefficient process in reality. This final step of the metastatic 
cascade represents the bottleneck of the whole process since only a tiny fraction of the large number 
of tumor cells that enter the circulatory system survives the travel. And from those the majority fail to 
extravasate from blood vessels resulting in an even smaller number of cells (less than 0.01%) that 
finally manage the successful colonization of distant organs (Fidler, 1970). Nevertheless, as single 
successfully spread cells are able to grow out to macro-metastases, each can play a decisive role. This 
emphasizes the importance to interfere with the colonization process via adequate therapies.  
Since many years, the focus of our group lies on the investigation of the situation in the brain. 
Once disseminated cancer cells arrive in secondary organs, they have to circumvent local immune 
defenses to take over the distant tissue and adapt to its prevailing supportive niches (Blazquez et al., 
2018; Chuang et al., 2013; Klemm et al., 2011; Pukrop et al., 2010; Pukrop et al., 2006; Rietkotter et 
al., 2015; Vanharanta et al., 2013). Again, the majority fail and die right at the beginning leaving only a 
small number of tumor cells that successfully survive the first immune response of the new host organ. 
They subsequently often stay in a latent phase and it can take weeks, months, or even years after the 
original seeding until they start to proliferate again. The following phases of metastatic colonization 
involve the formation of a micro-metastasis (<2 mm) and the establishment of a macro-metastasis 
(≥2 mm) with a specific metastatic microenvironment (MME). Once metastases exceed a certain size, 
they cause severe organ destruction and such target lesions (≥10 mm) can lead to organ failure and 
death (Blazquez et al., 2020b) (Figure 1).  
Although clinicians try to prevent the formation of a micro-metastasis with different adjuvant 
therapies, this time window still represents a diagnostic gap. A potential seeding is not detectable at 
this stage and can only be treated upon suspicion. Furthermore, even after successful seeding not all 
micro-metastases progress into macro-metastases and patients with this dormant form of the disease 
characterized by inactive micro-metastases can show long-term survival under asymptomatic chronic 
conditions (Murray, 2017). During early phases (Stage I–III), micro-metastases are not clearly 
demarcated from the surrounding tissue. Only when they progress into macro-metastases and further 
to target lesions, they can be differentiated based on their outgrowth pattern. 
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Figure 1: Metastatic colonization. Metastatic colonization can be subdivided into at least four different 
major phases: i) re-starting proliferation, ii) formation of a micro-metastasis (<2 mm), iii) establishing 
a macro-metastasis (≥2 mm) with its own metastatic microenvironment, and iv) organ destruction 
leading to organ failure and death. Taken from (Blazquez et al., 2020b) under a CC BY 4.0 license. 
 
1.1.2. Different patterns of colonization 
Various factors have been reported to strongly influence prognosis for the patient, including the 
biology of the entities, the existence of druggable mutations or the (non-) response to (immune) 
therapy. In recent years, several studies have acknowledged the presence of infiltrative tumor cells at 
the macro-metastasis/organ parenchyma interface (MMPI) as another factor with a significant impact 
on patient outcome. The MMPI is defined as the area where cells of the macro-metastasis (≥2 mm) 
and its metastatic microenvironment are in direct contact with the (healthy) adjacent organ 
parenchyma (Blazquez et al., 2020b). Clinicians and researchers had underestimated and overlooked 
this area before and simply assumed that the edge between metastatic and brain tissue was a clearly 
defined border. However, it has become evident in numerous histological analyses of MMPIs in brain 
metastases as well as liver and lung specimens that significant morphological differences exist even 
within the same tumor entity.  
The most important issue is the grade of infiltration. We distinguish between two types of MMPIs that 
essentially differ from each other: non-infiltrative and infiltrative growth. Non-infiltrative or displacing 
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This pattern is easy to recognize and has sharply defined borders. On the other hand, infiltrative MMPIs 
miss such a clear separation between metastasis and organ parenchyma, as tumor cells grow 
unrestricted in various patterns by infiltrating the surrounding tissue. While non-infiltrative metastases 
account for only 40% of brain metastases, the infiltrative type is found in 60% of cases (Blazquez et al., 
2020b). Moreover, these differences have been shown to be prognostic with severe impact on clinical 
practice (Figure 2). 
We already demonstrated the significant prognostic impact of the metastatic infiltration pattern in 
brain metastases in a previous study. In this prospective clinical basket trial, the 2-year overall survival 
(OS) of patients with non-infiltrative MMPIs was 43.5%, while that of patients with infiltrative MMPIs 
was only 6.6% (Siam et al., 2015). The situation was similar for liver metastases (Fonseca et al., 2018; 
van Dam et al., 2017) as well as metastases in the lung (Shiono et al., 2005). In general, the type of 
metastatic infiltration at the MMPI has a significant impact on survival. Non-infiltrative metastases 
account for a better prognosis with some patients being even long-term survivors while infiltrative 
metastases correlate with worse overall survival (Blazquez et al., 2020b). Therefore, the MMPI seems 
to be highly relevant for the correct management of metastatic disease and for reliable and 
reproducible research. 
 
Figure 2: Correlation of MMPI and overall survival. Several studies show a correlation between the 
growth pattern of metastases at the MMPI and the overall survival of patients in brain, liver and lung 
metastases. Infiltrative MMPIs correlate with worse overall survival. Survival curves from separate 
studies were combined in a modified comparative overview. Survival curve of patients with brain 
metastases (left panel) was taken from (Siam et al., 2015) under a CC BY 3.0 license. Survival curve of 
patients with liver metastases (middle panel) was taken from (van Dam et al., 2017) under a CC BY-NC-
SA 4.0 license. Survival curve of patients with lung metastases (right panel) was taken from (Shiono et 
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1.1.3. The macro-metastasis/organ parenchyma interface (MMPI) 
Several different MMPI patterns have been described for brain, liver and lung metastases in the past. 
However, the exact terms and definitions of the histopathological criteria largely varied between 
studies. In order to facilitate day-to-day application of common termination and thus enable fast and 
reliable MMPI pattern recognition, our group collected all designations found in the literature and 
developed uniform definitions (Blazquez et al., 2020b). We included these definitions into three main 
MMPI categories and nine subcategories (Figure 3): 
A. Displacing MMPI: with or without reactive pseudo-capsule, with a reactive multilayer 
pseudo-capsule 
B. Epithelial infiltrative MMPI: strand, cohort, glandular, angiotropic infiltration 
C. Diffuse infiltrative MMPI: diffuse infiltration with or without a visible macroscopic metastasis 
 
Figure 3: Macro-metastasis/organ parenchyma interface (MMPI) patterns. MMPI patterns are 
divided into three main categories: displacing, epithelial infiltrative and diffuse infiltrative MMPIs. 
Angiotropic infiltration (along the host tissues’ blood vessels) can demonstrate epithelial as well as 
diffuse characteristics. Adapted from (Blazquez et al., 2020b) under a CC BY 4.0 license. 
 
1.1.4. Infiltrative MMPI patterns in human breast cancer brain metastases 
As infiltrative metastases are associated with worse survival rates and represent a major problem, 
the following study focuses on infiltrative MMPI patterns. In breast cancer, they usually present 
themselves as epithelial but sometimes also as diffuse infiltrative (Siam et al., 2015). An epithelial 
cohort infiltrative MMPI pattern is defined as clusters or groups of epithelial tumor cells that 
collectively infiltrate the adjacent organ parenchyma and are physically separated from the metastatic 
Breast cancer / Colon cancer / Non-small cell lung cancer
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boundaries. On the other hand, a diffuse infiltrative MMPI pattern is characterized by single tumor 
cells that deeply infiltrate the adjacent tissue (>1 mm) in a chain- or swarm-like (in other words, 
diffuse) way. Alike epithelial infiltrating cells, those presenting a diffuse infiltrative MMPI pattern 
usually acquire a more mesenchymal-like morphology (Blazquez et al., 2020b). 
We could also confirm these distinguishable infiltration patterns in a recent study in an independent 
cohort of human brain metastases (Blazquez et al., 2020a) (Figure 4). 
 
Figure 4: Infiltrative MMPI patterns in human breast cancer brain metastases. Cytokeratin-7 (CK7) 
and cytokeratin-8 (CK8) staining in tissue sections of human cerebral metastases. Representative 
images of epithelial cohort (upper row) and diffuse (lower row) MMPI patterns observed in brain 
metastases of breast cancer patients. Adapted from (Blazquez et al., 2020a) under a CC BY 4.0 license. 
 
1.2. Target mechanisms in metastatic colonization 
Metastatic colonization has many faces and remains a process that needs to be intensively studied. 
Finding an Achilles’ heel of aggressive metastatic cancers is the overall goal and the reason why 
numerous researchers focus on various treatment strategies. Many different mechanisms are likely to 
cause colonization and express themselves through distinct phenotypes. As metastatic growth in the 
brain is one of the most aggressive and problematic forms due to the difficulties of complete removal 
by GTR, it provides a particular focus for target mechanism studies. It became already apparent that 
the efficacy of therapeutic concepts seems to be heavily dependent on the type of colonization and 
infiltration pattern. For example, antibody therapy against vascular endothelial growth factor A was 
only effective in preventing angiogenic growth during lung carcinoma metastasis formation but 
ineffective against vessel cooptive growth of melanoma cells (Kienast et al., 2010). 
As we are able to distinguish different infiltrative MMPI patterns, the question arises as to the 
existence of different mechanisms and underlying pathophysiology. This is a prerequisite for 
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1.2.1. Cell adhesion receptor E-cadherin 
The role of E-cadherin as a tumor suppressor gene in cancer development and progression has been 
extensively studied (Gall et al., 2013). Epithelial cadherin (E-cadherin), also known as Cadherin 1, is a 
single-pass transmembrane glycoprotein expressed by a variety of tissues and functions as a cell-cell 
adhesion receptor (Gall et al., 2013). 
E-cadherin is often inactivated in tumors of breast cancer patients (Bajrami et al., 2018) and clinical 
studies report lower incidence of metastases in breast cancer patients with increased E-cadherin 
expression (Li et al., 2017). Besides its implication in breast cancer, it also has been shown to have a 
prognostic value in ovarian cancer (Rosso et al., 2017), non-small cell lung cancer (Esheba et al., 2017) 
and many other types. The functional loss of E-cadherin is generally associated with poor prognosis 
and survival and its clinical relevance is rapidly expanding (Wong et al., 2018). Lower levels of 
E-cadherin are always associated with increased dissemination and aggressiveness. Nevertheless, 
there are still no direct medicine approaches targeting this remarkable characteristic. 
Loss of E-cadherin expression has often been associated with epithelial-mesenchymal transition (EMT) 
(Petrova et al., 2016). During the EMT process, tumor cells loose characteristic properties of epithelial 
cells including the apical-basal axis of polarity and cell-cell adhesion, and acquire properties of 
mesenchymal cells instead, including loose three-dimensional organization and increased motility 
(Romeo et al., 2019). However, this seems to be a chicken and egg issue, since there are controversial 
discussions whether the loss of E-cadherin is the cause or just an effect of EMT. Furthermore, EMT is 
probably not a black or white situation and cancer cells rather exhibit intermediate phenotypic and 
functional states (Romeo et al., 2019). Metastases often even completely retain E-cadherin expression 
excluding an absolute requirement of EMT for their occurrence (Petrova et al., 2016). We also 
previously noticed an upregulation of E-cadherin at the border of metastatic tissue and adjacent brain 
parenchyma in some epithelial infiltrative MMPIs and in the locally disseminated micro-metastases in 
our in vivo mouse models regardless of the cell line even when the metastatic core was E-cadherin 
negative or necrotic (Blazquez et al., 2020a). Petrova and colleagues argue that metastasis rather 
depends on reduced E-cadherin adhesive function and genetic deficits in E-cadherin cell surface 
regulation contribute to cancer progression (Petrova et al., 2016). In accordance, the tumorigenicity 
of cancer cells without detectable E-cadherin expression could be partially suppressed by re-
expression of this cell adhesion molecule in a previous in vitro study (Navarro et al., 1991). 
To capture its role in human brain metastases, we also evaluated the expression of E-cadherin at the 
MMPI in the previously mentioned patient material. Epithelial cohort infiltrative human breast cancer 
brain metastatic lesions expressed high levels of the epithelial marker E-cadherin, in particular at the 
MMPI, while the more aggressive diffuse infiltrative human breast cancer brain metastases showed no 
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expression at all (Figure 5 A). Additionally, we also found E-cadherin positive carcinoma cell clusters in 
adjacent blood vessels of human breast cancer brain metastases just like in our murine models 
(Blazquez et al., 2020a) (Figure 5 B).  
These observations emphasize the essential role of E-cadherin in the metastatic process and highlight 
the importance of considering different MMPI patterns as independent entities for the accurate study 
of metastatic colonization. 
 
Figure 5: E-cadherin expression in human breast cancer brain metastases. (A) E-cadherin (ECAD) 
staining in tissue sections of epithelial cohort infiltrative human breast cancer brain metastases 
(upper row) and diffuse infiltrative human breast cancer brain metastases (lower row). 
(B) Intravascular E-cadherin positive cell clusters in breast cancer brain metastases. Modified from 
(Blazquez et al., 2020a) under a CC BY 4.0 license. 
 
Padmanaban and colleagues recently showed the importance of E-cadherin for the whole metastatic 
process. Loss of E-cadherin resulted in reduced cancer cell proliferation and survival, circulating tumor 
cell number, seeding of cancer cells in distant organs and metastasis outgrowth (Padmanaban et al., 
2019). However, the authors provide no information which steps of the metastatic cascade are 
involved or how the colonization process in a distant organ is affected. As their model systems only 
cover the steps prior to colonization (such as intravasation, survival in the circulation and 
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1.2.2. Contact inhibition mechanisms and E-cadherin 
Normal cells control their outgrowth once they sense neighboring cells. They stop to proliferate with 
increasing cell density due to cell-cell contacts and this phenomenon is called contact inhibition of 
proliferation (Mendonsa et al., 2018). It is essential for the correct development of tissues and organs 
and only switched off in critical situations including the fast regeneration of tissues for closure of 
wounds. However, one of the hallmarks of cancer is uncontrolled growth due to the loss of contact 
inhibition (Hanahan et al., 2000, 2011).  
Without cell contact, the transcriptional activators Yes-associated protein (YAP) and transcriptional 
coactivator with PDZ-binding motif (TAZ) in the cytoplasm are active and can translocate to the 
nucleus, where they induce the expression of several growth factors and other genes promoting cell 
survival and proliferation upon binding to transcriptional enhancer factor TEF-1 (TEAD) (Dong et al., 
2007). Upon cell contact, the homophilic ligation of E-cadherin receptors in adjacent cell membranes 
leads to the release of growth inhibitory signals via different signaling cascades including the Hippo 
pathway (Gumbiner et al., 2014; Kim et al., 2011). Interestingly, E-cadherin can inhibit cell growth with 
these adherens junctions independently of other cell interactions (Perrais et al., 2007) although tight 
junctions and apical polarity complexes are also formed. Besides proliferation, the Hippo pathway also 
regulates cellular functions such as development and regeneration of tissue and plays a role in cancer 
progression and metastasis (Mendonsa et al., 2018). Downstream of the E-cadherin-catenin complex, 
several players, including kinases and scaffold proteins, orchestrate in a cascade as the core of the 
Hippo pathway finally resulting in the phosphorylation of YAP and TAZ. This stops their translocation 
to the nucleus, eventually leads to their degradation and thus prevents the expression of cell 
proliferation genes (Figure 6 A). 
Therefore, E-cadherin seems to play an important role in contact inhibition of proliferation and cancer 
progression (Mendonsa et al., 2018). In normal cells, E-cadherin establishes cell-cell contacts with 
increasing density and the cell-cell adhesion finally induces contact inhibition resulting in cells growing 
in a monolayer. Mutations or the loss of E-cadherin can lead to disrupted cell-cell adhesion and thus 
prevent the activation of the Hippo signaling kinase cascade. This results in the loss of contact 
inhibition and cells continue to proliferate and grow on top of each other (Figure 6 B).  
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Figure 6: Role of E-cadherin and Hippo signaling pathway in contact inhibition. (A) Model for an 
E-cadherin-mediated Hippo signaling pathway. Without cell contact, the Hippo pathway is inactivated. 
The transcriptional activators YAP and TAZ can translocate from the cytoplasm to the nucleus and bind 
TEAD resulting in the expression of different target genes and activation of cell proliferation and 
survival. Upon E-cadherin-mediated cell adhesion, the Hippo signaling pathway is activated and a 
multi-step kinase cascade leads to the phosphorylation of YAP/TAZ. Phosphorylated YAP remains in 
the cytoplasm, is eventually degraded and cell growth is inhibited. (B) Role of E-cadherin in contact 
inhibition. In cells with functional E-cadherin, cell-cell adhesion can induce contact inhibition with 
increasing density resulting in cells growing in a monolayer. Mutations or the loss of E-cadherin can 
lead to disrupted cell-cell adhesion and result in the loss of contact inhibition and cells proliferating 
continuously and growing on top of each other. 
 
Massague and colleagues revealed the importance of YAP/TAZ during metastasis outgrowth in vessel 
cooptive cancer models as well-established promoters of tumor growth and metastasis (Er et al., 
2018). This mechanism could be a feasible target for treatment of cancer metastases. The blockade of 
contact inhibition can be achieved by inhibition of the Hippo pathway and several inhibitory 
components already have proved to work as tumor suppressors (Zhao et al., 2010) among them also 
YAP inhibitors. However, a systematic analysis of YAP or cell contact inhibition in distinct metastatic 
colonization patterns has not been performed yet. Therefore, it remains unclear if YAP inhibition could 
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1.2.3. The metastatic microenvironment of brain metastases 
The area around tumors or cancer cells, the metastatic microenvironment, is comprised of various 
components. Besides the extracellular matrix (ECM) and surrounding blood vessels, it also contains 
different immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes and many 
signaling molecules (Spill et al., 2016). All those players have their specific roles and act together in a 
complex network. When foreign tumor cells reach a distant organ, they are detected by cells of the 
immune system, reliably attacked and killed by apoptosis. This protects the organ from further tumor 
growth and damage. Therefore, the MME plays an important role in the metastatic process and 
changes in the MME have been demonstrated to influence tumor development and growth as well as 
the efficacy of treatments (Spill et al., 2016).  
The CNS differs from other host organs and has a unique milieu. When a metastatic lesion occurs, the 
immune cells initially fight against the intruders and neuroinflammation as well as astrogliosis occur. 
Organ-foreign cells are isolated from the rest of the organ and colonization is prevented. The MME of 
brain metastases is mainly composed of microglia/macrophages, astrocytes and T cells.  
Microglia are the resident macrophage cells and main innate immune effectors in the brain tissue and 
are widely distributed in the healthy brain parenchyma (Berghoff et al., 2015). In case of an injury, they 
immediately accumulate at the area of the lesion and act as rapid responders to decrease inflammation 
and destroy the pathogens before neural damage occurs. Microglia also produce a number of growth 
and repair factors to promote repair of already damaged CNS tissue. Normally this very efficient 
process defends the organ from serious damage. However, besides their tumor suppressive function 
microglia can also help tumors to grow by suppressing the adaptive immune response (Berghoff et al., 
2015). We could visualize this tumor promoting function in a well established ex vivo brain slice 
coculture model with vital brain slices and malignant cancer cells. Invasive cancer cells were somehow 
able to recruit the aid of microglia/macrophages, attract them to the tumor site and hijack them to 
invade into the surrounding tissue (Chuang et al., 2013; Pukrop et al., 2010).  
Astrocytes are the most abundant glial cells of the CNS and easy to recognize by their characteristic 
star-shaped appearance (Xing et al., 2013). Although their main function is the maintenance of the 
blood-brain barrier (BBB) and nutrient supply for the brain tissue, they can be activated under 
pathological conditions and often accumulate around brain metastatic lesions also suggesting a 
potential tumor-supporting role (Xing et al., 2013). In a previous study of our group, the general glial 
response of astrocytes and microglia is depicted in human brain metastases (Figure 7 A).  
T cells are the main adaptive immune system effector cells, normally almost absent in healthy CNS 
and   only accumulate in the brain under pathological conditions (Berghoff et al., 2015). 
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Different subpopulations have opposite functions by either suppressing the tumor (cytotoxic T cells) 
or the immune response (regulatory T cells) and thus can generate an immune-suppressive 
microenvironment as well (Berghoff et al., 2015). 
In summary, metastatic cells have to overcome the local immune defense to colonize the brain tissue 
and key players of this immune response are microglia/macrophages, astrocytes and T cells. Figure 7 B 
shows a schematic model of the MME at infiltrative MMPIs based on previous findings (Blazquez et al., 
2020a; Chuang et al., 2013; Doron et al., 2019; Siam et al., 2015) and emphasizes the MMPI as a very 
reactive zone.  
 
Figure 7: The metastatic microenvironment (MME) of brain metastases. (A) Distribution of 
microglia/macrophages (MΦ) and astrocytes in human brain metastases: (A1) Activated 
microglia/macrophages (KiM1P) accumulate in the adjacent brain tissue and at the interface. The 
majority infiltrate into the metastatic tissue. (A2) Activated astrocytes (GFAP) accumulate in the 
adjacent brain tissue and form a barrier at the interface to the metastatic tissue. Images of human 
brain metastases were taken from (Chuang et al., 2013) with permission from John Wiley & Sons. (B) 
Schematic model of the MME at infiltrative MMPIs based on previous findings. Metastatic cells have 
to overcome the local immune defense to colonize the brain tissue. Key players of the immune 
response are microglia/macrophages, astrocytes and T cells. 
 
Taken together, the interactions between metastatic and immune cells influence every step of the 
metastatic cascade and the immune system can be both friend and foe. The fate of a tumor therefore 
depends on the balance between anti-tumor immunity and tumor-supporting inflammation. 
The mutual interference between cancer cells and immune cells opens up a range of new treatment 



































INTRODUCTION  13 
 
possibilities for cancer patients. Targeted immune therapies are promising candidates currently under 
investigation in neo-adjuvant as well as in metastatic settings of various carcinomas and some already 
have significantly improved the survival rates of cancer patients in stadium IV in several tumor entities. 
However, not every patient responds to such therapies or even develops a resistance during the course 
of treatment. It is presumed that this phenomenon relates to the immune exclusion phenotype, which 
is characterized by the absence of an immune infiltrate inside the metastatic lesion. In fact, recent 
studies indicate that tumor cells displaying a predominantly mesenchymal phenotype are associated 
with this immune exclusion (Romeo et al., 2019).  
We think that the MMPI pattern itself could have a direct influence on the recruitment and disposition 
of immune cells within the macro-metastasis, the local damage response and formation of the MME. 
In diffuse infiltrative patterns, metastatic cells generally grow in a less compact manner and are spread 
over a larger area. Immune cells could thus enter the metastatic region by passing the MMPI barrier 
and fight against the foreign intruders inside the metastatic lesion. In contrast, compact metastases of 
the epithelial infiltrative type could allow the formation of a barrier and provide a defined area for 
immune cells to attack. This could affect the response to specific therapies and the MMPI could thus 
serve as a prognostic tool in clinical practice. 
1.3. Mouse models for the study of metastatic colonization in the brain 
Various mouse models are available for the study of metastatic colonization in the brain. They all rely 
on the formation of metastases arising from successful tumor cells after injection into mice. 
We differentiate them based on the stage of the metastatic colonization process they represent best 
into early and late brain colonization mouse models (Figure 8). 
Early brain colonization models mainly focus on initial steps of the metastatic colonization process 
including the extravasation of tumor cells from the circulation and infiltration into target organ tissue. 
They differ in the site of tumor cell injection and can be subdivided into orthotopic (organ of origin) 
and ectopic models (organ different from origin). Although orthotopic models (for example, implanting 
breast cancer cells into mammary fat pad or colon cancer cells into cecal wall) can lead to spontaneous 
metastases in the brain, it usually takes a longer time. Many cells already fail during the first steps of 
the metastatic cascade when they have to seed from the primary tumor into the surrounding tissue, 
intravasate and survive in the circulation. Ectopic injections on the other hand show increased success 
rates in the formation of brain metastases as they are mainly performed directly into the circulatory 
system and thus enable a rapid transport of a larger number of tumor cells to distant organ sites 
including the brain. Popular injection sites range with increasing difficulty from fast and easy tail vein 
injections to intra-cardiac injections into the left ventricle and the more complex direct injection into 
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the internal carotid artery (Kienast et al., 2010; Latacz et al., 2020). However, they all have 
disadvantages, be it that the majority of cells is trapped in the lungs instead of the brain after a tail 
vein injection or the frequent colonization of other organs in an unpredictable manner after carotid 
artery injections.  
In all those early models, cancer cells have to break through the blood-brain barrier to establish 
metastases in the brain. It is still not known how exactly they accomplish this crossing. A recent study 
revealed that tumor cells release extracellular vesicles that can pass the BBB through transcytosis and 
alter cells of the barrier itself as well as host cells of the target tissue to weaken the blockade and make 
the brain parenchyma more susceptible for the colonization of metastatic cancer cells (Morad et al., 
2019). Nevertheless, only a small fraction of tumor cells manages the passage and metastatic lesions 
are not formed on a regular basis. Furthermore, the number of successful cells can not be controlled. 
This impedes a detailed study of MMPI patterns resulting from several different cell lines.  
In contrast, our late brain colonization model circumvents this hindrance via direct injection of tumor 
cells into the brain. By surrounding the BBB, we can measure the effects on colonization mechanisms 
of a large number of cells. In the highly aggressive cell lines, macro-metastases arise within a few days. 
The stereotactic injection technique is commonly used in various fields of brain research and has been 
previously established in our lab with different murine cancer cell lines (Blazquez et al., 2020a; 
Blazquez et al., 2018). This system represents the late colonization step of the brain very well and the 
resulting metastases are well comparable to the lesions observed in human patients. Our model has 
several advantages compared to the early colonization approach. The stereotactic procedure with 
fixed coordinates ensures that tumor cells are always injected into the same area in a reproducible 
manner. The number of injected cells can be precisely controlled and potential treatment effects are 
directly measurable. This facilitates the detailed characterization of MMPI patterns in a sufficient 
number of animals and further enables a comparison between entities and modified cell lines.  
When tumor cells form micro-metastases and further progress to macro-metastases during the last 
steps of metastatic colonization, they have to overcome the local immune defense to colonize in the 
tissue. As we use syngeneic models (injecting murine tumor cells into mice with a functional immune 
system) instead of the commonly used xenograft approach (tumor cells of human origin are injected 
into immunocompromised mice), we can study the MME in a realistic setting and aim to understand 
this important mechanism in the colonization of the brain. 
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Figure 8: Comparison of early and late brain colonization mouse models. Early brain colonization 
models are distinguished depending on the site of tumor cell injection. In the late brain colonization 
model, tumor cells are stereotactically injected directly into the cortex of syngeneic mice. The blood-
brain barrier represents the fundamental distinction between both approaches. In early models, it 
prevents the majority of tumor cells from entering the brain tissue and forming metastases. The late 
model circumvents this hindrance and ensures the reliable outgrowth of brain metastases for a 
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1.4. Aims of the study 
The metastatic infiltration pattern in brain metastases has a prognostic impact and makes the 
understanding of underlying mechanisms and pathophysiology in different MMPI patterns essential 
for clinical treatment studies. We previously developed uniform definitions to enable fast and reliable 
MMPI pattern recognition and confirmed them in human brain metastases in a recent study focusing 
on the infiltrative categories that are generally associated with worse survival rates.  
Diffuse infiltrative cells clearly differ from epithelial infiltrative ones in their pathophysiology. 
Therefore, we aim to elaborate the potentially responsible underlying mechanisms. We think that the 
infiltration pattern correlates with overall survival, has an influence on the metastatic 
microenvironment and might result from differences in cellular signaling mechanisms. Furthermore, 
we hypothesize that the cell adhesion protein E-cadherin is not only a characteristic marker for the 
type of infiltration, but also plays a critical functional role. 
Thus, the first aim of this thesis is the genetic modification of the innate level of E-cadherin in the 
corresponding cell lines of our brain metastasis mouse models representing the different infiltrative 
MMPI patterns. Initially, the resulting overexpression and knockdown cell lines will be characterized 
in vitro and subsequently injected into the brains of syngeneic mice to investigate the functional 
impact of E-cadherin level on survival, infiltration grade and the metastatic microenvironment in vivo. 
An additional aim will be the establishment of a characteristic gene expression signature with a 
potentially prognostic impact. 
In the frame of this study, I want to contribute to our understanding of the role of E-cadherin during 
metastatic colonization in the context of the MMPI phenotype and shed some light on the mechanisms 
underlying metastatic infiltration of tumor cells in the brain parenchyma. 
 
In detail, the following aims are pursued in this study: 
1) Opposing genetic modification of E-cadherin in diffuse and epithelial infiltrative cell lines via 
lentiviral overexpression or knockdown 
2) Characterization of resulting functional effects concerning proliferation, 2D migratory and invasive 
capacity, 3D culture outgrowth ability and contact inhibition mechanisms in vitro  
3) Investigation of E-cadherin modification effects on overall survival, MMPI pattern, infiltration 
grade, angiogenesis and MME in brain metastasis mouse models in vivo  
4) Identification of a characteristic gene expression signature as a potential prognostic tool 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Biological materials 
2.1.1.1. Bacterial strains 
The bacterial strains used in this thesis are listed in Table 1. 
Table 1: Bacterial strains. 
Name ccdB resistance Application Source 
DB3.1 yes amplification of plasmid DNA Invitrogen 
DH5alpha no amplification of plasmid DNA Invitrogen 
 
2.1.1.2. Cell lines 
2.1.1.2.1. Lentiviral production cell line 
The lentiviral production cell line used in this thesis is listed in Table 2. 
Table 2: Lentiviral production cell line. 
Name Species/cell type Origin Reference 
HEK293T human embryonic kidney ATCC (Wesel) (Graham et al., 1977) 
 
2.1.1.2.2. Parental murine tumor cell lines 
The parental murine tumor cell lines used in this thesis are listed in Table 3. 
Table 3: Parental murine tumor cell lines. 
Name Species/cell type Background Origin/obtained from Reference 
410.4 mouse breast cancer BALB/c 
Prof. F. Balkwill 
(London, UK) 
(Miller et al., 1983) 
CMT93Var mouse colon cancer C57BL/6 
Dr. med. C. Hackl 
(Regensburg) 
(Franks et al., 1978) 
CT26 mouse colon cancer BALB/c ATCC (Wesel) (Brattain et al., 1980) 
E0771-LG mouse breast cancer C57BL/6 
Prof. J. Pollard 
(Edinburgh, UK) 
(Kitamura et al., 2019) 
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2.1.1.2.3. Modified murine tumor cell lines 
The modified murine tumor cell lines used in this thesis are listed in Table 4. 
Table 4: Modified murine tumor cell lines. 
Name Origin E-cadherin modification 
410.4-pLKO.1-scrambled-shRNA 410.4 Control 
410.4-pLKO.1-mE-cadherin-shRNA 410.4 Knockdown 
CMT93Var-pLKO.1-scrambled-shRNA CMT93Var Control 
CMT93Var-pLKO.1-mE-cadherin-shRNA CMT93Var Knockdown 
CT26-pLenti-empty CT26 Control 
CT26-pLenti-mE-cadherin CT26 Overexpression 
E0771-LG-pLX302-empty E0771-LG Control 
E0771-LG-pLX302-mE-cadherin E0771-LG Overexpression 
 
2.1.1.3. Mouse strains 
Adult mice were obtained from Charles River (Hannover, Germany) and constantly kept under 
standard laboratory conditions in the animal facility. All animals were fed a soy-free diet.  
The mouse strains used in this thesis are listed in Table 5. 
Table 5: Mouse strains. 
Name Syngeneic intracortical injections Source 
BALB/c 410.4, CT26 Charles River 
C57BL/6 CMT93Var, E0771-LG Charles River 
 
2.1.2. Chemicals and reagents 
The chemicals and reagents used in this thesis are listed in Table 6. 
Table 6: Chemicals and reagents. 
Product Company 
2-Mercaptoethanol Sigma-Aldrich 
2-Propanol 70% (v/v) B. Braun 
Acetic acid Merck Millipore 
Agar Sigma-Aldrich 
Agarose Biozym Scientific 
Agarose NEEO ultra-quality Carl Roth 
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Ammonium persulfate (APS) VWR 
Ampicillin Carl Roth 
Antibody diluent Dako 
Adenosine 5′-triphosphate (ATP) disodium salt hydrate Sigma-Aldrich 
Bepanthen eye and nose ointment Bayer Vital GmbH 
Bovine serum albumin (BSA) Carl Roth 
BSA standard ampules Gibco/Thermo Fisher Scientific 
Bromophenol blue Carl Roth, Pharmacia Biotech 
Chloramphenicol Carl Roth 
Crystal violet solution Sigma-Aldrich 
Diethyl ether Merck Millipore 
Dimethyl sulfoxide Sigma-Aldrich 
Deoxyribonucleic acid (DNA) gel loading dye (6x) Thermo Fisher Scientific 
Domitor 1 mg ml–1 Orion Pharma 
Eosin Y solution Carl Roth 
Ethanol (EtOH) Merck Millipore, Carl Roth 
Ethidium bromide (EtBr) Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Merck Millipore, Carl Roth 
Extracellular matrix R&D Systems 
ExtrAvidin-Peroxidase Sigma-Aldrich 
Fluorescent mounting medium Dako 
Formic acid Carl Roth 
GeneRule 1 kilo bases (kb) DNA ladder Thermo Fisher Scientific 
GeneRuler 50 bp DNA ladder Thermo Fisher Scientific 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
Hematoxylin solution Merck 
Hydrochloric acid 37%  Carl Roth 
Hydrochloric acid solution (adjust pH) Fluka Analytical 
Hydroxytricarballylic acid Merck 
Isopropanol Merck Millipore 
Kanamycin Carl Roth 
Ketamin 10%  Medistar 
Metamizol 500 mg ml–1 WDT 
Methanol Merck Millipore 
Methylene blue Sigma-Aldrich 
Modified milk powder (MMP), blotting grade             
(nonfat dry milk) 
Carl Roth 
NaCl 0.9% isotonic saline solution B. Braun 
Orange DNA loading dye (6x) Thermo Fisher Scientific 
Paraformaldehyde (PFA) Merck Millipore 
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Paraplast bulk Leica 
PBS powder without Ca2+, Mg2+ Merck 
Perhydrol hydrogen peroxide 30% Merck 
Phosphatase inhibitor PhosSTOP (10x) Roche 
Polybrene Sigma-Aldrich 
Polyethylenimine Polysciences 
Ponceau S solution AppliChem 
Potassium acetate Merck 
Precision Plus Protein Dual Color standard Bio-Rad 
Protease inhibitor cocktail tablets, EDTA free Roche 
Restore Western blot stripping buffer Thermo Fisher Scientific 
Rimadyl Carprofen Zoetis 
RNaseOUT recombinant ribonuclease inhibitor (40 U/μl) Invitrogen/Thermo Fisher Scientific 
Roti phenol/chloroform/isoamyl alcohol Carl Roth 
Roti-Histokitt II Carl Roth 
Rotiphorese Gel 30 (30% (v/v) acrylamide/bisacrylamide 
solution) 
Carl Roth 
Rotipuran trichloromethane/chloroform Carl Roth 
Sodium acetate water-free Carl Roth 
Sodium chloride (NaCl) Carl Roth, Thermo Fisher Scientific 
Sodium deoxycholate (>97%) Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Carl Roth, Merck 
Sodium hydroxide (NaOH) solution (adjust pH) Merck 
Softasept N B. Braun 
Target Retrieval solution, citrate pH 6.1 (10x) Dako 
Tetramethylethylendiamin (TEMED) Sigma-Aldrich 
Thiazolyl blue tetrazolium bromide Sigma-Aldrich 
Tri-Sodium citrate dihydrate Merck 
Tris wash buffer (pH 6) Merck Millipore 
Triton X-100 Sigma-Aldrich 
Trizma acetate (Tris-Acetate) Sigma-Aldrich 
Trizma base (Tris-Base) Sigma-Aldrich 
Trizma HCl (Tris-HCl) Sigma-Aldrich 
TRIzol reagent Invitrogen/Thermo Fisher Scientific 
Trypton Becton-Dickinson 
Tween 20 Sigma-Aldrich 
UltraPure DNase/RNase-free distilled water Invitrogen/Thermo Fisher Scientific 
Water, DPEC-treated Sigma-Aldrich 
Xylol Carl Roth 
Yeast extract Becton-Dickinson 
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2.1.3. Bacterial media and agarose plates 
Selective culture medium with a dilution of 1:1000 of the required antibiotic stock concentration was 
used for cultivation of Escherichia coli (E. coli) strains under sterile conditions. Stock concentrations 
were 100 mg ml−1 for ampicillin, 50 mg ml−1 for kanamycin and 30 mg ml−1 for chloramphenicol. 
Agarose plates and media were stored at 4 °C and preheated before usage. 
The bacterial media and reagents used in this thesis are listed in Table 7. They were prepared with 
sterile H2O and, if necessary, subsequently autoclaved. 
Table 7: Bacterial media and reagents. 
Name  Composition 
Lysogeny broth (LB) medium 1% tryptone 
 0.5% yeast extract 
 1% NaCl 
 ad H2O 
LB0 agar plates 10% tryptone 
 5% yeast extract 
 5% NaCl 
 15% agar 
  pH 7.0 
LBamp agar plates  LB0 
 100 mg ml−1 ampicillin 
LBkana agar plates  LB0 
 50 mg ml−1 kanamycin 
LBchlor agar plates  LB0 
 30 mg ml−1 chloramphenicol 
 100 mg ml−1 ampicillin 
Yeast extract tryptone agar (YTA) medium 16% tryptone 





MATERIALS AND METHODS  22 
 
2.1.4. Cell culture media and additives 
The media and additives used for the culture of cell lines in this thesis are listed in Table 8. 
Table 8: Cell culture media and additives. 
Product Company 
Dulbecco’s modified Eagle medium (DMEM) (1 g l−1 glucose) Merck Millipore 
Dulbecco’s modified Eagle medium (4.5 g l−1 glucose) Sigma-Aldrich 
Dulbecco’s phosphate buffered saline (PBS) without Ca2+, Mg2+ Gibco/Thermo Fisher Scientific 
Fetal calf serum (FCS) PAN Biotech, Life technologies 
Geneticin (G418) Roche, Sigma-Aldrich 
Penicillin/Streptomycin (P/S) Merck Millipore, Sigma-Aldrich 
Puromycin Sigma-Aldrich 
Roswell Park Memorial Institute (RPMI) 1640 medium Gibco/Thermo Fisher Scientific 
Trypsin-EDTA (10x) Sigma-Aldrich 
 
2.1.5. Buffers and solutions 
The buffers and solutions used in this thesis are listed in Table 9. They were prepared with sterile H2O 
and, if necessary, subsequently autoclaved. 
Table 9: Buffers and solutions. 
Name  Composition 
6x DNA loading dye blue 10 mM Tris-Base/Tris-HCl 
 0.03% bromophenol blue 
Ampicillin 1 g ampicillin 
  10 ml H2O 
Blotting buffer 25 mM Tris-Base/Tris-HCl 
 192 mM glycine 
 20% (v/v) methanol 
 ad 1 l H2O 
BSA 5% 5% (w/v) BSA in TBST 
Chloramphenicol 300 mg chloramphenicol 
  10 ml H2O 
Citrate buffer  solution A: 
 2.1 g tri-sodium citrate dihydrate in 
100 ml H2O 
  solution B: 
 29.41 g hydroxytricarballylic acid in 
1 l H2O 
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 2 ml solution A 
 98 ml solution B 
 ad 1 l H2O 
  pH 6.0 
Crystal violet staining solution 0.005% crystal violet solution 
 10% EtOH 
Electrophoresis buffer 25 mM Tris-Base/Tris-HCl 
 192 mM glycine 
 0.1% (w/v) SDS 
 ad 1 l H2O 
HCl alcohol 0.22% 1 l isopropanol 
 6 ml hydrochloric acid 37% 
Kanamycin 500 mg kanamycin 
  10 ml H2O 
Laemmli buffer (4x) 2 g 5 ml−1 SDS in H2O 
 10 mg bromophenol blue 
 40% (v/v) glycerol 
 20% (v/v) stacking gel buffer 
 20% (v/v) 2-mercaptoethanol 
MMP 5% 5% (w/v) MMP in TBST 
MTT lysis buffer 5% (v/v) formic acid in isopropanol 
MTT stock solution 5 mg ml−1 MTT in PBS 
P1 mini buffer 50 mM Tris-Base/Tris-HCl (pH 8.0) 
 10 mM EDTA 
 100 µg ribonuclease A 
 ad H2O 
P2 mini buffer 200 mM NaOH 
 1% SDS 
 ad H2O 
P3 mini buffer 3 M potassium acetate 
 ad H2O 
Peroxidase solution 3% 10% hydrogen peroxide 30% 
 90% PBS 
PFA solution 4% 24 g PFA 
 540 ml distilled water (dH2O) 
  solve at 60 °C 
 6–9 drops NaOH 
 60 ml 10x PBS 
  pH 7.3 
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Resolving gel buffer 1.5 M Tris-Base/Tris-HCl 
 2% (w/v) SDS 
  pH 8.8 
RIPA lysis buffer 50 mM Tris-Base/Tris-HCl (pH 7.2) 
 150 mM NaCl 
 0.1% (w/v) SDS 
 0.5% (w/v) Na-deoxycholate 
 1% Triton X-100 
  added fresh: 
 10x phosphatase inhibitor 
 100x protease inhibitor 
Stacking gel buffer 0.5 M Tris-Base/Tris-HCl 
 2% (w/v) SDS 
  pH 6.8 
Tris-acetate-EDTA (TAE) buffer 40 mM Tris-Acetate 
 1 mM EDTA 
 0.1% glacial acetic acid 
 ad H2O 
Tris-buffered saline with Tween20 (TBST) 20 mM Tris-Base/Tris-HCl 
150 mM NaCl 
ad 1 l H2O 
 pH 7.6 
0.1% (v/v) Tween20 
Tris-EDTA (TE) buffer 5 ml Tris-Base/Tris-HCl 
 1 ml EDTA 
 494 ml H2O 
  pH 8.0 
Triton X 0.5% 0.5% (v/v) Triton X-100 in PBS 
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2.1.6. Antibodies and fluorescent dyes 
The antibodies and fluorescent dyes used in this thesis are listed in Table 10. 
Table 10: Antibodies and fluorescent dyes. 
Name Source Label Application/Dilution Company/Cat. Nr. 










WB (1:1000 in BSA) 
Abcam (#ab59434) 
DAPI — — IF (1:1000) Sigma-Aldrich (#D8417) 
E-cadherin (24E10) Rabbit — 
IF (1:50), IHC (1:200), 
WB (1:1000 in BSA) 
Cell Signaling (#3195) 
E-cadherin (Clone 36) Mouse — WB (1:1000 in BSA) BD (#610181) 
Glial Fibrillary Acidic 
Protein 
Rabbit — IHC (1:200) Dako (#Z0334) 
HSP90α/β (F-8) Mouse — WB (1:5000 in BSA) Santa Cruz (#sc-13119) 
Iba-1 Rabbit — IHC (1:1000) Wako (#019-19741) 
Mouse IgG (H+L)-HRP Donkey HRP WB (1:10,000) Jackson (#715-035-150) 
Mouse IgG+IgM 
(H+L)-FITC 
Goat FITC IF (1:100) Dianova (#115-095-068) 




FITC IF (1:100) Sigma-Aldrich (#P5282) 
Phospho-YAP (Ser127) Rabbit — WB (1:1000 in MMP) Cell Signaling (#4911) 
Rabbit IgG (H+L)-Biotin Goat Biotin IHC (1:250) Dianova (#111-065-144) 
Rabbit IgG (H+L)-FITC Goat FITC IF (1:300) 
Thermo Fisher Scientific 
(#31635) 
Rabbit IgG (H+L)-HRP Donkey HRP WB (1:10,000) Jackson (#711-035-152) 
Rabbit IgG-HRP Goat HRP WB (1:2000) Santa Cruz (#sc-2004) 
Vimentin (D21H3) XP Rabbit — 
IF (1:50), IHC (1:100), 
WB (1:1000 in BSA) 
Cell Signaling (#5741) 
YAP (D8H1X) XP Rabbit — WB (1:1000 in MMP) Cell Signaling (#14074) 
β-Actin (AC-15) Mouse — WB (1:10,000 in BSA) Sigma-Aldrich (#A5441) 
β-Actin (C4) Mouse — WB (1:1000 in BSA) Santa Cruz (#sc-47778) 
β-Catenin (E-5) Mouse — 
IF (1:50), WB (1:1000 
in MMP) 
Santa Cruz (#sc-7963) 
BSA: bovine serum albumin, FITC: fluorescein isothiocyanate, HRP: horseradish peroxidase, 
IF: immunofluorescence, IHC: immunohistochemistry, MMP: modified milk powder, WB: Western blot 
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2.1.7. Oligonucleotides 
The oligonucleotides listed in Table 11 were designed with MIT server and used for shRNA constructs. 
Table 11: Oligonucleotides for shRNA constructs. 
Name Sequence (5′–3′) Source 
control-siRNA-F 
















The oligonucleotides listed in Table 12 were used for sequencing of vector constructs. 
Table 12: Sequencing primers for cloning vectors. 
Primer Used for vector Sequence (5′–3′) Source 
M13-seq-F pENTR CGTTGTAAAACGACGGCCAG Microsynth 
M13-seq-R pENTR CAGGAAACAGCTATGAC Microsynth 
hU6-seq-F pLKO.1 GGGCCTATTTCCCATGATTC Microsynth 
pLKO-seq-R pLKO.1 AAGTGGATCTCTGCTGTCCC Microsynth 
 
The primers for qRT-PCRs listed in Table 13 were designed with the PerlPrimer software. 
Table 13: Primers for qRT-PCR. 
Name Description Direction Sequence (5′–3′) Source 
mmBlvrb Biliverdin Reductase B 
Forward TAAGATTCTGCAAGAGTCAGG Sigma-Aldrich 
Reverse CCAGTTAGTGGTTGGTCTC  Sigma-Aldrich 
mmCDH1 Cadherin 1 
Forward GAAATCACATCTTATACCGCTC Sigma-Aldrich 
Reverse CGTCTTCTCTGTCCATCTC Sigma-Aldrich 
mmCLDN4 Claudin-4 
Forward CCAGCAACTATGTGTAAGGT Sigma-Aldrich 
Reverse GATAACAAAGGCAATGTGGA Sigma-Aldrich 
mmCLDN7 Claudin-7 
Forward CCGAATAGCTATGACTGGAG Sigma-Aldrich 




Forward GCTCTATGAGATCTTCACCTG Sigma-Aldrich 
Reverse GCAATGATATCTCCATTCTCG Sigma-Aldrich 
     
     






Forward CATCTTGGGCTACACTGAG Sigma-Aldrich 




Forward CTCAATGAGCTGCAATGTC Sigma-Aldrich 




Forward GTCTGCCTGGATAAGTACAG Sigma-Aldrich 
Reverse CTAGCTGAGTGTAGTTTACGT Sigma-Aldrich 
mmITGA2 Integrin Alpha-2 
Forward GGTCCTAAATTCATCTTCTCC Sigma-Aldrich 
Reverse TCTGTTTGTATCCCAGTCAG Sigma-Aldrich 
mmITGA3 Integrin Alpha-3 
Forward ATCAATGTGACCAATTCACC Sigma-Aldrich 





Forward CAACTGTGATAGGTCTAATGG Sigma-Aldrich 
Reverse ATAGCATTCACAAACACGAC Sigma-Aldrich 
mmKRT19 Cytokeratin-19 
Forward CACTACTTTAAGACCATCGAG Sigma-Aldrich 
Reverse ATCTGTAGGACAATCTTGGAG Sigma-Aldrich 
mmKRT8 Cytokeratin-8 
Forward ATGAACAAGGTGGAACTAGAG Sigma-Aldrich 
Reverse ATCTCCTCTTCATGGATCTG Sigma-Aldrich 
mmL1CAM 
L1 cell adhesion 
molecule 
Forward CCCACTTAGGATCTACTGGA Sigma-Aldrich 





Forward CTTTACCTCCTATGCAACGA Sigma-Aldrich 
Reverse ACCTTGTTGGTTATCCTCTG Sigma-Aldrich 
mmPAK2 
p21 (RAC1) Activated 
Kinase 2 (DPYSL3-
Interacting Kinase) 
Forward AAGTTCTACGACTCCAACAC Sigma-Aldrich 




Forward TGTCCAAACTAGGAGATGTC Sigma-Aldrich 
Reverse CCTTGGCAAAGTAGTTCAG Sigma-Aldrich 
mmSNAI1 
Snail Family Zinc 
Finger 1 
Forward TGAAGATGCACATCCGAAGC Sigma-Aldrich 
Reverse CAGTGGGAGCAGGAGAATG Sigma-Aldrich 
mmSNAI2 
Snail Family Zinc 
Finger 2 
Forward CAAGGACACATTAGAACTCAC Sigma-Aldrich 




Transcription Factor 1 
Forward GTACATCGACTTCCTGTACCA Sigma-Aldrich 




Transcription Factor 2 
Forward TACATAGACTTCCTCTACCAGG Sigma-Aldrich 
Reverse GGTCATCTTATTGTCCATCTCG Sigma-Aldrich 
mmVimentin Vimentin 
Forward CGGCTGCGAGAGAAATTGC Sigma-Aldrich 






Forward CATGGACGAGATGGATACAG Sigma-Aldrich 
Reverse GAGAGGGATCAGATCTTCAG Sigma-Aldrich 





Forward AACACAAGTAACCTCATCCT Sigma-Aldrich 




Forward GTTACAGATGGAGAAGGAGAG Sigma-Aldrich 
Reverse GATTGATATTCCGTATTGCCTG Sigma-Aldrich 
mmZEB1 
Zinc Finger E-box 
Binding Homeobox 1 
Forward CAGTATTACCAGGAGGCA Sigma-Aldrich 
Reverse CACACTCGTTGTCTTTCAC Sigma-Aldrich 
mmZEB2 
Zinc Finger E-box 
Binding Homeobox 2 
Forward CCACGATCCAGACCACAATTA Sigma-Aldrich 
Reverse TACTCTTCGATGCTCACTGC Sigma-Aldrich 
 
2.1.8. Plasmids 
The plasmids used in this thesis are listed in Table 14. 
Table 14: Plasmids. 
Plasmid Characteristic 
Bacterial resistance 
in E. coli 
Selectable marker Source 












Neo DEST (685-3) 
Gateway destination 
vector 
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2.1.9. Enzymes 
The specific enzymes and restriction enzymes used in this thesis are listed in Table 15 and Table 16. 
Table 15: Specific enzymes. 
Name Buffer Source 
FAST-alkaline phosphatase (AP) 10x FAST-AP buffer Thermo Fisher Scientific 
T4 DNA ligase T4 ligase buffer Thermo Fisher Scientific 
T4 polynucleotide kinase (PNK) 10x PNK reaction buffer A Thermo Fisher Scientific 
DNase I (10 U μl−1) 10x DNase I incubation buffer Roche 
Ribonuclease A — Roth 
 
Table 16: Restriction enzymes. 
Name Restriction site Buffer Source 
BshT I (AgeI) A/CCGGT 10x orange Fermentas/Thermo Fisher Scientific 
EcoRI G/AATTC 10x EcoRI buffer Fermentas/Thermo Fisher Scientific 
NdeI CA/TATG 10x orange Fermentas/Thermo Fisher Scientific 
PsyI (Tth111I) GACN/NNGTC 10x blue Fermentas/Thermo Fisher Scientific 
 
2.1.10. Commercial kits 
The commercial kits used in this thesis are listed in Table 17 and were used according to 
manufacturer’s instructions. 
Table 17: Commercial kits. 
Product Utilization Company 
BrdU cell proliferation ELISA kit Measuring cell proliferation Abcam 
Clarity Western ECL substrate Developing Western blot Bio-Rad 
Dako REAL detection system, alkaline 
phosphatase/RED, rabbit/mouse 
IHC stainings Dako 




Gateway LR Clonase II enzyme mix LR Clonase reaction Thermo Fisher Scientific 
High Pure RNA isolation kit RNA preparation Roche 
iScript cDNA synthesis kit cDNA synthesis Bio-Rad 
iTaq Universal SYBR Green supermix qRT-PCR Bio-Rad 
Liquid DAB+ substrate chromogen system IHC stainings Dako 
MycoAlert mycoplasma detection kit Mycoplasma test Lonza 
Nucleo Bond PC 20/100 Midi-preparation Magery-Nagel 
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Nucleo Spin gel and PCR clean-up Vector purification Magery-Nagel 
SignalFire ECL reagent Developing Western blot Cell Signaling 
Trans-Blot Turbo RTA mini nitrocellulose 
transfer kit 
Western blot Bio-Rad 
ZytoChem Plus (HRP) Anti-Rabbit kit IHC stainings Zytomed Systems 
 
2.1.11. Consumables and instruments 
The consumables and instruments used in this thesis are listed in Table 18. 
Table 18: Consumables and instruments. 
Product Company 
10 cm petri dish (coated) Sarstedt 
10 cm petri dish (un-coated) Sarstedt 
10 mm low-phytoestrogen and soy-free diet SSNIF 
384-well plates (FrameStar skirted PCR plate) 4titude 
96 Biosphere filter tips (0.1–10 µl) Sarstedt 
96 Biosphere filter tips (2–20 µl) Sarstedt 
96-well plates Nunc 
Alu foil Roth 
Amersham Protran membrane (0.45 μm, nitrocellulose) Sigma-Aldrich 
Autoclavable bags SteriClin 
Bone wax B. Braun 
Bulb-headed probe Wameda 
Cell culture flasks (25/75 cm2) Sarstedt 
Cell scrapper (25 cm) Sarstedt 
Centrifuge tubes (15/50 ml) Sarstedt 
Combitips advanced (0.1 ml) Eppendorf 
Cryotubes (1.8 ml) Thermo Fisher Scientific 
Disposable glass pasteur pipettes (230 mm) VWR 
Disposable pestle tissue homogenizer (1.5 ml) VWR 
Dubois decapitation scissors, curved end Hermle 
Embedding cassettes UniLink R. Langenbrinck GmbH 
ES-Compresses Hartmann 
Folded filters (Qual.) (Ø 240 mm) Sartorius 
Gauze balls Gazin 
Glass coverslips (18 × 18 mm) Carl Roth 
Glass coverslips (Ø 12 mm) Carl Roth 
Graduated filter tips, TipOne (10/100/1000 μl) Sarstedt 
Hamilton microliter syringe (701N) (10 μl) VWR 
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Immersol 518F oil Carl Zeiss 
Iris scissors, straight Hermle 
Micro tube (1.5 ml) Sarstedt 
Microscope slides (25 × 75 × 1 mm) Thermo Fisher Scientific 
Microtome blades R-35 Feather 
Multiply-Pro cup (0.2 ml) Sarstedt 
Nitril extra-sensitive gloves Nitrisense 
Nitrocellulose blotting membrane (0.45 µm) GE Healthcare Life Sciences 
Noyes eye scissors, straight pattern Hermle 
Nuclease-free reaction tubes (0.5/1.5 ml) Eppendorf 
Parafilm M laboratory film Pechiney Plastic packaging 
pH indicator sticks T.H. Geyer 
Pipette tips (10/20/200/1000 µl) Sarstedt 
Pipette tips, epT.I.P.S. standard (10/100/1000 μl) Eppendorf 
Polycarbonate membrane (10 μm pore size) Pieper Filter 
qPCR adhesive clear seal 4titude 
Reaction tubes (0.2/0.5/1.5/2 ml) Sarstedt 
Rotilabo blotting papers (1.5 mm) Carl Roth 
SafeSeal micro tube (2 ml) Sarstedt 
Safety-Multifly-Set infusion cannulas Sarstedt 
Sample vials T.H.Geyer 
Semkin standard forceps Hermle 
Seralon polyamide suture (DR-009, USP 7/0, EP 0.5) Serag-Wiessner GmbH 
Serological pipettes (2/5/10 ml) Sarstedt 
Serological pipettes (10/50 ml) Greiner Bio-one 
Serological pipettes (25 ml) Nerbe Plus 
Serological pipettes, Stripetten (2/5 ml) Corning 
Sterican needle (22G, 27G) B. Braun 
Sterile scalpel Feather 
Syringe with Luer-Lok connection fitting (1/5/10 ml) B. Braun 
TC plates (6/12/24/96-well) Sarstedt 
TC dish 150, standard  Sarstedt 
Tissue forceps, straight pattern Hermle 
Trans-Blot Turbo mini nitrocellulose transfer pack Bio-Rad 
Trans-Blot Turbo mini-size nitrocellulose membranes Bio-Rad 
Trans-Blot Turbo mini-size transfer stacks Bio-Rad 
Wecker spatula Hermle 
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2.1.12. Equipment 
The lab equipment used in this thesis is listed in Table 19. 
Table 19: Equipment. 
Product Label Company 
Analytical balance R180D Sartorius 
Autoclave 5050 ELV Tuttnauer 
Autoclave Varioklav 135S HP Medizintechnik GmbH 
Automatic flake ice machine Scotsman AF100 Scotsman 
Block thermostat HLC BT 130 Ditabis/HLC 
Cell counting chamber Neubauer Improved  LO Laboroptik Marienfeld 
Cell culture incubator CB 160 Binder 
Cell culture incubator Heraeus Thermo Fisher Scientific 
Centrifuge Biofuge 15 Sepatech 
Centrifuge Biofuge fresco Thermo Fisher Scientific 
Centrifuge Biofuge pico Thermo Fisher Scientific 
Centrifuge CT15RE Himac 
Centrifuge Microstar 12 VWR 
Chemical balance BL 1500 S Sartorius 
Chemical balance L610D Sartorius 
Chemical balance SI-2002A Denver Instrument 
Chemiluminescence system ImageQuant LAS-4000 Fujifilm 
CO2 incubator BB 6220 Heraeus Instruments 
Confocal laser scanning microscope Leica TCS SP8 Leica Microsystems 
Cooling plate CP 60 Microm 
Drying cabinet UT6200 Heraeus Instruments 
Drying chamber UT 6120 Thermo Fisher Scientific 
Ductless recirculating fume hood CaptairBio I-130 Erlab 
Electric pipetting aid Accu-jet pro Brand 
Electric pipetting aid Pipetboy Integra 
Electrophoresis power supply EPS 301 Amersham Pharmacia Biotech 
Electrophoresis power supply LKB GPS200/400 Pharmacia 
Electrophoresis system Mini-PROTEAN Tetra cell Bio-Rad 
ELISA reader TECAN Sunrise Infinite F50 Tecan Group 
Floor centrifuge Varifuge 3.0 RS Heraeus Instruments 
Gel imaging system Gel Doc XR+ Bio-Rad 
Heating and drying table MEDAX  Medax 
Heating/shaking block Thermomixer 5436 Eppendorf 
Heating/shaking block Thermomixer R Eppendorf 
Incubator shaker Unitron Infors HT 
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Inverted microscope PrimoVert Carl Zeiss 
Laminar air flow bench LaminAir HB2472 Heraeus Instruments 
Laminar flow hood Herasafe HS18 Heraeus Instruments 
Light microscope Eclipse TS100 Nikon 
Light microscope Olympus CX40  Olympus 
LightCycler QuantStudio 5, 384-well Thermo Fisher Scientific 
Light/fluorescence microscope EVOS FL Thermo Fisher Scientific 
Magnetic stirring bar retriever MR3001 Heidolph Instruments 
Magnetic stirrer and heating plate IKA RCT  Ikamag 
Microliter pipette, automatical Multipette plus Eppendorf 
Microliter pipettes 
100–1000µl, 20–200µl,   
2–20µl, 0.2–2µl 
Gilson/Eppendorf 
Microwave 8018 E Privileg 
Microwave KOR 6D07SL Daewoo 
Mini centrifuge ProFuge 10K Stratagene 
Mini shaker IKA MS2  IKA Lab equipment 
Mini shaker Sunflower 3D BioSan 
pH meter 538 MultiCal WTW 
pH meter CG842 Schott 
Platform shaker Duomex 1030 Heidolph Instruments 
Power supply Standard Power Pack P25 Biometra  
Roller shaker RS-TR05 Phoenix Intrument 
Single-lens reflex camera Canon EOS 600D  Canon 
Slides scanner system Pannoramic 250 Sysmex 
Sliding microtome HM 400 R Microm 
Spectrophotometer NanoDrop 1000 Thermo Fisher Scientific 
Spectrophotometer NanoDrop 2000  Thermo Fisher Scientific 
Stereotaxic drill Jacobs Chuck (18,000 rpm) Kopf Instruments 
Surface shaker Reax 3 Heidolph Instruments 
Table centrifuge 5810R Eppendorf 
Table centrifuge Allegra X-15R Beckman Coulter 
Table centrifuge Megafuge 1.0 Sepatech Kendro Laboratory Products 
Table centrifuge Megafuge 3.0R Heraeus Instruments 
Table centrifuge Multifuge 3 Heraeus Instruments 
Thermal cycler PTC-200 MJ Research 
Tissue float bath GFL 1052 GFL 
Transilluminator Ultraviolet (UV) slider Intas 
Tumble mixer RM5 Nichols Institute Diagnostics 
Ultra-precise small animal 
stereotaxic instrument 
Model 963 Kopf Instruments 
Vortex shaker REAX 2000 Heidolph Instruments 
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Vortex shaker Vortex Genie 2 Intas 
Water bath SW-20C Julabo GmbH 
Water purification system MilliQ  Millipore 
Western blot transfer system Trans-Blot SD Semi-Dry  Bio-Rad 
Western blot transfer system Trans-Blot Turbo Bio-Rad 
 
2.1.13. Software products and databases 
The software products and databases used in this thesis are listed in Table 20. 
Table 20: Software products and databases. 
Product Utilization Company 
BioGPS (database) Database for gene and protein function BioGPS 
CaseViewer (version 2.3) Imaging editor for slide images 3DHISTECH Ltd. 
DNA Dynamo (version 1.498) Theoretical cloning, sequence analysis 
Blue Tractor 
Software Ltd 
EndNote (version X8.2) Citation program Clarivate Analytics 
Genevestigator (version 7) Designing primers Nebion AG 
GraphPad Prism (version 7) Graphs and statistics GraphPad Software 
Heatmapper (online tool) Creating heatmaps omicX 
Image Lab (on device) Image analysis of agarose gels Bio-Rad 
ImageJ (win64) (version 1.51s) Analyzing data, editing pictures Wayne Rasband 
ImageQuant LAS 4000 (on device) Chemiluminescence imaging Fujifilm 
LAS X (Leica Application Suite X) 
(version 3.7) 
Imaging editor for confocal images Leica Microsystems 
Microsoft Office 2013 
Managing data, writing text, 
editing pictures 
Microsoft 




Database for genomic information, 
BLAST tool 
NCBI 
PerlPrimer (version 1.1.21) Designing primers (Marshall, 2004) 
QuantStudio Design & Analysis 
(version 1.5.0) 










2.2.1.1. Knockdown vector 
For generation of stable cell lines showing a downregulation of E-cadherin, short hairpin RNA (shRNA) 
vectors had to be constructed. An overview of the cloning workflow is shown in Figure 9. 
 
Figure 9: Knockdown vector workflow. For the construction of a knockdown vector, shRNA insert and 
vector are prepared with restriction enzymes, ligated and amplified in bacteria. After successful 
delivery to a cell nucleus, double-stranded RNA is continuously expressed from the construct in the 
nucleus, transported into the cytoplasm and leads to permanent silencing of the gene of interest. 
Modified from (http://www.addgene.org/protocols/plko/). 
 
Designing tools were used to identify active E-cadherin shRNA sequences as well as a control shRNA 
sequence (scrambled shRNA) and oligonucleotides were ordered from a synthesizing company 
(Microsynth). These short pieces of synthetic single-stranded DNA, which were complementary to the 
target messenger RNA (mRNA), were then fused to double-stranded inserts. Both ends were designed 






















MATERIALS AND METHODS  36 
 
After introduction of the vector construct into a host cell and successful delivery to the cell nucleus, 
double-stranded RNA was continuously expressed from the construct in the nucleus and transported 
into the cytoplasm. There it could bind target mRNA and inactivate it, which in turn caused sequence-
specific gene silencing. 
2.2.1.1.1. shRNA insert preparation 
Preparation of the shRNA insert included oligonucleotide phosphorylation, denaturation of all 
secondary structures and annealing of complementary strands. 
2.2.1.1.1.1. Phosphorylation of oligonucleotides 
Reagents 
 Oligonucleotide forward (100 µM) 
 Oligonucleotide reverse (100 µM) 
 T4 polynucleotide kinase 
 10x PNK reaction buffer A 
 ATP (2 mM) 
Procedure 
For each shRNA, 5 µl oligonucleotide forward, 5 µl oligonucleotide reverse, 1 µl buffer, 0.5 µl ATP and 
0.5 µl PNK were mixed together in small tubes and the mixture was incubated overnight at 37 °C. On 
the next day, PNK was heat-inactivated for 10 min at 75 °C and the phosphorylated oligonucleotides 
were centrifuged down shortly. 
2.2.1.1.1.2. Annealing of phosphorylated oligonucleotides 
For the annealing of the phosphorylated oligonucleotides, 15 µl TE buffer was added, vortexed shortly 
and boiled for 2 min at 95 °C. The tube was cooled down to room temperature (RT) for 1 h and stored 
on ice. 
2.2.1.1.2. Vector preparation 
The pLKO.1 vector had to be prepared for shRNA construct insertion. One of the most common 
methods in molecular biology is cloning by restriction digest. Insert and expression vector have to be 
formerly designed or digested to create compatible ends. This enables the cloning of the desired insert 
into a certain expression vector. Agarose gel electrophoresis can be used to purify the digested vector 
from any undigested rests. To minimize the risk of re-ligation the vector is cut with two enzymes and 
dephosphorylated using alkaline phosphatase.  
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2.2.1.1.2.1. Cutting of vector 
Reagents 
 Restriction enzymes (AgeI + EcoRI) 
 10x Compatible restriction buffer 
 pLKO.1 puro plasmid 
Procedure 
1 µg plasmid, 4 µl buffer and 2 µl enzyme were filled up with double-distilled water (ddH2O) to a total 
volume of 40 µl, mixed well and centrifuged down for 20 s at 16,000 g. The mixture was incubated 
overnight at 37 °C and the digested vector was purified from a 1% methylene blue stained agarose gel 
on the next day. 
2.2.1.1.2.2. Agarose gel electrophoresis 
Agarose gel electrophoresis is a common method used to purify cutted vectors after plasmid digestion 
and for control digestion of plasmid DNA. For vector purification, the agarose gels were stained with 
methylene blue and for plasmid DNA control digestion they were stained with ethidium bromide. 
As both chemicals incorporate into double-stranded DNA, they could be visualized directly in the gel 
(methylene blue) or under UV light (EtBr). Molecular weight markers were used to determine the 
molecular size of the DNA product. 
Reagents 
 Agarose 
 TAE buffer 
 Ethidium bromide (10 mg ml−1) (for control digestion of plasmid DNA) 
 Methylene blue (for purification of digested vector) 
 Loading dye (6x DNA gel loading dye, 6x Orange DNA loading dye) 
 Standard (Gene Ruler 1 kb DNA ladder, 50 bp DNA ladder) 
Procedure 
0.7 g agarose was boiled with 70 ml TAE buffer. For control digestion of plasmid DNA, 20 µl ethidium 
bromide was added to the melted agarose. The gel mixture was poured in the gel holder, the gel comb 
was inserted and polymerization took place for 1 h at RT. The gel was then placed in the gel box 
(electrophoresis unit), fully covered with TAE buffer and the gel comb was removed. 4 μl loading dye 
was added to 20 μl of each sample and 10 μl DNA ladder standard solution and the samples were 
loaded in the wells. The electrophoresis was performed for approximately 30 min at 130 V. The bands 
were visualized with methylene blue or under UV light in case of EtBr addition. 
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2.2.1.1.2.3. Purification of vector 
The required band was cut out from the methylene-blue stained gel as accurate as possible and 
transferred into a 1.5 ml Eppendorf tube. Then the desired cutted vector was purified with the 
Nucleo Spin Gel and PCR Clean-Up Kit according to the manufacturer’s instructions. 
2.2.1.1.2.4. Dephosphorylation of vector 
To avoid the re-ligation of the digested and purified vector, the 5′ end had to be dephosphorylated. 
Reagents 
 Purified vector 
 FAST-AP 
 10x FAST-AP buffer 
Procedure 
26 µl of the purified vector was mixed with 3 µl buffer and 1 µl FAST-AP. The mixture was centrifuged 
shortly and incubated at least 30 minutes at 37 °C before the enzyme was heat-inactivated for 20 min 
at 75 °C. 
2.2.1.1.3. Ligation of construct 
The ligation of shRNA insert and vector was the last step of the cloning procedure. 
Reagents 
 T4 DNA ligase 
 T4 ligase buffer 
 pLKO.1 vector, digested and purified 
 shRNA insert 
Procedure 
Three ligations were set up according to Table 21. The ligations were incubated 3 h at RT or overnight 
at 16 °C and then transformed into DH5alpha competent cells and plated on ampicillin plates as 
explained later (see 2.2.1.3). 
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Table 21: Setup for construct ligation. 
 Control Ligation 
ddH2O 17.25 µl 16.25 µl 
T4 ligase buffer 2 µl 2 µl 
Insert — 1 µl 
Vector 0.5 µl 0.5 µl 
T4 DNA ligase 0.25 µl 0.25 µl 
 
2.2.1.2. Overexpression vector 
For generation of stable cell lines showing an upregulation of E-cadherin, expression vectors had to be 
constructed. After introduction of the vector construct into a host cell and successful delivery to the 
cell nucleus, E-cadherin mRNA was continuously expressed from the construct in the nucleus and 
transported into the cytoplasm where it was translated into protein at the ribosomes. As the parental 
cell lines showed different resistances to selection antibiotics, different expression vectors were 
required. For speed and efficiency, the Gateway cloning technology was chosen. It has been developed 
by Invitrogen to easily insert a gene of interest (GOI) into various destination vectors for usage in cell 
culture without labor-intensive and time-consuming procedures like in classical molecular cloning 
processes. 
2.2.1.2.1. Gateway cloning technology 
2.2.1.2.1.1. Preparation of Gateway entry vector 
In the first step, the GOI had to be cloned into an entry vector. The entry vector containing the mouse 
E-cadherin gene cassette (pENTR-Cdh1) was a gift from Jamie Davies (Addgene plasmid #49776; 
http://n2t.net/addgene:49776; RRID:Addgene_49776). 
2.2.1.2.1.2. Transfer of gene cassette into Gateway destination vector 
In the second step, the GOI from the entry vector had to be subcloned into a destination vector using 
an enzyme-mediated site-specific recombination reaction (LR reaction) which produced the expression 
vector (Figure 10).  
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Figure 10: Step 2 of Gateway cloning technology. The entry vector is transcriptionally silent and 
contains the gene of interest (GOI) flanked by the attL1 and attL2 recombination sites as well as the 
gene for kanamycin resistance (kanR). In order to produce the desired expression vector, the GOI has 
to be subcloned into a destination vector that contains all the sequence information necessary for 
expression: two recombination sites (attR1 and attR2) that flank a gene for negative selection, ccdB 
(the encoded protein is toxic for the standard E. coli strains) and the gene for ampicillin resistance 
(ampR). Both plasmids are mixed and the LR Clonase enzyme mix is added. In a directional specific 
reaction, attL1 reacts with attR1 and attL2 with attR2. Two constructs, the intended expression vector 
and a by-product, are the result of this recombination. Two forms of selection, the antibiotic resistance 
and the negative selection by the toxic ccdB protein, affect the expression vector and ensure high levels 




 Destination vectors (pLX302 and pLenti CMV/TO Neo DEST (685-3)) 
 Entry vector (pENTR-Cdh1) 
 Gateway LR Clonase II enzyme mix 
Procedure 
50 ng destination vector, 75 ng entry vector and 0.25 µl LR Clonase were mixed to a total volume of 
5 µl with ddH2O, centrifuged shortly and incubated for at least 2 h at 25 °C. Afterwards, 2 µl LR reaction 
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2.2.1.3. Transformation of chemically competent E. coli cells 
This method is used to transfer a desired ligated plasmid into bacterial cells for cultivation and 
amplification of the amount of plasmid. In this thesis, the E. coli strains DH5alpha and DB3.1 were used 
for transformation. The cells became competent by the CaCl2 method, which made the cell membrane 
permeable to plasmid DNA. An overview of the amplified plasmids with the respective competent 
E. coli strains and selection antibiotics is shown in Table 22. 
Table 22: Overview of amplified plasmids. 
Plasmid Competent E. coli strain Selection antibiotic 
pENTR-Cdh1 DH5alpha Kanamycin 
pLenti CMV/TO Neo DEST (685-3) DB3.1 Chloramphenicol + Ampicillin 
pLenti-mE-cadherin DH5alpha Ampicillin 
pLKO.1 DH5alpha Ampicillin 
pLKO.1-mE-cadherin-shRNA DH5alpha Ampicillin 
pLKO.1-scrambled-shRNA DH5alpha Ampicillin 
pLX302 DB3.1 Chloramphenicol + Ampicillin 
pLX302-mE-cadherin DH5alpha Ampicillin 
 
Reagents 
 Competent E. coli cells (DH5alpha, DB3.1) 
 Vector (ligation mix or LR reaction mix) 
 LB medium 
 LB plates with appropriate antibiotic (selection plates) 
Procedure 
A tube of competent E. coli cells was slowly thawed on ice. Plasmid DNA (20 µl of the ligation mix or 
2 µl of the LR reaction mix) was added to the cells, flicked and the mixture was incubated on ice for 
30 min. Heat shock was performed for 1 min at 42 °C and the mixture was placed back on ice for 5 min. 
Next, 200 μl pre-warmed (37 °C) LB medium without antibiotics was added and the mixture was 
shacked for 30 min at 37 °C. Meanwhile, selection plates were pre-warmed at 37 °C. Finally, the 
mixture was spread onto a selection plate and incubated inverted overnight at 37 °C. 
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2.2.1.4. DNA preparation 
After the transformation process, in which vector DNA was amplified only in selected cells containing 
the vector of interest, the DNA had to be isolated. In the first step of DNA preparation, cells from grown 
colonies were picked from the plate with sterile tips and inoculated in 2 ml LB medium (overnight) or 
YTA medium (several hours) supplemented with 2 µl appropriate selection antibiotic (see 2.2.1.3). 
After amplification overnight at 37 °C with continuous agitation, the mini-preparation and following 
midi-preparation were used to isolate the plasmid DNA. 
2.2.1.4.1. Mini-preparation 
The mini-preparation of plasmid DNA is a small-scale isolation of plasmid DNA from bacteria used to 
test constructs after restriction digestion on agarose gels and select positive clones for further 
amplification. 
Reagents 
 P1 mini buffer 
 P2 mini buffer 
 P3 mini buffer 
 100% EtOH 
 70% EtOH 
Procedure 
1.5 ml of the overnight culture was poured into an Eppendorf tube and centrifuged for 1 min at 3500 g. 
The pellet was resuspended in 100 μl P1 mini buffer. 200 μl P2 mini buffer was added and vortexed. 
After addition of 150 μl P3 mini buffer, tubes were inverted 3–4 times. The samples were centrifuged 
for 6 min at 19,000 g at 4 °C while new tubes with 900 μl 100% EtOH were prepared. The supernatant 
was transferred into the prepared tubes and mixed well by inverting 6–8 times. The samples were 
centrifuged for 12 min at 21,500 g at 4 °C and the supernatant was discarded. The pellets were washed 
with 1 ml 70% EtOH and centrifuged for 3 min at 19,000 g. Supernatant was removed completely and 
the pellets were dried at 65 °C in an incubator and finally dissolved in 25 μl ddH2O. 
2.2.1.4.2. Restriction digestion 
In the next step, isolated plasmid DNA was tested for positive insertion of desired construct. Restriction 
enzymes were used to cut the plasmid DNA in a site-specific manner and agarose gel electrophoresis 
was used to separate different band patterns and identify plasmids with correct insertion. 
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The enzymes used for restriction digestion of each plasmid and expected positive band patterns are 
shown in Table 23. 
Table 23: Setup for restriction digestion of plasmids. 
Plasmid Restriction enzymes Expected positive band sizes 
pLenti-mE-cadherin PsyI (= Tth111I) 7192 bp + 3674 bp 
pLKO.1 puro for all shRNAs NdeI + EcoRI 6958 bp + 126 bp 
pLX302-mE-cadherin PsyI (= Tth111I) 8750 bp + 1907 bp 
 
Reagents 
 Plasmid DNA from mini-preparation 
 Appropriate buffer 
 Restriction enzymes 
Procedure 
10 µl plasmid DNA, 2 µl buffer and 0.5 µl of each restriction enzyme were mixed with ddH2O to a final 
volume of 20 µl and incubated for 1 h at 37 °C. Agarose gel electrophoresis was performed as described 
previously (see 2.2.1.1.2.2) and band patterns were verified in a transilluminator under UV light. 
2.2.1.4.3. Midi-preparation and sequencing 
The midi-preparation of plasmid DNA is a large-scale isolation of plasmid DNA from bacteria used to 
produce large amounts of the construct for later usage (for example, lentiviral particle production). 
After successful control digestion, the positive clones could be inoculated for further amplification and 
midi-preparation. An Erlenmeyer flask was prepared with 55 ml LB medium and 55 µl appropriate 
selection antibiotic (see 2.2.1.3). 5 µl of the remaining overnight mini-cultures was added to the flasks 
and midi-cultures were incubated overnight at 37 °C with continuous agitation. On the next day, the 
midi-cultures were centrifuged, plasmid DNA was purified with the Nucleo Bond PC 20/100 kit 
according to the manufacturer’s instructions, and a sample was sent to Microsynth AG for further 
sequencing. 
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2.2.2. Cell culture methods 
2.2.2.1. Maintenance of murine tumor cell lines 
Tumor cells were cultivated at 37 °C and 5% CO2 in a humidified incubator. They were passaged twice 
a week by washing once with PBS, detaching by incubation with 1 ml 1x Trypsin-EDTA for up to 15 min 
and splitting in a ratio of 1:5–1:20. All experiments were performed with mycoplasma-free cells 
confirmed by regular tests. For maintenance of various cell lines over a longer period, they were frozen 
in dimethyl sulfoxide with 90% FCS and stored in liquid nitrogen. An overview of all cell lines with 
respective media and supplements is shown in Table 24. 
Table 24: Cell lines with respective media and supplements. 
Cell line Culture medium Supplement Selection antibiotic 
410.4 DMEM (1 g l−1) 10% FCS — 
410.4-pLKO.1-mE-cadherin-shRNA DMEM (1 g l−1) 10% FCS 1 µg ml−1 puromycin 
410.4-pLKO.1-scrambled-shRNA DMEM (1 g l−1) 10% FCS 1 µg ml−1 puromycin 
CMT93Var DMEM (1 g l−1) 10% FCS — 
CMT93Var-pLKO.1-mE-cadherin-shRNA DMEM (1 g l−1) 10% FCS 1 µg ml−1 puromycin 
CMT93Var-pLKO.1-scrambled-shRNA DMEM (1 g l−1) 10% FCS 1 µg ml−1 puromycin 
CT26 RPMI 1640 10% FCS — 
CT26-pLenti-empty RPMI 1640 10% FCS 400 µg ml−1 G418 
CT26-pLenti-mE-cadherin RPMI 1640 10% FCS 400 µg ml−1 G418 
E0771-LG RPMI 1640 10% FCS — 
E0771-LG-pLX302-empty RPMI 1640 10% FCS 1 µg ml−1 puromycin 
E0771-LG-pLX302-mE-cadherin RPMI 1640 10% FCS 1 µg ml−1 puromycin 
HEK293T DMEM (4.5 g l−1) 10% FCS — 
 
2.2.2.2. Lentivirus-mediated gene delivery (transduction) 
Cell lines with stable knockdown or overexpression of the cell adhesion protein E-cadherin were 
generated through shRNA-mediated gene silencing or introduction of expression vectors by lentivirus-
mediated gene delivery. After transduction, lentiviral vectors could integrate into the nucleus of the 
target cells and led to stable expression of the gene of interest. The following procedures were carried 
out in a S2 cell culture lab and 1% P/S was added to the culture medium to avoid contaminations. 
2.2.2.2.1. Lentiviral particle preparation 
For virus preparation, 8 × 106 HEK293T cells were seeded in a 150 mm cell culture dish and allowed to 
adhere overnight to reach a confluence of 80%. On the next morning, the medium was replaced with 
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20 ml serum-free DMEM (4.5 g l−1 glucose). 15 µg lentiviral plasmid, 3.75 µg enveloping plasmid 
pMD2.G and 11.25 µg packaging plasmid pCMV-dR8.2-dvpr were mixed with DMEM (4.5 g l−1 glucose) 
to a total volume of 1230 µl, vortexed and 120 µl polyethylenimine was added. The mixture was 
vortexed again for 10 s, incubated for 15 min at RT and added dropwise to the cells. Plates were 
incubated for 6 h at 37 °C before the medium was replaced with 30 ml DMEM (4.5 g l−1 glucose) with 
10% FCS.  
For virus collection, the medium was collected after 72 h and centrifuged for 15 min at 3000 g to 
remove large cell particles. The supernatant was transferred into new tubes and centrifuged for 2 h at 
75,000 g and 4 °C to pellet viral particles. The pellet was dissolved in 150 µl DMEM (4.5 g l−1 glucose) 
with 10% FCS by gentle pipetting and left on ice overnight at 4 °C. On the next morning, the viral 
particle suspension was mixed again and frozen in small aliquots at −80 °C.  
2.2.2.2.2. Transduction of target cells 
The day before transduction, tumor cells were seeded in 100 mm cell culture dishes and allowed to 
adhere overnight to reach a confluence of 60–80%. On the next morning, the medium was replaced 
with only 8 ml of the appropriate culture medium with 10% FCS. 8 µl Polybrene (8 mg ml−1) and 50 µl 
of the viral particle suspension was simultaneously added dropwise to the plate and evenly distributed 
by gentle circular movements. Plates were incubated for 6 h at 37 °C before the medium was replaced 
with 10 ml of the appropriate culture medium with 10% FCS. On the next day, appropriate selection 
antibiotics (puromycin or G418) were added and plates were incubated to get rid of any untransduced 
tumor cells. The selection medium was replaced every other day until single colonies remained. 
2.2.2.2.3. Selection of single clones 
Single clones were selected using a microscope, picked with sterile tips and transferred into 24-well 
plates containing appropriate culture medium with 10% FCS and selection antibiotics. Cells were 
expanded by appropriate cell-culture techniques until sufficient cell numbers were available for 
protein isolation to quantify the expression level of E-cadherin by Western blot analysis (see 2.2.4). 
Positive clones were further expanded in 100 mm cell culture dishes. 
2.2.2.2.4. Viral particle test 
The absence of any viral particles in the modified cell lines was confirmed by a marker rescue assay 
(Forestell et al., 1996). Virus test cell lines were chosen according to their sensitivity to selection 
antibiotics of modified cell lines confirmed by antibiotic kill curves. An overview of the test setup is 
shown in Table 25. Modified cells were incubated for 48 h in culture medium without selection 
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antibiotic. Meanwhile, 2 × 106 virus test cells were seeded in 100 mm cell culture dishes and allowed 
to adhere overnight to reach a confluence of 50%. On the next morning, the medium of the modified 
cell lines was collected and centrifuged for 15 min at 3000 g to remove large cell particles. The medium 
of the virus test cell lines was replaced with the supernatant and 10 µl Polybrene (8 mg ml−1) was added 
dropwise to the plates and evenly distributed by gentle circular movements. Plates were incubated for 
72 h at 37 °C before appropriate selection antibiotics were added and plates were further incubated 
for up to two weeks. The selection medium was replaced every other day and confluence of remaining 
cells was assessed until no surviving cells were visible (virus test negative) or single colonies remained 
(virus test positive). In the latter case, the procedure had to be repeated. Viral particle-free modified 
cell lines could be then transferred into a S1 cell culture lab. 
Table 25: Setup for viral particle test. 
Modified cell line Virus test cell line Selection antibiotic 
410.4-pLKO.1 variants HEK293T 0.75 µg ml−1 puromycin 
CMT93Var-pLKO.1 variants HEK293T 0.75 µg ml−1 puromycin 
CT26-pLenti variants 410.4 1000 µg ml−1 G418 
E0771-LG-pLX302 variants HEK293T 0.75 µg ml−1 puromycin 
 
2.2.2.2.5. Stability of transduction 
The modified cell lines were cultivated in the absence of selection antibiotics for up to four weeks and 
protein lysates were isolated once a week. Stability of transduction was confirmed by Western blot 
analysis (see 2.2.4). This was essential for subsequent animal experiments without use of antibiotics. 
2.2.2.3. Assessment of cell viability and proliferation 
In the beginning, cell lines were tested for basic features such as cell viability and proliferation. 
All cellular assays were conducted at least in triplicate and in case of modified tumor cell lines in culture 
media without selection antibiotics. 
2.2.2.3.1. Cell proliferation 
To assess cell proliferation rates, 5 × 104, 1 × 105 and 1.5 × 105 cells per well were seeded in duplicates 
in 24-well plates and incubated for 48 h. Cells were then trypsinized and the cell number was 
determined. The proliferation rate was calculated as follows: 
proliferation rate = 
mean cell number (48 h)
seeded cell number
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2.2.2.3.2. MTT assay 
The viability of cells can be determined by assessment of their metabolic activity. The colorimetric MTT 
assay measures the reduction of the soluble yellow tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to the insoluble purple formazan. This process is driven by 
NAD(P)H-dependent cellular oxidoreductase enzymes in the endoplasmatic reticulum and is only 
carried out by living cells. In apoptotic or necrotic cells with an altered metabolism this process is 
impaired.  
5 × 104 cells per well were seeded in duplicates in 24-well plates and incubated for 24 h, 48 h and 72 h. 
At each end point, confluence and amount of dead cells were assessed. The medium was replaced with 
500 µl 10% MTT solution in culture medium and cells were incubated for 4 h at 37 °C. The medium was 
carefully aspired and the formazan complexes were lysed in 500 µl MTT lysis buffer for 10 min at RT in 
the dark on a shaker. The intensity was proportional to the amount of enzyme activity in the cells and 
a photometer was used to quantify the colored reaction product by measuring the extinction at 
550 nm in triplicates. 
2.2.2.3.3. BrdU assay 
The viability of cells can also be determined by assessment of the amount of newly synthesized DNA 
of actively proliferating cells. The colorimetric BrdU assay detects BrdU that can be incorporated into 
the genomic DNA of proliferating cells during DNA synthesis in place of thymidine.  
2 × 104 cells per well were seeded in triplicates in 96-well plates and incubated overnight. 
Subsequently, the BrdU Cell Proliferation ELISA Kit was used according to manufacturer’s instructions. 
Briefly, cells were labeled by the addition of BrdU reagent for 4 h at 37 °C. The following fixation of the 
cells for 30 min at RT led to the denaturation of DNA. After addition of a detector anti-BrdU monoclonal 
antibody, which bound to any incorporated BrdU within 1 h, secondary horseradish peroxidase (HRP)-
conjugated goat anti-mouse antibody was added for 30 min to bind to the detector antibody. Finally, 
the peroxidase catalyzed the added substrate tetra-methylbenzidine during an incubation time of 
30 min which converted the solution from colorless to blue and finally to yellow after the addition of 
a stop solution. The intensity was proportional to the amount of incorporated BrdU in the cells and a 
photometer was used to quantify the colored reaction product by measuring the extinction at 450 nm. 
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2.2.2.4. Functional in vitro assays 
Next, cell lines were tested in various functional assays concerning migration behavior and invasive 
capacity as well as spheroid and colony formation ability in vitro. All cellular assays were conducted at 
least in triplicate and in case of modified tumor cell lines in culture media without selection antibiotics. 
2.2.2.4.1. Cell migration assay with turned coverslips 
The ability of tumor cells to migrate into the surrounding area was analyzed by ECM-based migration 
assays using turned coverslips (Figure 11). 
Coverslips were placed into 24-well plates and coated with ECM diluted 1:4 in serum-free medium. 
5 × 105 cells were seeded onto coated coverslips and incubated for 24 h until they reached confluence. 
On the next day, coverslips were turned over upside-down into 6-well plates coated with ECM and 
incubated for up to 96 h. The distance of migrated cells was measured after 24 h (start) and 72 h or 
96 h (end) depending on the cell line using the EVOS FL microscope. Migration speed (µm per day) and 
number of spreaders (cells per mm²) were analyzed using the ImageJ software. 
 




TIME t = start t = end
24h 48–72h
ECM overlay Medium Tumor cell 24-well 6-wellCoverslip
SPREADERSMIGRATION DISTANCEMIGRATION FRONTRAW PICTURE
24–48h
90%
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2.2.2.4.2. Cell invasion assay in a modified Boyden chamber 
The ability of tumor cells to invade through a membrane was analyzed by micro-invasion assays in a 
modified Boyden chamber (Figure 12). 
The modified Boyden chamber consists of two plates, a lower one with normal wells and an upper one 
with wells without bottom. Both plates can be sealed tightly with screws. First, the base wells were 
completely filled with culture medium and sealed with a polycarbonate membrane (10 µm pore 
diameter) previously coated with ECM diluted 1:4 in serum-free medium. The upper plate was placed 
onto the membrane, top wells were filled with culture medium and allowed to equilibrate for 30 min 
at 37 °C. Next, the equilibration medium was removed, 1 × 105 cells were seeded into top wells and 
incubated for 96 h. Afterwards, the chamber was carefully disassembled and the medium in base wells 
was resuspended thoroughly to detach the tumor cells that had invaded through the membrane from 
top wells. Finally, the number of invaded cells was counted using a Neubauer counting chamber. 
 
Figure 12: Schematic of cell invasion assay in a modified Boyden chamber.  
 
2.2.2.4.3. Colony formation assay in soft agar 
The ability of tumor cells to grow in anchorage-independent conditions was analyzed by soft agar 
colony formation assays (Figure 13). 
For the base agar layer, 1.0% agarose was mixed with supplemented culture medium (20% FCS, 1% P/S) 
in equal parts, layered into 6-well plates and allowed to solidify for 30 min at RT. For the top agar layer, 
5 × 104 cells were resuspended in supplemented culture medium (10% FCS, 1% P/S) mixed with 0.5% 
agarose and layered onto 1.0% agar beds in 6-well plates. Supplemented culture medium (10% FCS, 
1% P/S) was added on top of cells and replaced with fresh medium twice a week for up to five weeks 
(depending on cell line). Images were taken of five fields for each well on three subsequent focus layers 
using the EVOS FL microscope. Colonies were counted using the ImageJ software and classified into 
three groups: small (0.001–0.005 mm²), medium (0.0051–0.05 mm²) and large (>0.05 mm²). Finally, 
TIME t = start t = end
96h
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the wells were stained with 0.5 ml crystal violet staining solution for 1 h at 37 °C, washed twice with 
ddH2O and whole well images were taken with a single-lens reflex camera. 
 
Figure 13: Schematic of colony formation assay in soft agar.  
 
2.2.2.4.4. Spheroid formation assay using hanging drop method 
The ability of tumor cells to form a spheroid in anchorage-independent conditions and its subsequent 
outgrowth were analyzed by spheroid formation assays using the hanging drop method (Figure 14). 
First, a single cell suspension (0.25 × 105 in 0.5 ml) was prepared. The bottom of a 100 mm cell culture 
dish was filled with 10 ml PBS to act as a hydration chamber. The lid was inverted and 25 µl drops of 
the cell suspension (1250 cells per drop) were placed onto it with sufficient distance between them. 
The lid was carefully inverted, placed onto the PBS-filled bottom chamber and incubated for 72 h 
leading to the formation of spheroids in those hanging drops. Next, 24-well plates were prepared with 
1 ml culture medium per well. After careful removal of the PBS, the plate was inverted and pictures 
(pre) were taken from spheroids using the EVOS FL microscope. Formed spheroids were then very 
carefully transferred in separated 24-wells and incubated for up to 96 h. One image was taken after 
3 h when spheroids had settled down (start) and then every 24 h until the end of the experiment at 
96 h (end). Spheroid outgrowth (mm²) was analyzed using the ImageJ software. 
TIME t = end
days weeks15min
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Figure 14: Schematic of spheroid formation assay using hanging drop method.  
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2.2.3. In vivo experiments 
All animal work was approved by the local veterinary authorities from the Government of Bavaria 
based on European guidelines and national regulations of the German animal protection act 
(permission no. 55.2-2532-2-908). 
2.2.3.1. Maintenance of animals 
Adult female mice were obtained from Charles River (Hannover, Germany) and constantly kept under 
standard laboratory conditions (12 h light/dark cycle, lights on at 07:00 h, 22 ± 2 °C, 50 ± 5% humidity, 
low-phytoestrogen and soy-free diet and tap water ad libitum). They were group-housed in standard 
mouse cages with sawdust bedding and allowed to habituate for at least three weeks after arrival. 
At the beginning of the experiments, all mice were 12 to 13 weeks old. 
2.2.3.2. Cancer cell preparation for injection 
One or two days prior to the experiment, cells were seeded in culture flasks and allowed to adhere to 
reach a confluence of 70–80%. First, the level of confluence was assessed and bright-field images were 
taken. Gel matrix was prepared, consisting of one part of culture medium and two parts of ECM, and 
kept at 4 °C. Cells were trypsinized, counted and the desired number of cells (1 × 103 cells per animal) 
was centrifuged for 5 min at 800 g. Supernatant was removed, cells were resuspended in gel matrix 
(3 µl per animal) and stored on ice until injection. 
2.2.3.3. Stereotactical intracortical injection 
To assess the effects of E-cadherin modification in our late brain colonization in vivo model, control 
and modified tumor cells were stereotactically injected into the cortical region of syngeneic mice as 
depicted in Figure 15. Briefly, anesthetic solution consisting of 100 µl Ketamin 10%, 25 µl Domitor 
(1 mg ml−1) and 875 µl NaCl 0.9% was prepared (B). The mouse was weighted (A) and anesthetized by 
intraperitoneal injection of the anesthetic solution (7.5 µl g−1 body weight for BALB/c, 5 µl g−1 body 
weight for C57BL/6) (C). Eyes were protected against dehydration during the whole process by 
Bepanthen application. After disinfection, a small incision was made in the middle of the head and the 
periosteum of the right skull cup was carefully removed with a sterile scalpel (D). Next, the mouse was 
placed into a stereotaxic frame and fixed with ear bars in order to hold the skull in a horizontal position 
to the ground (E). A drill hole of approximately 1 mm of diameter was stereotactically bored 1.5 mm 
rostral and 1.5 mm right lateral of the bregma using a stereotaxic tooth-technical drill (F+G). 
An opening or damaging of the dura mater must be avoided during this process. The previously 
prepared cell suspension was mixed and 3 µl were drawn up in a 10 µl Hamilton syringe with tapered 
MATERIALS AND METHODS  53 
 
cannula tip which was then fixed in the holder of the stereotaxic frame in a position directly above the 
skull hole and with the open end of the cannula to the left side. The cannula was inserted 3.5 mm deep 
in the brain and pulled back 0.5 mm forming a small cavity for the cell suspension. Subsequently, the 
cells were injected directly into the cortical region of the brain over a period of 60 seconds and the 
cannula was left in the same position for additional two minutes to ensure the establishment of the 
cells in the brain parenchyma (H). After removal of the cannula and simultaneous rinse of the injection 
site with NaCl 0.9%, the skull hole was closed with bone wax. The skin on the head was sutured (I), 
a painkiller (10% Rimadyl in NaCl 0.9%) was injected subcutaneously (5 µg g−1 body weight) (J) and the 
mouse was placed on a thermal plate to recover from anesthesia (K). 
 
Figure 15: Stereotactical intracortical injection of tumor cells. A 12-to-13-week-old mouse is 
(A) weighed and (B+C) put under anesthesia by intraperitoneal injection. (D) A small incision is made 
in the middle of the head and the periosteum of the right skull cup is removed carefully with the help 
of a sterile scalpel. (E) The mouse is placed into a stereotaxic frame and (F+G) a drill hole of 
approximately 1 mm of diameter is stereotactically bored 1.5 mm rostral and 1.5 mm right lateral of 
the bregma. (H) The cell suspension (3 µl) is stereotactically injected into the cortex using a Hamilton 
syringe. (I) The skin is stitched up and (J) a painkiller is administered subcutaneously. (K) Finally, the 
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2.2.3.4. Animal monitoring and Hanging Wire test 
After injection, mice were regularly monitored for their physical fitness and any emerging sensory or 
motor deficits. Animals were weighed at least once a week, as body weight loss is often an indicator 
for or accompanied by neurological symptoms. As soon as the mice showed abnormalities in their 
behavior, they were submitted to the Hanging Wire test. This test evaluates motor functions by 
assessing muscle strength, coordination, and orientation of the animals and is useful to indirectly 
identify neurological dysfunctions caused by metastatic outgrowth (Blazquez et al., 2018). Briefly, a 
wire was stretched between two platforms 35 cm above the ground of a cage covered with soft 
bedding. Animals were hang with their fore limbs to the wire and had to reach one of the platforms. 
Mice that did not manage this task within 60 seconds or dropped to the ground were sacrificed due to 
advanced metastatic growth. 
2.2.3.5. Perfusion and brain tissue sample collection 
A perfusion set with 10 ml PBS in a syringe was prepared. The mouse was anesthetized with diethyl 
ether and an incision was made in the skin of the abdomen. The thorax was opened and the 
peritoneum was cut through to expose the heart. The needle was inserted into the left main heart 
chamber and a small hole was cut into the right cardiac atrium for the drainage of blood during 
injection of PBS. The perfusion washed out the blood from the circulatory system and stiffened the 
brain tissue. The mouse was decapitated, the brain was taken out and cut in pieces according to the 
schematic in Figure 16. The anterior parts were immediately shock frozen in liquid nitrogen and stored 
at −80 °C until homogenization for RNA isolation and further gene expression analysis by quantitative 
real-time polymerase chain reactions (qRT-PCR) (see 2.2.5.4). The posterior part of the metastatic 
brain was fixated in 4% PFA for 48 h, washed and stored in PBS at RT until embedding in paraffin and 
further investigation of MMPI patterns by immunohistochemical (IHC) stainings (see 2.2.6.2). 
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2.2.4. Protein biochemical methods 
2.2.4.1. Protein isolation 
For the generation of whole cell lysates, 2.5 × 105 cells per well were seeded in 6-well plates and 
incubated for 24 h, 48 h and 72 h. Confluence was assessed and images were taken with the EVOS FL 
microscope. Cells were washed once with cold PBS and harvested from the well with 50–100 µl RIPA 
lysis buffer using a cell scraper. The detergent components Na-deoxycholate and Triton X-100 helped 
to solubilize proteins while protease and phosphatase inhibitors prevented proteolysis and inactivated 
phosphatases. After incubation for 30 min on ice, lysates were centrifuged for 10 min at 16,000 g and 
4 °C to pellet cell debris and DNA. Supernatants containing dissolved proteins were collected and 
stored at −20 °C.  
2.2.4.2. Protein quantification 
A colorimetric method for determining the total level of protein in a solution is the detergent 
compatible protein assay. It is similar to the widely used Lowry assay (Lowry et al., 1951), but has been 
modified to save time. The assay is based on the formation of complexes between Cu2+ and peptide 
bonds of the protein sample in alkaline medium. Cu2+ is reduced to Cu1+, which further reacts with the 
Folin-Ciocalteu reagent finally resulting in a blue color. The intensity is proportional to the amount of 
total protein concentration in the sample and can be quantified.  
Samples were diluted in 10 µl ddH2O (1:20) and a BSA standard curve (0/25/125/250/500/1000/ 
15,000 µg ml−1) was included in each measurement. The assay was carried out according to the 
manufacturer’s instructions and a photometer was used to quantify the colored reaction product by 
measuring the extinction at 700 nm in duplicates. 
2.2.4.3. Protein separation by SDS-PAGE 
Proteins from whole cell lysates were separated according to their molecular weight by discontinuous 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (Laemmli, 1970) by using 
two-layer gels. After preparation and polymerization of the resolving gel (10%), a stacking gel (5%) was 
layered on top (Table 26). Protein samples (10–20 µg) were mixed with 4x Laemmli loading buffer and 
denaturated for 5 min at 95 °C. Protein disulfide bonds were reduced by the 2-Mercaptoethanol 
content of the buffer and the SDS ingredient quantitatively bound to proteins and applied a negative 
charge in proportion to their mass, which enabled the separation according to their molecular weight 
during the electrophoresis. The gel was placed in an electrophoresis chamber filled with 
electrophoresis buffer. The samples were loaded onto the gel and a prestained protein standard 
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marker was included to determine protein size. Proteins were first pooled in the stacking gel for 30 min 
at 90 V and subsequently separated in the resolving gel for around 90 min at 130 V. 
Table 26: Composition of resolving and stacking gels. 
Component Resolving gel 10% Stacking gel 5% 
ddH2O 1975 µl 1725 µl 
Acrylamide solution (30%) 1675 µl 415 µl 
Resolving gel buffer 1250 µl — 
Stacking gel buffer — 315 µl 
APS (10%) (w/v) 50 µl 25 µl 
TEMED 5 µl 2.5 µl 
 
2.2.4.4. Protein analysis by Western blot 
After separation through SDS-PAGE, proteins were transferred onto a nitrocellulose membrane for 
subsequent detection by specific antibodies. Resolving gel, nitrocellulose membrane and Whatman 
blotting paper were equilibrated in appropriate blotting buffer and stacked together in a blot sandwich 
with the gel on top of the membrane covered by two sheets of paper on each side. The protein transfer 
was performed using either a traditional semi-dry transfer system (Trans-Blot SD Semi-Dry) at 15 V for 
90 min at RT or a high-performance transfer system (Trans-Blot Turbo) at 25 V for 7 min at RT. 
Afterwards, the membrane was stained with 0.5% Ponceau S solution to verify loading and transfer 
efficiency. After thorough washing of the membrane with TBST, unspecific binding sites were saturated 
by incubation with blocking solution (5% MMP or 5% BSA in TBST) for 1 h at RT. Next, membranes were 
incubated with the specific primary antibodies (see 2.1.6) in the corresponding blocking solution (MMP 
or BSA) overnight at 4 °C. Membranes were washed three times with TBST for 5 min each, incubated 
with secondary HRP-conjugated antibodies (see 2.1.6) in the corresponding blocking solution for 1 h 
at RT and washed again three times in TBST for 5 min each. Substrate was added according to 
manufacturer’s instructions (Clarity Western ECL substrate or SignalFire ECL Reagent) to detect the 
HRP. This enzyme catalyzed the oxidation of luminol and produced a chemiluminescence signal, which 
was detected in the LAS-4000 imager. Protein expression was quantified by analyzing the intensities 
of bands with the ImageJ software and calculating the ratio of protein of interest to corresponding 
loading control (β-actin or heat shock protein 90 (HSP90)).  
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2.2.5. Gene expression analysis 
2.2.5.1. Isolation of total RNA from tumor cells 
For the isolation of total RNA from tumor cells, 2.5 × 105 cells per well were seeded in 6-well plates 
and incubated for 24 h, 48 h and 72 h. Isolation was performed using the spin column-based High Pure 
RNA isolation kit according to manufacturer’s instructions. Briefly, cells were washed once with PBS 
and lysed in 400 µl lysis/binding buffer supplemented with 200 µl PBS. The buffer components made 
cell membranes permeable, induced protein denaturation and inactivated RNases. After vortexing for 
15 s to support cell lysis, the samples were loaded onto spin columns and centrifuged for 15 s at 
8000 g. Nucleic acids bound to the column while proteins, salts and cellular debris passed through and 
were discarded afterwards. 10 µl DNase I in 90 µl DNase I incubation buffer was added directly on the 
column and incubated for 15 min at RT to digest the bound DNA. After three washing steps with 
different buffers, the remaining RNA was eluted into a new tube with 50 µl nuclease-free water by 
centrifugation for 1 min at 8000 g. Concentration and purity of the RNA were measured using a 
NanoDrop spectrophotometer and samples were stored at −80 °C. 
2.2.5.2. Isolation of total RNA from brain tissues 
Total RNA was extracted from murine brain metastases samples that had been dissected after the end 
of in vivo experiments (see 2.2.3.5). RNA extraction had to be carried out under RNase free conditions 
to prevent the degradation of the RNA. Isolation was performed using the TRIzol reagent. It consists 
of phenol for phase separation and guanidine isothicocyanate for denaturation of proteins as well as 
RNases. Small tissue samples were homogenized in 1 ml TRIzol, 200 µl chloroform was added, mixed 
for 15 s and incubated for 5 min at RT. Samples were centrifuged for 15 min at 20,000 g and 4 °C which 
resulted in an upper aqueous phase containing the RNA and a lower red organic phase made up of the 
chloroform and phenol dissolving the hydrophobic lipids. DNA also precipitated into the organic phase 
due to the acidity of the mixture. In the interphase, the hydrophilic proteins were present. To proceed 
with the RNA extraction, the aqueous supernatant was transferred into a clean tube without disrupting 
the interphase layer. To precipitate RNA out of the phase, 500 µl isopropanol was added and the 
mixture was incubated for 10 min at RT. Following centrifugation for 30 min at 13,000 g and 4 °C, the 
RNA pellet was washed in 1 ml 70% EtOH for 10 min at 20,000 g and 4 °C. During this time, a DNA 
digestion mix was prepared with 1 µl DNase I (10 U µl−1), 0.5 µl RNase OUT (40 U µl−1), 5 µl 10x DNase I 
incubation buffer and nuclease-free water to a final volume of 50 µl. The pellet was resuspended in 
this DNA digestion mix and incubated for 20 min at 37 °C in order to remove any contaminating DNA. 
The remaining RNA was purified by adding 150 µl nuclease-free water and 200 µl 
phenol/chloroform/isoamyl alcohol. Vortexing for 30 s and centrifugation for 2 min at 20,000 g and 
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4 °C resulted again in a phase separation with an upper aqueous phase containing the RNA. The 
aqueous supernatant was transferred into a clean tube again and 20 µl sodium acetate (3 M, pH 4.8) 
and 200 µl isopropanol was added. After incubation for 30 min at 4 °C, the samples were centrifuged 
for 30 min at 20,000 g and 4 °C to precipitate the RNA. The pellet was washed twice in 1 ml ice-cold 
70% EtOH for 5 min at 20,000 g and 4 °C and air-dried for 10–15 min at 37 °C. Finally, the RNA pellet 
was eluted with 20 µl nuclease-free water for 10 min at 42 °C. Concentration and purity of the RNA 
were measured using a NanoDrop spectrophotometer and samples were stored at −80 °C. 
2.2.5.3. Reverse transcription 
The isolated RNA was reverse transcribed into complementary DNA (cDNA) using the iScript cDNA 
synthesis kit. 1 μg of total RNA was mixed with 4 µl 5x iScript reaction mix and 1 µl iScript reverse 
transcriptase and nuclease-free water was added to a final volume of 20 μl. The reaction mix was 
incubated in a thermal cycler for 5 min at 25 °C to anneal the primers. Next, cDNA was synthesized for 
30 min at 42 °C and the enzymatic reaction was stopped afterwards by degradation of the reverse 
transcriptase for 5 min at 85 °C. After cooling, each sample was diluted with nuclease-free water in a 
ratio of 1:5 and stored at −20 °C for up to one month. 
2.2.5.4. Quantitative real-time PCR 
Changes in gene expression can be analyzed with quantitative real-time PCR. This method uses cDNA 
as a template and SYBR Green as a detection dye due to its ability to intercalate into all double stranded 
DNA and emit green light at 522 nm. In the first step, hot-start iTaq DNA polymerase was activated. 
Next, amplification of the gene of interest happened during 40 cycles of DNA denaturation, primer 
annealing and elongation. The fluorescent signal intensity increased proportionally to the amount of 
amplified GOI and could be plotted versus the cycle number. The Ct value was defined by the number 
of the cycle in which the fluorescence reached the threshold level and was normalized to the 
expression of two housekeeping genes (HK) (= ΔCt value). Following amplification, a melting curve was 
produced by slowly heating up the samples, while constantly measuring the green fluorescence. 
This procedure gave the melting point of the amplified DNA. 
The primers used for this thesis (see 2.1.7) were designed as described in 2.2.5.4.1. All procedures 
were carried out on ice. The reaction mixture consisted of 5.6 μl iTaq Universal SYBR Green Supermix, 
each 0.3 μl of forward and reverse primers (10 µM) and 1.8 μl nuclease-free water. For each gene, 8 µl 
of the corresponding reaction mix was prepared in a 384-well plate in triplicates. 2 µl cDNA solution 
(10 ng diluted in nuclease-free water in a ratio 1:1) was added to each well, the plate was sealed and 
centrifuged for 5 min at 400 g and 4 °C. Negative controls (no primer, no template) were included, 
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qRT-PCR was carried out using the QuantStudio 5 Real-Time PCR System according to the following 
protocol (Table 27) and analyzed with the QuantStudio Design & Analysis software. Gene expression 
of murine cell line and brain tissue samples was quantified relative to the expression of the 
housekeeping genes Gapdh and Pgk1. To allow statistical evaluation of groups including samples 
where fluorescence did not reach the threshold level within the scale, the Ct value was set to 40.0 
(equivalent to no expression). Purity of the qRT-PCR products was determined through analysis of their 
respective melting curves.  
Table 27: Protocol of qRT-PCR program. 
Step Temperature Duration Repetition 
Activation of Taq DNA polymerase: 95 °C 12 min  
Denaturation: 95 °C 15 s 
40 cycles 
Annealing and elongation: 60 °C 1 min 
Melting curve analysis: 95 °C 15 s  
 60–95 °C 2 °C/min  
 
2.2.5.4.1. Establishment of primers for qRT-PCR reactions 
For each GOI, a specific primer pair is needed for qRT-PCR analyses. The PerlPrimer software (Marshall, 
2004) was used to design several primer pairs per target and their efficiency was subsequently tested 
to choose the most suitable ones. Comparable primer efficiencies are essential for the analysis of 
relative gene expression using ΔCt values as this method assumes an amplification efficiency of 100%. 
A primer efficiency of 100% means that during each PCR cycle the PCR product is exactly doubled. 
The BioGPS database (C. Wu et al., 2009) was used to choose appropriate positive controls, which were 
cell lines or tissues showing high expression of the GOI. First, cDNA of those positive controls was 
produced and serial dilution series were prepared. Next, qRT-PCR was performed as described in 
2.2.5.4 and the measured Ct values were plotted against the amount of input cDNA. The QuantStudio 
Design & Analysis software was used to calculate the slope of the resulting graph. A slope of –3.33 
equals a primer efficiency of 100%. Primers with an efficiency of 90–110% were chosen for further 
analysis. 
2.2.5.4.2. Data visualization with heatmaps 
To visualize gene expression data from a large number of qRT-PCR samples, heatmaps were created 
using the free available online tool Heatmapper from omicX (https://omictools.com/heatmapper-
tool). It further enabled the unsupervised hierarchical clustering of genes depicted by dendrograms to 
reveal sample groups with similar expression profiles. 
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2.2.6. Staining 
2.2.6.1. Staining of tumor cells 
5 × 104 cells were seeded on coverslips in 24-well plates and incubated for 48 h at 37 °C. After fixation 
with 300 µl 4% PFA for 10 min at RT, coverslips were washed twice with 500 µl PBS for 5 min. 
The following staining procedures were performed at RT and are described below (see 2.2.6.1.1 and 
2.2.6.1.2). Finally, coverslips were turned and placed onto slides with fluorescent mounting medium 
and allowed to solidify for 24 h at 4 °C. Slides were stored at 4 °C until images could be taken with a 
SP8 Leica confocal laser scanning microscope. 
2.2.6.1.1. Phalloidin staining 
Phalloidin is a phallotoxin derived from the death cap mushroom (Amanita phalloides), which is often 
used for visualization of cell morphology in microscopy. The bicyclic peptide selectively binds to actin 
filaments, which are present in almost all eukaryotic cells, and thus can make cellular structures visible 
by previous conjugation to fluorescent dyes (for example, FITC).  
First, coverslips were incubated in 0.5% Triton X solution for 10 min to make cell membranes 
permeable. Following incubation in blocking buffer for 30 min, cells were stained with FITC-conjugated 
Phalloidin (see 2.1.6) for 1 h. For visualization of cell nuclei, coverslips were incubated with DAPI for 
5 min. Washing steps were included in between each time (Table 28). 
Table 28: Phalloidin staining protocol. 
Reagent Incubation 
500 µl PBS 5 min wash 
500 µl 0.5% Triton X-100 in PBS 10 min 
500 µl PBS 3 x 5 min wash 
500 µl blocking buffer (1% BSA in PBS) 30 min 
500 µl PBS 3 x 5 min wash 
200 µl Phalloidin-FITC in blocking buffer 1 h 
500 µl PBS 3 x 5 min wash 
200 µl DAPI (1:2000 in PBS) 5 min 
 
2.2.6.1.2. Immunofluorescence staining 
Cellular localization of E-cadherin was visualized with immunofluorescence (IF) stainings. 
First, coverslips were incubated in 0.5% Triton X solution for 10 min to make cell membranes 
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permeable. After subsequent incubation in blocking buffer for 30 min to block unspecific binding sites, 
cells were stained with primary antibody against E-cadherin (see 2.1.6) for 2 h. Secondary FITC-
conjugated antibody (see 2.1.6) was added for 1 h to bind to the primary antibody. For visualization of 
cell nuclei, coverslips were incubated with DAPI for 5 min. Washing steps were included in between 
each time (Table 29). Negative controls (only secondary antibody) were performed to exclude 
unspecific staining. 
Table 29: IF staining protocol. 
Reagent Incubation 
500 µl PBS 5 min wash 
500 µl 0.5% Triton X-100 in PBS 10 min 
500 µl PBS 3 x 5 min wash 
500 µl blocking buffer (1% BSA in PBS) 30 min 
500 µl PBS 3 x 5 min wash 
200 µl primary antibody in blocking buffer 2 h 
500 µl PBS 3 x 5 min wash 
200 µl secondary antibody in blocking buffer 1 h 
500 µl PBS 3 x 5 min wash 
200 µl DAPI (1:2000 in PBS) 5 min 
 
2.2.6.2. Staining of brain tissues 
Collected brain tissues (see 2.2.3.5) were routinely processed into cassettes, dehydrated and 
embedded in paraffin at the Institute of Pathology of the University Hospital Regensburg. Next, they 
were sectioned into 3 µm slices with a sliding microtome, floated on a warm water bath to remove 
wrinkles and placed on glass slides by a technical assistant. Slices were allowed to dry overnight at RT 
and backed in an oven for 30 min at 60 °C on the next day. For the staining protocols, tissue samples 
were taken through a decreasing alcohol concentration series (Table 30) consisting of short changes 
of xylol, alcohol and water to hydrate the tissue. The subsequent staining steps varied between 
investigated targets and are described below (see 2.2.6.2.1 and 2.2.6.2.2). Afterwards, samples were 
rinsed, taken back through an increasing alcohol concentration series (Table 30) consisting of short 
changes of water, alcohol, and xylol to dehydrate the tissue and finally sealed with coverslips using 
Roti-Histokitt II. Samples were scanned at the Institute of Pathology of the University Hospital 
Regensburg using the Pannoramic 250 slides scanner system, prepared with the CaseViewer software 
and further analyzed using the ImageJ software.  
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Table 30: Alcohol concentration series for staining of brain tissue. 
Decreasing alcohol concentration series  Increasing alcohol concentration series 
Reagent Incubation  Reagent Incubation 
Xylol 5–10 min  Deionized water short 
Xylol 5–10 min  70% EtOH 3–5 min 
100% EtOH 3–5 min  96% EtOH 3–5 min 
100% EtOH 3–5 min  96% EtOH 3–5 min 
96% EtOH 3–5 min  100% EtOH 3–5 min 
96% EtOH 3–5 min  100% EtOH 3–5 min 
70% EtOH 3–5 min  Xylol 5–10 min 
Deionized water short  Xylol 5–10 min 
 
2.2.6.2.1. Hematoxylin and eosin staining 
Hematoxylin and eosin (H&E) staining is still the gold standard to visualize cell morphology in tissue 
sections and recognize different tissue types. Nucleic acids are stained by the blue-purple colored 
hematoxylin and proteins are stained by the pink eosin. This results in blue cell nuclei and pink 
cytoplasm and extracellular matrix in H&E stained tissues (Cardiff et al., 2014). After hydrating the 
tissue, slices were stained with the nuclear dye hematoxylin, washed, and counterstained with eosin 
(Table 31). 
Table 31: H&E staining protocol. 
Reagent Incubation 
Hematoxylin 5 min 
Warm tap water 5–10 min 
72% dH2O/28% HCl alcohol 0.22%  short 
Warm tap water 5–10 min 
Eosin + 1 drop of 100% acetic acid 3 min 
Warm tap water 3 min 
 
2.2.6.2.2. Immunohistochemical staining 
Different immunohistochemical stainings were used to visualize morphological features of brain 
metastases. For evaluation of the MMPI pattern, brain slices were stained against vimentin (VIM) for 
diffuse infiltrative mouse models and cytokeratin-8 (CK8) for epithelial infiltrative ones. For evaluation 
of E-cadherin expression, brain slices were stained against E-cadherin (ECAD). For visualization of 
angiotropic infiltration, endothelial cells were stained with cluster of differentiation 31 (CD31) 
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antibody. For evaluation of the corresponding MME, brain slices were stained with the following 
immune panel: microglia/macrophages were detected with allograft inflammatory factor 1 (IBA1), 
astrocytes with glial fibrillary acidic protein (GFAP) and T cells with cluster of differentiation 3 (CD3). 
2.2.6.2.2.1. CD3, CK8 and IBA1 staining 
After hydrating the tissue, slices were incubated in 1x Target Retrieval solution for 30 min at 330 W in 
a microwave to break protein cross-links, expose the epitopes and antigens and enhance staining 
intensity. They were allowed to cool down and incubated in 3% peroxidase solution to block 
endogenous peroxidase activity in the tissue. Unspecific binding sites were blocked with antibody 
diluent before slices were stained with the corresponding first antibodies (see 2.1.6) overnight at RT. 
Secondary biotin-conjugated goat anti-rabbit antibody was added for 1 h at RT to bind to the primary 
antibody. The slices were incubated with ExtrAvidin-Peroxidase for 1 h at RT in order to form 
conjugates between the ExtrAvidin protein and biotin. Next, samples were incubated in a substrate-
chromogen diaminobenzidine (DAB) solution for 10 min at RT in the dark. The peroxidase catalyzed 
the substrate DAB resulting in stable, brown colored stain at the site of the target antigen. 
For visualization of cell nuclei, the slices were finally stained with hematoxylin for 20 s. Washing steps 
were included in between each time (Table 32). 
Table 32: IHC staining protocol for CD3, CK8 and IBA1. 
Reagent Incubation 
1x Target Retrieval solution, citrate pH 6.1 30 min 330 W, allow to cool down 
Deionized water short wash 3x 
Tris wash buffer (pH 6) 10 min wash 
100 µl 3% peroxidase solution 10 min 
Tris wash buffer (pH 6) 10 min wash 
100 µl antibody diluent 20 min 
100 µl primary antibody in antibody diluent overnight at RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl Rabbit IgG (H+L)-Biotin (1:250) in antibody diluent 1 h RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl ExtrAvidin-Peroxidase (1:1000) in antibody diluent 1 h RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl DAB solution (1:50) 10 min RT 
Tris wash buffer (pH 6) 10 min wash 
Hematoxylin 20 s 
Warm tap water 1 min wash 
Deionized water short wash 
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2.2.6.2.2.2. CD31 and VIM staining 
After hydrating the tissue, slices were incubated in citrate buffer for 30 min at 330 W in a microwave 
to break protein cross-links, expose the epitopes and antigens and enhance staining intensity. 
They were allowed to cool down and incubated in 3% peroxidase solution to block endogenous 
peroxidase activity in the tissue. Unspecific binding sites were blocked with antibody diluent before 
slices were stained with the corresponding first antibodies (see 2.1.6) for 1 h at RT. Secondary biotin-
conjugated goat anti-rabbit antibody was added for 1 h at RT to bind to the primary antibody. 
The slices were incubated with Streptavidin-HRP-Conjugate (Reagent 3, ZytoChem Plus (HRP) Anti-
Rabbit kit) for 15 min at RT in order to form conjugates between the streptavidin protein and biotin. 
Next, samples were incubated in a substrate-chromogen DAB solution for 10 min at RT in the dark. 
The peroxidase catalyzed the substrate DAB resulting in stable, brown colored stain at the site of the 
target antigen. For visualization of cell nuclei, the slices were finally stained with hematoxylin for 20 s. 
Washing steps were included in between each time (Table 33). 
Table 33: IHC staining protocol for CD31 and VIM. 
Reagent Incubation 
Citrate buffer pH 6 30 min 330 W, allow to cool down 
Deionized water short wash 3x 
Tris wash buffer (pH 6) 10 min wash 
100 µl 3% peroxidase solution 10 min 
Tris wash buffer (pH 6) 10 min wash 
100 µl antibody diluent 20 min 
100 µl primary antibody in antibody diluent 1 h RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl Rabbit IgG (H+L)-Biotin (1:250) in antibody diluent 1 h RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl Streptavidin-HRP-Conjugate (Reagent 3) 15 min RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl DAB solution (1:50) 10 min RT 
Tris wash buffer (pH 6) 10 min wash 
Hematoxylin 20 s 
Warm tap water 1 min wash 
Deionized water short wash 
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2.2.6.2.2.3. ECAD staining 
After hydrating the tissue, slices were incubated in 1x Target Retrieval solution for 30 min at 330 W in 
a microwave to break protein cross-links, expose the epitopes and antigens and enhance staining 
intensity. They were allowed to cool down and stored overnight at 4 °C. On the next day, they were 
incubated in 3% peroxidase solution to block endogenous peroxidase activity in the tissue. 
Unspecific binding sites were blocked with blocking solution (Reagent 1, ZytoChem Plus (HRP) 
Anti-Rabbit kit) before slices were stained with the first antibody (see 2.1.6) for 3 h at RT. Biotinylated 
secondary anti-rabbit antibody (Reagent 2, ZytoChem Plus (HRP) Anti-Rabbit kit) was added for 30 min 
at RT to bind to the primary antibody. The slices were incubated with Streptavidin-HRP-Conjugate 
(Reagent 3, ZytoChem Plus (HRP) Anti-Rabbit kit) for 15 min at RT in order to form conjugates between 
the streptavidin protein and biotin. Next, samples were incubated in a substrate-chromogen DAB 
solution for 10 min at RT in the dark. The peroxidase catalyzed the substrate DAB resulting in stable, 
brown colored stain at the site of the target antigen. For visualization of cell nuclei, the slices were 
finally stained with hematoxylin for 2 min. Washing steps were included in between each time 
(Table 34). 
Table 34: IHC staining protocol for ECAD. 
Reagent Incubation 
1x Target Retrieval solution, citrate pH 6.1 30 min 330 W, allow to cool down 
Deionized water short wash 3x, 
incubate overnight at 4 °C 
Tris wash buffer (pH 6) 10 min wash 
100 µl 3% peroxidase solution 10 min 
Tris wash buffer (pH 6) 10 min wash 
100 µl blocking solution (Reagent 1) 8 min 
Tris wash buffer (pH 6) 5 min wash 
100 µl primary antibody in blocking solution (Reagent 1) 3 h RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl biotinylated secondary antibody, rabbit (Reagent 2) 30 min RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl Streptavidin-HRP-Conjugate (Reagent 3) 15 min RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl DAB solution (1:50) 10 min RT 
dH2O stop reaction 
Hematoxylin 2 min 
Warm tap water 1 min wash 
Deionized water short wash 
MATERIALS AND METHODS  66 
 
2.2.6.2.2.4. GFAP staining 
After hydrating the tissue, slices were incubated in 1x Target Retrieval solution for 30 min at 330 W in 
a microwave to break protein cross-links, expose the epitopes and antigens and enhance staining 
intensity. They were allowed to cool down and stored overnight at 4 °C. On the next day, they were 
incubated in 3% peroxidase solution to block endogenous peroxidase activity in the tissue. 
Unspecific binding sites were blocked with antibody diluent before slices were stained with the first 
antibody (see 2.1.6) for 1 h at RT. Biotinylated secondary antibody (Reagent AB2, Dako REAL detection 
system) was added for 15 min at RT to bind to the primary antibody. The slices were incubated with 
streptavidin alkaline phosphatase (Reagent AP, Dako REAL detection system) for 15 min at RT in order 
to form conjugates between the streptavidin protein and biotin. Next, samples were incubated with 
chromogen solution (Chromogens Red 1 + 2 + 3 (1:25) in AP substrate buffer, Dako REAL detection 
system) for 1.5 min at RT in the dark. The alkaline phosphatase catalyzed the hydrolysis of phosphate 
groups from the substrate molecules resulting in stable, red colored stain at the site of the target 
antigen. For visualization of cell nuclei, the slices were finally stained with hematoxylin for 2 min. 
Washing steps were included in between each time (Table 35). 
Table 35: IHC staining protocol for GFAP. 
Reagent Incubation 
1x Target Retrieval solution, citrate pH 6.1 30 min 330 W, allow to cool down 
Deionized water short wash 3x, 
incubate overnight at 4 °C 
Tris wash buffer (pH 6) 10 min wash 
100 µl 3% peroxidase solution 10 min 
Tris wash buffer (pH 6) 10 min wash 
100 µl antibody diluent 20 min 
100 µl primary antibody in antibody diluent 1 h RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl biotinylated secondary antibody (Reagent AB2) 15 min RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl streptavidin alkaline phosphatase (Reagent AP) 15 min RT 
Tris wash buffer (pH 6) 10 min wash 
100 µl chromogen solution (Chromogens Red 1 + 2 + 3 
(1:25) in AP substrate buffer) 
1.5 min RT 
Tris wash buffer (pH 6) 10 min wash 
Hematoxylin 20 s 
Warm tap water 1 min wash 
Deionized water short wash 
MATERIALS AND METHODS  67 
 
2.2.6.2.3. Quantification of immunohistochemical staining 
After stained brain slices had been scanned, images of whole brain slices or different regions of interest 
(ROI) were taken with the CaseViewer software and further analyzed using the ImageJ software. For 
this purpose, different methods were established to quantify the expression of E-cadherin, assess the 
number of endothelial cells and evaluate the immune reaction of the metastatic microenvironment 
with spatial resolution. This enabled a quantifiable comparison of changes in E-cadherin levels (ECAD), 
angiotropic infiltration (CD31) or the microenvironment concerning microglia/macrophage response 
(IBA1), astrocytic reaction (GFAP) and T cell response (CD3) between entities and after genetic 
modification of the different models. Three representative samples were analyzed for each group. 
2.2.6.2.3.1. Quantification of ECAD staining 
E-cadherin staining was quantified in images of whole brain slices. Briefly, the channels of the RGB 
image were split using color deconvolution. The brown channel was selected, a previously established 
threshold (defined by pre-analysis) was applied and the percentage of stained area was measured in 
relation to whole brain area. 
2.2.6.2.3.2. Quantification of CD31 staining 
CD31 staining was quantified in images of whole brain slices. First, ROIs were defined manually for 
brain and metastatic tissue based on the clearly identifiable MMPI and the size of the respective areas 
was measured. Next, the channels of the RGB image were split using color deconvolution. The brown 
channel was selected and converted to a mask. Particles representing endothelial cells were separately 
counted in ROIs of both brain and metastatic tissue based on previously established settings (defined 
by pre-analysis). Microvessel density was calculated as counts per mm² in respective tissue (Figure 17). 
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2.2.6.2.3.3. Quantification of IBA1, GFAP and CD3 staining 
IBA1, GFAP and CD3 stainings were quantified in triplicate images of selected ROIs. The following ROIs 
were evaluated: metastatic core, metastatic margin, MMPI, adjacent brain tissue and contralateral 
brain tissue (Figure 18).  
IBA1/GFAP 
Briefly, the channels of the RGB images were split using color deconvolution. The appropriate channels 
(brown for IBA1, red for GFAP) were selected and previously established thresholds (defined by 
pre-analysis) were applied. Finally, the percentage of stained area was measured. 
CD3 
The channels of the RGB image were split using color deconvolution and the brown channel was 
selected. Briefly, the contrast was enhanced and a suitable threshold was applied before the image 
was converted to a mask. After noise removal and watershed separation, particles representing T cells 
were counted based on previously established settings (defined by pre-analysis). T cell density was 
calculated as counts per mm² in respective brain region. 
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2.2.7. Microscopy 
2.2.7.1. Bright field microscopy 
Cell morphology of parental and modified tumor cells was evaluated by bright field microscopy. 
2.5 × 105 cells were seeded in 6-well plates and incubated for up to 72 h at 37 °C. After 24 h, 48 h and 
72 h, images were taken after washing the cells with PBS to visualize cell morphology at different 
stages of confluence using the EVOS FL microscope at 4x and 10x magnification. This device was also 
used to take images for analysis of various functional in vitro assays investigating migration, colony 
formation and spheroid formation. 
2.2.7.2. Confocal microscopy 
Phalloidin and immunofluorescence stainings of parental and modified tumor cells were evaluated 
with a SP8 Leica confocal laser scanning microscope and the corresponding LAS X software. 
Two different lasers (405 nm for DAPI, 488 nm for FITC) were used to acquire images with a 63x oil 
immersion objective. To avoid cross-talk between channels a sequential acquisition mode was applied. 
 
2.2.8. Statistical analysis 
All experiments were performed at least in biological triplicates unless stated otherwise. Statistical 
analysis was performed with GraphPad Prism 7 software. Data sets were analyzed with unpaired t-test 
(one variable, two groups), one-way analysis of variance (ANOVA) (one variable, three or more groups), 
or two-way ANOVA with or without repeated measurements (two variables, two or more groups) 
depending on the experimental design. ANOVAs were followed by appropriate post-hoc tests including 
Dunnett’s (comparing every mean to a control mean), Tukey’s (comparing every mean with every other 
mean) or Sidak’s (comparing selected pairs of means) multiple comparisons. For Kaplan-Meier survival 
analysis, a log-rank test was performed. For contingency tables, a chi-square test was used. Data are 
displayed as mean + standard deviation (SD) unless stated otherwise. P values less than 0.05 were 
considered as being statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data 
were plotted with GraphPad Prism 7 software. 
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3. Results 
The existence of different MMPI patterns and their prognostic impact strongly suggested the study of 
their underlying mechanisms and pathophysiology. It is necessary to understand these differences on 
a molecular level for the identification of potential effective treatments. Hence, appropriate mouse 
models were required for the detailed study of the different infiltrative MMPI patterns identified in 
human brain metastases as described in the introduction (see 1.1.4). 
The first step of this thesis was to choose suitable brain metastasis mouse models and compare their 
morphological features. One of the key differences between diffuse and epithelial infiltrative MMPI 
models was their innate level of E-cadherin, a cell adhesion receptor that seems to play an essential 
role in the metastatic process. In addition, initial comparisons of the metastatic microenvironment 
already showed differences in immune infiltrate components between models. 
A detailed characterization of the respective diffuse and epithelial infiltrative murine brain metastasis 
model cell lines confirmed the significant differences in their migration behavior and invasive capacity 
in vitro. Since low levels of E-cadherin were associated with higher migration and invasiveness across 
entities, the modification of this cell adhesion receptor in the metastatic outgrowth models appeared 
to be a suitable target to switch the pattern of the MMPIs.  
The establishment of stable overexpression and knockdown cell lines was accomplished by opposing 
genetic modifications of the innate E-cadherin expression using a lentiviral approach. This enabled the 
comparative study of E-cadherin level effects on brain colonization. The first part focused on the direct 
impact on the cell lines by performing the same panel of in vitro assays as used for the wild-type 
characterization. Across entities, the gain of E-cadherin decreased migration and invasive capacity, 
while the artificial loss made them more invasive. 
Because of these promising in vitro findings, the modified cell lines were injected into syngeneic mice 
and investigated in the in vivo situation. In the animal model, the overexpression of E-cadherin led to 
less aggressive metastases while the knockdown even increased aggressiveness and infiltrative 
metastatic outgrowth. Both approaches altered the MMPI and had a significant impact on overall 
survival and the metastatic microenvironment. 
An additional aim of this thesis was to find prognostic gene targets that could represent a tool to 
classify the outcome of patients with metastases based on the analysis of their tumor gene expression 
signature. Indeed, we could establish a gene signature that clearly differed between diffuse and 
epithelial infiltrative cell lines of mesenchymal or epithelial character. It reliably distinguished between 
metastases according to the associated survival rates in our mouse models and even demonstrated its 
prognostic impact in human patient samples. 
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3.1. Brain metastasis mouse models 
For the following study of the role of E-cadherin in metastatic brain colonization, the first step was to 
choose suitable brain metastasis mouse models that represent the different infiltrative MMPI patterns 
observed in human brain metastases. As already described in the introduction, our group has 
established a late brain colonization model, where tumor cells are stereotactically implanted into the 
cortex of syngeneic mice, for a variety of murine cancer cell lines. As the mice have a functional 
immune system, the simultaneous investigation of MMPI patterns and MME mechanisms in an intact 
system is possible.  
3.1.1. MMPI patterns in brain metastasis mouse models 
I decided to study the mechanisms in different entities commonly involved in brain metastases in order 
to find mechanisms that are robust between entities and could be generally valid. Therefore, I chose 
breast and colon entities as both cancer types are among the ones accounting for the highest risk of 
brain metastases formation. I was able to match both infiltrative MMPI patterns to two of our brain 
metastasis mouse models, one of breast and the other one of colon origin. Different histological 
markers were used for the detection of metastatic growth and MMPI pattern in the brain parenchyma: 
the mesenchymal marker vimentin for diffuse infiltrative models and the epithelial marker 
cytokeratin-8 for epithelial infiltrative ones.  
The diffuse infiltrative MMPI pattern was best recognizable in the E0771-LG model, a highly 
tumorigenic breast cancer cell line, and the CT26 model, a highly metastatic colon cancer cell line 
(Figure 19 A). Vimentin shows cell-specific expression in intermediate filaments of cells with 
mesenchymal origin and is used to visualize growth patterns of carcinomas without noticeable 
expression of epithelial markers. The vimentin staining revealed diffuse infiltration with a visible 
macroscopic metastasis characterized by tumor cells with mesenchymal-like features deeply 
infiltrating the adjacent tissue (Blazquez et al., 2020b).  
The epithelial infiltrative MMPI pattern was best recognizable in the 410.4 model, a moderate 
metastatic breast cancer cell line, and the CMT93Var model, a low to moderate metastatic colon 
cancer cell line (Figure 19 B). Cytokeratin-8 shows cell-specific expression in intermediate filaments of 
epithelial cells and is widely used in pathology for the diagnosis of adenocarcinoma. The cytokeratin-8 
staining revealed epithelial infiltration characterized by clusters of tumor cells physically separated 
from the metastatic border that collectively infiltrated into the adjacent brain parenchyma as cohorts 
or, in case of CMT93Var, as clusters with an inner lumen in a glandular appearance (Blazquez et al., 
2020b). 
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Figure 19: MMPI patterns in brain metastasis mouse models. IHC staining of vimentin (VIM) and 
cytokeratin-8 (CK8) in tissue sections of brain metastases of (A) diffuse infiltrative E0771-LG (breast) 
and CT26 (colon) and (B) epithelial infiltrative 410.4 (breast) and CMT93Var (colon) cancer cells. 
Representative images of coronal brain sections and images of the MMPI at higher magnifications 
are shown. 
 
3.1.2. E-cadherin expression in brain metastasis mouse models 
Analogous to the human models, I compared the E-cadherin expression in the brain tissue samples 
between diffuse and epithelial infiltrative brain metastasis mouse models with immunohistochemistry 
analyses. The diffuse infiltrative MMPI models E0771-LG (breast) and CT26 (colon) showed no visible 
E-cadherin staining (Figure 20 A) while the epithelial infiltrative MMPI models 410.4 (breast) and 
CMT93Var (colon) showed pronounced E-cadherin staining within the metastatic tissue (Figure 20 B). 
In case of the epithelial infiltrative models, the E-cadherin staining revealed again the characteristic 
epithelial patterns with cluster and glandular infiltration. The quantification of ECAD staining 
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Figure 20: E-cadherin expression in brain metastasis mouse models. IHC staining of E-cadherin (ECAD) 
in tissue sections of brain metastases of (A) diffuse infiltrative E0771-LG (breast) and CT26 (colon) and 
(B) epithelial infiltrative 410.4 (breast) and CMT93Var (colon) cancer cells. Representative images of 
coronal brain sections and images of the MMPI at higher magnifications are shown. (C) Quantification 
of E-cadherin staining is indicated as the percentage of stained area in whole brain slices (mean + SD, 
n = 3; two-way ANOVA followed by Tukey’s multiple comparisons; *P < 0.05). 
 
3.1.3. Metastatic microenvironment in brain metastasis mouse models 
Since different infiltrative MMPI patterns could influence the immune cell composition within the 
macro-metastasis and the formation of the MME, I compared the expression of major CNS immune 
response components at the MMPI between diffuse and epithelial infiltrative models. Initial 
histological stainings of the metastatic brain tissue with an activated microglia/macrophage marker 
(IBA1), GFAP as a marker for astrocytic activation and a pan-T cell marker (CD3) already revealed 
noticeable MMPI pattern-specific differences. While both breast cancer models showed a clear 
activation of astrocytes, I saw enormous morphological differences in other immune cell composition. 
The epithelial type, represented by 410.4, displayed high levels of activated microglia/macrophages 
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Figure 21: Metastatic microenvironment in brain metastasis mouse models. IHC staining of immune 
response components in tissue sections of brain metastases of (A) diffuse infiltrative E0771-LG and 
(B) epithelial infiltrative 410.4 breast cancer cells. Brain metastases were stained with antibodies 
against activated microglia/macrophages (MΦ) (IBA1), activated astrocytes (GFAP) and T cells (CD3). 
Representative images of coronal brain sections and images of the MMPI at higher magnifications 
are shown. 
 
These profound morphological differences in the MME emphasized the importance of a systematic 
investigation and quantification of microenvironment components in all available animal models via 
immunohistological and morphometric analyses.  
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3.2. Characterization of murine brain metastasis model cell lines 
I went on with the detailed in vitro characterization of the murine brain metastasis model cell lines 
that generated the diffuse and epithelial infiltrative MMPI patterns. The diffuse infiltrative cell lines 
E0771-LG (breast) and CT26 (colon) were compared to the epithelial infiltrative cell lines 410.4 (breast) 
and CMT93Var (colon) first concerning basic features such as morphology, protein expression and 
proliferation rates. I continued with various 2D and 3D functional assays assessing migration behavior 
and invasive capacity as well as spheroid and colony formation ability. This was followed by the study 
of contact inhibition mechanisms. Finally, I performed gene screenings and developed characteristic 
expression signatures for the respective MMPI model cell lines. 
3.2.1. Basic characterization of murine brain metastasis model cell lines 
The E0771-LG cell line is a highly metastatic subclone isolated from experimental lung metastases 
originating from the parental E0771 cell line, which was originally isolated from a spontaneous 
mammary gland tumor of a C57BL/6 mouse (Kitamura et al., 2019). It was obtained from Prof. J. Pollard 
(Edinburgh, UK) and has a very high metastatic potential. The CT26 cell line is an undifferentiated colon 
carcinoma line originally isolated from an N-nitroso-N-methylurethane induced colon tumor of a 
BALB/c mouse (Brattain et al., 1980). It is commercially available at ATCC and has a high metastatic 
property and tumor initiating potential. Both cell lines are adherent and display a mesenchymal 
phenotype with fibroblast-like morphology (Figure 22 A1). 
The 410.4 cell line was generated through serial transplantations of 410 LM derived from a single lung 
nodule isolated after subcutaneous injection of a single spontaneously arising mammary tumor of a 
BALB/cfC3H mouse (Miller et al., 1983). It was obtained from Prof. F. Balkwill (London, UK) and has a 
moderate metastatic potential. The CMT93Var cell line is a more metastatic subclone of the 
commercially available parental polyploid colorectal CMT93 originally isolated from a rectal tumor of 
a C57BL/6 mouse (Franks et al., 1978). The variant has been shown to be more aggressive when 
injected intracortically compared to the parental line and was obtained from Dr. med. C. Hackl 
(Regensburg). CMT93Var cells have a low to moderate metastatic potential. Both cell lines are 
adherent and display an epithelial phenotype with cobblestone-like morphology and pronounced cell-
cell contacts when they reach confluence (Figure 22 A2).  
I reinforced the differences in E-cadherin expression between the diffuse and epithelial infiltrative cell 
lines morphologically by immunofluorescence and on protein and RNA level by Western blot and 
quantitative RT-PCR analysis, respectively. The morphological features and the localization of 
E-cadherin on a cellular level are depicted in detail in confocal images of Phalloidin and E-cadherin 
stainings (Figure 22 B). In epithelial cell lines, E-cadherin was mainly localized in the cell membranes, 
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especially at regions of cell-cell contacts. Both epithelial cell lines expressed higher protein and RNA 
levels of the epithelial markers E-cadherin, cytokeratin-8 and β-catenin while the diffuse cell line 
E0771-LG displayed extremely high levels of the mesenchymal marker vimentin (Figure 22 C+D). 
Despite those distinct molecular characteristics, I could not observe any MMPI pattern-specific 
differences concerning cell proliferation or survival rates (Figure 22 E–G).  
 
Figure 22: Basic characterization of murine brain metastasis model cell lines in vitro. 
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and CMT93Var (CMT) (colon) cells are characterized concerning morphology, protein expression, 
proliferation and viability in vitro. (A) Phase contrast images of (A1) diffuse and (A2) epithelial murine 
breast and colon cancer cells. Enlarged sections of the characteristic cell morphology are also shown. 
(B) Confocal microscopy images of (B1) diffuse and (B2) epithelial murine breast and colon cancer cells 
after Phalloidin or E-cadherin staining of cells (green) and nuclear staining with DAPI (blue). All scale 
bars represent 30 µm. (C) Western blot analysis of epithelial (E-cadherin (ECAD), cytokeratin-8 (CK8) 
and β-catenin (β-CAT)) and mesenchymal markers (vimentin (VIM)). (C1) Representative bands for all 
indicated proteins and one representative loading control are shown (B: breast, C: colon, DIFF: diffuse, 
EPI: epithelial). (C2) Quantification of E-cadherin protein expression is displayed as band intensities 
normalized to corresponding loading controls (HSP90). (D) Quantitative RT-PCR analysis of E-cadherin 
(Cdh1). Gapdh and Pgk1 were used as housekeeping genes (HK; shown are mean and individual values). 
(E) Cell proliferation rate, (F) BrdU cell proliferation analysis and (G) MTT assay showing cell survival 
after 48 h (mean + SD, n = 3; two-way ANOVA followed by Tukey’s multiple comparisons; 
****P < 0.0001, n.s. = not significant). 
 
3.2.2. Functional characterization of murine brain metastasis model cell lines 
Our group uses a broad spectrum of functional 2D and 3D assays to assess migration behavior and 
invasive capacity as well as spheroid and colony formation ability in vitro that have been established 
and refined over the years (see 2.2.2.4). In these assays, I could observe pronounced MMPI pattern-
specific differences concerning migration, invasion and spheroid outgrowth.  
The ECM-based migration assay using turned coverslips analyzes the ability of tumor cells to migrate 
into the surrounding area. The diffuse infiltrative cell lines migrated faster and displayed significantly 
more spreaders, which are single tumor cells detached from the migration front that deeply invade 
into the surrounding area (Figure 23 A). Furthermore, the diffuse cell lines had a slightly higher invasive 
capacity compared to the epithelial cell lines when I analyzed the ability of tumor cells to invade 
through a membrane by micro-invasion assays in a modified Boyden chamber (Figure 23 B). 
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Figure 23: Functional 2D characterization of murine brain metastasis model cell lines in vitro. 
Diffuse infiltrative E0771-LG (E0) (breast) and CT26 (colon) cells and epithelial infiltrative 410.4 (breast) 
and CMT93Var (CMT) (colon) cells are characterized concerning migration behavior and invasive 
capacity in vitro. (A) ECM-based migration assay. (A1) Migration speed is indicated as μm per day, 
(A2) number of spreaders is displayed as cells per mm² and (A3) representative images are shown. 
Scale bars represent 500 μm. (B) Modified Boyden chamber invasion assay. The invasive capacity is 
indicated as number of invaded cells through a membrane (mean + SD, n = 3; two-way ANOVA 
followed by Tukey’s multiple comparisons; *P < 0.05, ***P < 0.001, n.s. = not significant). 
 
Besides those 2D methods, I also used 3D cell culture models that mimic the formation of micro-
metastases and metastatic outgrowth in the brain. I investigated the ability of the different infiltrative 
cell lines to form spheroids in anchorage-independent conditions in hanging drops and analyzed their 
subsequent outgrowth in wells. Both diffuse cell lines formed spheroids with larger outgrowth 
compared to the epithelial 410.4 and the CMT93Var was not able to form quantifiable spheroids at all 
(Figure 24 A). The situation was similar when I analyzed their ability to grow in anchorage-independent 
conditions in soft agar (Figure 24 B). Compared to the diffuse CT26 less colonies grew in case of both 
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Figure 24: Functional 3D characterization of murine brain metastasis model cell lines in vitro. 
Diffuse infiltrative E0771-LG (E0) (breast) and CT26 (colon) cells and epithelial infiltrative 410.4 (breast) 
and CMT93Var (CMT) (colon) cells are characterized concerning spheroid outgrowth and colony 
formation ability in vitro. (A) Spheroid formation assay using hanging drop method. (A1) Spheroid 
outgrowth is indicated in mm² and (A2) representative images are shown. Scale bars represent 500 μm 
(mean + SD, n = 3; two-way ANOVA with repeated measures followed by Tukey’s multiple 
comparisons; ***P < 0.001, ****P < 0.0001 (E0771-LG/CT26/410.4 vs. CMT93Var); #P < 0.05, 
###P < 0.001 (CT26 vs. 410.4)). (A3) Spheroid outgrowth after 96 h is displayed separately in mm² 
(mean + SD, n = 3; two-way ANOVA followed by Tukey’s multiple comparisons; *P < 0.05; n.sph. = no 
outgrowth of quantifiable spheroids). (B) Colony formation assay in soft agar. (B1) Number of colonies 
per 30 mm², (B2) percentage of colony size separated into three groups (S: small, M: medium, L: large) 
and (B3) representative images are shown. Scale bars represent 200 µm (mean + SD, n = 3; 
Comparison S M L
E0 vs. CT26 n.s. n.s. n.s.
E0 vs. 410.4 * * n.s.
E0 vs. CMT n.s. ** n.s.
CT26 vs. 410.4 n.s. n.s. n.s.
CT26 vs. CMT n.s. n.s. n.s.
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two-way ANOVA followed by Tukey’s multiple comparisons; *P < 0.05, **P < 0.01, ***P < 0.001, 
n.s. = not significant). 
 
3.2.3. Contact inhibition mechanisms in murine brain metastasis model cell 
lines 
As already explained in the introduction, the mechanisms of contact inhibition and the cell-adhesion 
receptor E-cadherin are inseparably linked (see 1.2.2). Due to the pronounced differences in innate 
E-cadherin levels between the diffuse and epithelial infiltrative murine brain metastasis model cell 
lines, the next logical step was to examine these mechanisms and draw a comparison between them.  
I therefore investigated the mechanisms of contact inhibition in the diffuse and epithelial infiltrative 
cell lines by quantification of the protein ratio of the Hippo signaling pathway component YAP and its 
phosphorylated form phospho-YAP (p-YAP) in a confluence assay. In case of intact contact inhibition, 
the p-YAP/YAP ratio rises with increasing confluence. Although all cell lines grew to confluence in a 
similar way after cultivation for up to 96 h (Figure 25 A), I saw huge differences in the p-YAP/YAP ratio. 
The epithelial infiltrative cell lines (410.4 and CMT93Var) showed functional contact inhibition with a 
rising ratio whereas both diffuse infiltrative cell lines (E0771-LG and CT26) showed a tonic YAP signaling 
and seemed to be independent of contact inhibition (Figure 25 B). I could therefore confirm contact 
inhibition as one mechanism that clearly differed between the diffuse and epithelial infiltrative MMPI 
models. This could be an important target for specific tumor therapies in patients.  
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Figure 25: Contact inhibition mechanisms in murine brain metastasis model cell lines in vitro. 
Diffuse infiltrative E0771-LG (breast) and CT26 (colon) cells and epithelial infiltrative 410.4 (breast) and 
CMT93Var (colon) cells are characterized concerning contact inhibition mechanisms in vitro. 
(A) Confluence assay. (A1) Representative images at low and high confluence are shown and (A2) level 
of cellular confluence during cultivation is displayed in percent. Scale bars represent 200 µm. 
(B) Western blot analysis of phospho-YAP (p-YAP) and YAP over time as measurement for functional 
contact inhibition. (B1) Protein band intensities of p-YAP and YAP were normalized to corresponding 
loading controls (ACTIN) and the ratio was calculated. Quantification of p-YAP/YAP expression is 
displayed as fold change over 24 h. (B2) Representative bands for all indicated proteins and one 
representative loading control are shown (mean + SD, n = 3; two-way ANOVA followed by Dunnett’s 
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3.2.4. Gene expression signature of murine brain metastasis model cell lines 
To further characterize the differences between diffuse and epithelial infiltrative murine brain 
metastasis model cell lines, I performed quantitative RT-PCR screenings of selected gene targets based 
on previous proteomics analyses and microarray data in our lab and found several differentially 
expressed genes (DEGs) (Figure 26). By clustering the gene expression data, I could identify two 
clusters with distinct patterns: genes in cluster 1 were highly expressed in diffuse infiltrative cell lines 
while cluster 2 consisted of genes showing high expression in epithelial infiltrative cell lines. 
 
Figure 26: Gene expression signature of murine brain metastasis model cell lines. Quantitative 
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cells and epithelial infiltrative 410.4 (breast) and CMT93Var (colon) cells. Gapdh and Pgk1 were used 
as housekeeping genes (HK). (A) Heatmap displaying log2 transformed z-scores of 24 genes. 
Unsupervised hierarchical clustering reveals two gene clusters with distinct expression profiles, as 
highlighted by dendrogram coloring (orange, green). (B) Representative candidate genes of 
(B1) cluster 1 (‘HIGH in DIFFUSE’) and (B2) cluster 2 (‘HIGH in EPITHELIAL’) (mean and individual values, 
n = 3; two-way ANOVA followed by Tukey’s multiple comparisons; *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001). 
 
In summary, the data demonstrated the existence of significant differences between the diffuse and 
epithelial infiltrative MMPI cell types. On the one hand, the diffuse infiltrative E0771-LG and CT26 lost 
the expression of E-cadherin, had no functional contact inhibition and showed increased migration and 
invasion capacity compared to the epithelial type. They seem to be independent of E-cadherin 
expression for successful organ colonization. 
In contrast, the epithelial infiltrative 410.4 and CMT93Var cells retained the expression of this adhesion 
molecule at the MMPI infiltration front, showed intact contact inhibition and had a lower migration 
and invasion capacity compared to the diffuse type. They seem to depend on E-cadherin expression 
and epithelial barrier formation for initial outgrowth and 3D colony formation in vitro. 
The different dependencies of the diffuse and epithelial infiltrative cell lines on E-cadherin point to 
different molecular mechanisms supporting both types of breast and colon cancer infiltration at the 
MMPI. Due to these findings, former observations in our group (Blazquez et al., 2020a) and other 
publications emphasizing its importance for metastasis and cancer progression (Mendonsa et al., 2018; 
Padmanaban et al., 2019), I decided to focus on the role of the cell adhesion receptor E-cadherin in 
the further course of this thesis.  
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3.3. E-cadherin modifications in murine brain metastasis model cell lines 
The specific genetic modification of E-cadherin in the metastatic outgrowth models appeared to be a 
suitable target to switch the pattern of the MMPIs. Therefore, I established stable cell lines with altered 
levels of E-cadherin and continued with a detailed characterization concerning their morphology, 
molecular characteristics, migratory and invasive behavior as well as 3D outgrowth ability in vitro. 
Additionally, I assessed the impact of modified E-cadherin levels on contact inhibition mechanisms. 
3.3.1. Establishment of E-cadherin modifications in murine brain metastasis 
model cell lines 
Taken together, the data pointed to a different role of E-cadherin at the MMPI of diffuse and epithelial 
infiltrative MMPI models. Thus, to further investigate the impact of E-cadherin on infiltration and 
colonization of brain metastases, I specifically modified the expression of E-cadherin according to the 
MMPI phenotypes in an opposing way (Table 36). 
 
Table 36: E-cadherin modifications in murine brain metastasis model cell lines. The diffuse infiltrative 
E0771-LG (breast) and CT26 (colon) cell lines were stably transfected with empty (CTL) or E-cadherin 
expression (OE) vectors. The epithelial infiltrative 410.4 (breast) and CMT93Var (colon) cells were 
stably transfected with scrambled shRNA (CTL) or E-cadherin shRNA (sh) vectors. 
 
For the generation of cell lines with stable overexpression or knockdown of the cell adhesion protein 
E-cadherin, I introduced expression vectors or shRNA-mediated gene silencing by lentivirus-mediated 
gene delivery (transduction). After transduction, lentiviral vectors can integrate into the nucleus of the 
target cells and lead to stable expression of the gene of interest. This method enables the extensive 
study of modified cell lines in cell culture without the need for repeated reintroduction of constructs 
into the cells for maintenance of manipulation effect and furthermore enables the study of long-term 
effects in in vivo models without additional administration of potentially interfering substances. 
Entity Breast
Parental cell line E0771-LG 410.4
MMPI pattern Diffuse Epithelial
E-cadherin expression Low High
Genetic modification Empty vector E-cadherin vector Scrambled shRNA E-cadherin shRNA
Modified cell line E0771-LG CTL E0771-LG OE 410.4 CTL 410.4 sh
Entity Colon
Parental cell line CT26 CMT93Var
MMPI pattern Diffuse Epithelial
E-cadherin expression Low High
Genetic modification Empty vector E-cadherin vector Scrambled shRNA E-cadherin shRNA
Modified cell line CT26 CTL CT26 OE CMT93Var CTL CMT93Var sh
E-cadherin overexpression E-cadherin knockdown
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I started with the construction of different E-cadherin expression vectors, scrambled shRNA vectors 
and E-cadherin shRNA vectors, which involved numerous molecular cloning processes (data not 
shown). A detailed description of cloning procedures is listed in the methods section (see 2.2.1). Next, 
I produced lentiviral particles containing the respective constructs and generated the different 
modified cell lines by lentiviral transductions. I used empty (CTL) or E-cadherin expression (OE) vectors 
in the diffuse infiltrative E0771-LG (breast) and CT26 (colon) cell lines for upregulation of E-cadherin 
on the one hand, and scrambled shRNA (CTL) or E-cadherin shRNA (sh) vectors in the epithelial 
infiltrative 410.4 (breast) and CMT93Var (colon) cell lines for downregulation of E-cadherin on the 
other hand. For each parental cell line, I chose one control and two different modified cell lines with 
the most pronounced changes in E-cadherin levels for the further studies (data not shown). A detailed 
description of lentiviral transduction procedures is listed in the methods section (see 2.2.2.2). 
3.3.1.1. E-cadherin overexpression in diffuse infiltrative cell lines 
First, I confirmed the successful stable lentiviral transduction of E0771-LG and CT26 breast and colon 
cancer cells resulting in control (CTL) and E-cadherin-overexpression (OE) lines on protein and RNA 
level by Western blot and quantitative RT-PCR analysis (Figure 27 A–C, I–K). Contrary to the current 
concept of EMT, these modifications did not substantially affect other cell characteristic markers on 
protein level. There was neither an increase of the epithelial marker cytokeratin-8 nor a decrease of 
the mesenchymal marker vimentin. Instead, both proteins showed stable levels across all groups. 
However, the level of β-catenin, a binding partner of E-cadherin, was increased particularly in CT26 
(Figure 27 A1+I1). 
As expected, the modification of E-cadherin had a significant impact on cell morphology. E-cadherin 
overexpression in E0771-LG and CT26 cells changed their mesenchymal phenotype with fibroblast-like 
morphology (control lines) towards a more epithelial-like phenotype with some cobblestone-like 
features (E0771-LG OE) or star-like morphology (CT26 OE) with increased cell-cell contacts 
(Figure 27 D+L).  
The overexpression of E-cadherin was also visible on the cellular level. Morphological features and the 
localization of E-cadherin within the cells are depicted in detail in confocal images of Phalloidin and 
E-cadherin stainings. Compared to the control situation without any stained areas, a weak E-cadherin 
staining was visible in all OE lines, especially in CT26 (Figure 27 E+M). However, E-cadherin was mainly 
localized in the cytoplasm of cells, which was different from the situation observed in epithelial wild-
type cell lines where E-cadherin was mainly localized at the cell membranes and especially in regions 
of cell-cell contacts (see 3.2.1). 
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Figure 27: E-cadherin overexpression in diffuse infiltrative murine brain metastasis model cell lines. 
Characterization of (A–H) E0771-LG and (I–P) CT26 control (CTL) and E-cadherin-overexpression (OE) 
breast and colon cancer cells after stable lentiviral transduction of E0771-LG and CT26 with the empty 
vector or E-cadherin vector, respectively. (A+I) Western blot analysis of epithelial (E-cadherin (ECAD), 
cytokeratin-8 (CK8) and β-catenin (β-CAT)) and mesenchymal markers (vimentin (VIM)). 
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shown. (A2+I2) Quantification of E-cadherin protein expression is displayed as band intensities 
normalized to corresponding loading controls (HSP90). (B+J) Stability of E-cadherin overexpression 
verified by Western blot analysis after cultivation without selection antibiotics for up to four weeks. 
Representative blots are shown. (C+K) Quantitative RT-PCR analysis of E-cadherin (Cdh1). Gapdh and 
Pgk1 were used as housekeeping genes (HK; shown are mean and individual values). (D+L) Phase 
contrast images. Enlarged sections of the changed cell morphology are also shown. (E+M) Confocal 
microscopy images after Phalloidin or E-cadherin staining of cells (green) and nuclear staining with 
DAPI (blue). Scale bars represent 30 µm. (F+N) Cell proliferation rate, (G+O) BrdU cell proliferation 
analysis and (H+P) MTT assay showing cell survival after 48 h are displayed as fold change over control 
cell line (mean + SD, n = 3; one-way ANOVA followed by Dunnett’s multiple comparisons; *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant). 
 
Overall, the overexpression of E-cadherin had no major effects on cell proliferation and survival rates 
in E0771-LG or CT26 (Figure 27 F–H, N–P). This was particularly important for the following functional 
characterization of the cells, as it precluded proliferation-induced effects of E-cadherin modification 
on migration and invasion. 
3.3.1.2. E-cadherin knockdown in epithelial infiltrative cell lines 
In the same manner, I confirmed the successful stable lentiviral transduction of 410.4 and CMT93Var 
breast and colon cancer cells resulting in control (CTL) and E-cadherin-knockdown (sh) lines on protein 
and RNA level by Western blot and quantitative RT-PCR analysis (Figure 28 A–C, I–K). Again, these 
modifications did not substantially affect other cell characteristic markers on protein level. There was 
neither a decrease of the epithelial marker cytokeratin-8 nor an increase of the mesenchymal marker 
vimentin. However, the level of the E-cadherin binding partner β-catenin was decreased particularly in 
410.4 (Figure 28 A1+I1).  
As expected, also the downregulation of E-cadherin had a significant impact on cell morphology. 
E-cadherin knockdown in 410.4 and CMT93Var cells turned their epithelial phenotype with 
cobblestone-like morphology (control lines) towards a more mesenchymal-like phenotype with 
fibroblast-like features and less cell-cell contacts (Figure 28 D+L).  
The knockdown of E-cadherin was also visible on the cellular level. Morphological features and the 
localization of E-cadherin within the cells are depicted in detail in confocal images of Phalloidin and 
E-cadherin stainings. Compared to the control situation with strong E-cadherin expression mainly 
localized at the cell membranes, especially in regions of cell-cell contacts, only a weak E-cadherin 
staining was visible in both sh lines (Figure 28 E+M). Interestingly, the diminished E-cadherin signal was 
mainly localized in the cytoplasm of cells instead of the cell membrane. This reflected the situation in 
the E-cadherin overexpression cell lines (see 3.3.1.1). 
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Figure 28: E-cadherin knockdown in epithelial infiltrative murine brain metastasis model cell lines. 
Characterization of (A–H) 410.4 and (I–P) CMT93Var control (CTL) and E-cadherin-knockdown (sh) 
breast and colon cancer cells after stable lentiviral transduction of 410.4 and CMT93Var with the 
scrambled shRNA or E-cadherin shRNA, respectively. (A+I) Western blot analysis of epithelial 
(E-cadherin (ECAD), cytokeratin-8 (CK8) and β-catenin (β-CAT)) and mesenchymal markers (vimentin 
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are shown. (A2+I2) For quantification of E-cadherin protein expression, band intensities were 
normalized to corresponding loading controls (HSP90) and are displayed as fold change over control 
cell line. (B+J) Stability of E-cadherin overexpression verified by Western blot analysis after cultivation 
without selection antibiotics for up to four weeks. Representative blots are shown. (C+K) Quantitative 
RT-PCR analysis of E-cadherin (Cdh1). Gapdh and Pgk1 were used as housekeeping genes (HK; shown 
are mean and individual values). (D+L) Phase contrast images. Enlarged sections of the changed cell 
morphology are also shown. (E+M) Confocal microscopy images after Phalloidin or E-cadherin staining 
of cells (green) and nuclear staining with DAPI (blue). Scale bars represent 30 µm. (F+N) Cell 
proliferation rate, (G+O) BrdU cell proliferation analysis and (H+P) MTT assay showing cell survival 
after 48 h are displayed as fold change over control cell line (mean + SD, n = 3; one-way ANOVA 
followed by Dunnett’s multiple comparisons; **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not 
significant). 
 
Consistent with the findings from the E-cadherin overexpression, also the knockdown of E-cadherin 
overall had no major effects on cell proliferation and survival rates in 410.4 or CMT93Var 
(Figure 28 F-H, N–P). 
3.3.2. Characterization of E-cadherin modifications in murine brain 
metastasis model cell lines 
Having confirmed that the E-cadherin modifications had no major effects on cell proliferation and 
survival rates in neither of the groups, I could preclude any proliferation-induced effects in the 
following experiments. I continued with the detailed molecular and functional characterization of all 
modified murine brain metastasis model cell lines investigating the gene expression of DEGs via 
qRT-PCRs (see 3.2.4) and using the same functional assays assessing migration behavior and invasive 
capacity as well as spheroid and colony formation ability as previously for the parental wild-type cell 
lines (see 3.2.2). 
3.3.2.1. No effect of E-cadherin modifications on gene expression signature 
By quantitative RT-PCR analysis of previously identified DEGs in all modified cell lines, I confirmed that 
the E-cadherin modifications did not alter the gene expression signature of the diffuse and epithelial 
infiltrative cell lines to any substantial extent (Figure 29). Although the altered level of E-cadherin was 
clearly visible in the heatmap, it was not reflected in the rest of the signature. Unsupervised 
hierarchical clustering still revealed the same two gene clusters with sole high expression in diffuse 
cells with mesenchymal character or epithelial cells with epithelial character as described earlier 
(see 3.2.4) independent of E-cadherin modifications. That means that E-cadherin alone was not able 
to switch the signature that included cell adhesion markers, ECM binding integrins, EMT markers, 
cytoskeletal components and metabolic genes. 
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Figure 29: No effect of E-cadherin modifications on gene expression signature. Quantitative RT-PCR 
analysis of previously established differentially expressed genes in murine brain metastasis model cell 
lines after E-cadherin modifications (CTL: control, OE: E-cadherin-overexpression, sh: E-cadherin-
knockdown). Gapdh and Pgk1 were used as housekeeping genes. Heatmap displaying log2 transformed 
z-scores. Unsupervised hierarchical clustering reveals the same two gene clusters with distinct 
expression profiles independent of E-cadherin modification (cluster 1 (‘HIGH in DIFFUSE’) and cluster 2 
(‘HIGH in EPITHELIAL’)), as highlighted by dendrogram coloring (orange, green). 
 
3.3.2.2. Reduced migration and invasive capacity after E-cadherin 
overexpression 
E-cadherin overexpression led to a significant decrease in the migration speed in E0771-LG breast 
cancer cells and a significantly reduced number of spreaders in CT26 colon cancer cells in the ECM-
based migration assay using turned coverslips (Figure 30 A+D). Additionally, invasive capacity of cells 
with upregulated E-cadherin levels was significantly decreased in micro-invasion assays in a modified 
Boyden chamber compared to control cells (Figure 30 B+E).  
Furthermore, E-cadherin overexpression also had an impact on spheroid outgrowth. Initially all groups 
were able to form spheroids under anchorage-independent conditions in hanging drops, but I observed 
a significant reduction of the outgrowth area after overexpression of E-cadherin in both models in 
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Figure 30: Effects of E-cadherin overexpression on migration, invasion and spheroid outgrowth in 
vitro. Functional characterization of (A–C) E0771-LG and (D–F) CT26 control (CTL) and E-cadherin-
overexpression (OE) breast and colon cancer cells in vitro. (A+D) ECM-based migration assay. (A1+D1) 
Migration speed is indicated as μm per day, (A2+D2) number of spreaders is displayed as cells per mm² 
and (A3+D3) representative images are shown. Scale bars represent 500 μm. (B+E) Modified Boyden 
chamber invasion assay. The invasiveness of OE cells is indicated as fold change over control cells 
(mean + SD, n = 3; one-way ANOVA followed by Dunnett’s multiple comparisons; *P < 0.05, **P < 0.01, 
n.s. = not significant). (C+F) Spheroid formation assay using hanging drop method. (C1+F1) Spheroid 
outgrowth is indicated in mm² over time and (C2+F2) representative images are shown. Scale bars 
represent 500 μm (mean + SD, n = 3; two-way ANOVA with repeated measures followed by Dunnett’s 
DIFFUSE
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multiple comparisons; E0771-LG: ***P < 0.001, ****P < 0.0001 (CTL vs. OE#1); #P < 0.05, ###P < 0.001 
(CTL vs. OE#2); CT26: ****P < 0.0001 (CTL vs. OE#1/OE#2)). (C3+F3) Spheroid outgrowth after 96 h is 
displayed separately in mm² (mean + SD, n = 3; one-way ANOVA followed by Dunnett’s multiple 
comparisons; *P < 0.05, **P < 0.01, ***P < 0.001). 
 
3.3.2.3. Increased migration and invasive capacity after E-cadherin 
knockdown 
In contrast, E-cadherin knockdown in 410.4 breast and CMT93Var colon cancer cells significantly 
increased the migration speed and the number of spreaders in the ECM-based migration assay using 
turned coverslips (Figure 31 A+D) as well as the invasive capacity in micro-invasion assays in a modified 
Boyden chamber compared to control cells (Figure 31 B+E).  
However, and contrary to expectation, the downregulation of E-cadherin did not lead to an increase 
of the spheroid outgrowth area and even had an impact on spheroid formation ability. In contrast to 
the control line, the 410.4 breast cancer knockdown cells were not even able to form spheroids under 
anchorage-independent conditions in hanging drops any more and remained as single cells growing to 
confluency over time (Figure 31 C). This observation represents an interesting finding and indicates 
that the epithelial infiltrative 410.4 cells highly depend on E-cadherin for their initial outgrowth and 
spheroid formation. The situation was similar in all CMT93Var colon cancer lines where neither the 
control nor the knockdown cells were able to form quantifiable spheroids (Figure 31 F). Although it 
was not a surprise in this case, as already the wild-type cell line had shown no spheroid formation 
ability compared to the other diffuse and epithelial infiltrative cell lines. The impact of E-cadherin on 
colonization thus seems to be context-dependent. 
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Figure 31: Effects of E-cadherin knockdown on migration, invasion and spheroid outgrowth in vitro. 
Functional characterization of (A–C) 410.4 and (D–F) CMT93Var control (CTL) and E-cadherin-
knockdown (sh) breast and colon cancer cells in vitro. (A+D) ECM-based migration assay. (A1+D1) 
Migration speed is indicated as μm per day, (A2+D2) number of spreaders is displayed as cells per mm² 
and (A3+D3) representative images are shown. Scale bars represent 500 μm. (B+E) Modified Boyden 
chamber invasion assay. The invasiveness of sh cells is indicated as fold change over control cells (mean 
+ SD, n = 3; one-way ANOVA followed by Dunnett’s multiple comparisons; *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001, n.s. = not significant). (C+F) Spheroid formation assay using hanging 
drop method. (C1+F1) Spheroid outgrowth is indicated in mm² over time and (C2+F2) representative 
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measures followed by Dunnett’s multiple comparisons; 410.4: ****P < 0.0001 (CTL vs. sh#1/sh#2); 
n.sph. = no outgrowth of quantifiable spheroids). (C3+F3) Spheroid outgrowth after 96 h is displayed 
separately in mm² (mean + SD, n = 3; one-way ANOVA followed by Dunnett’s multiple comparisons; 
****P < 0.0001; n.sph. = no outgrowth of quantifiable spheroids). 
 
3.3.2.4. Colony formation ability after E-cadherin modifications 
Nevertheless, all cell lines were still able to grow in anchorage-independent conditions in soft agar 
independent of the E-cadherin modifications. Although I observed a slight decrease in colony number 
in one overexpression line in both diffuse E0771-LG (data not shown) and CT26 (Figure 32 A) and a 
noticeable increase in both knockdown lines of the epithelial 410.4 (Figure 32 B) in concordance with 
previous findings, none of these changes were significant. Again, differences between control and 
knockdown groups for CMT93Var were almost not quantifiable due to the low number of colonies 
(data not shown), as expected after the initial characterization of wild-type cell lines where CMT93Var 
also displayed the lowest colony rates compared to the other diffuse and epithelial infiltrative cell lines. 
 
Figure 32: Effects of E-cadherin modifications on colony formation in vitro. Colony formation assay in 
soft agar of (A) CT26 control (CTL) and E-cadherin-overexpression (OE) colon cancer cells and (B) 410.4 
control (CTL) and E-cadherin-knockdown (sh) breast cancer cells. (A1+B1) Number of colonies per 
30 mm² is displayed (mean + SD, n = 3; one-way ANOVA followed by Dunnett’s multiple comparisons; 
n.s. = not significant). (A2+B2) Percentage of colony size separated into three groups (S: small, 
M: medium, L: large) is indicated (mean + SD, n = 3; two-way ANOVA followed by Dunnett’s multiple 
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3.3.3. Effects of E-cadherin modifications on contact inhibition mechanisms 
Having identified contact inhibition as one mechanism that clearly differed between diffuse and 
epithelial infiltrative MMPI model cell lines (see 3.2.3), the next step was to clarify whether E-cadherin 
modifications had an impact on this system. Again, I performed confluence assays with all modified 
cell lines and quantified the protein ratio of phospho-YAP and YAP, which rises with increasing 
confluence in case of intact contact inhibition.  
3.3.3.1. No rescue of contact inhibition after E-cadherin overexpression 
Contrary to expectations, E-cadherin overexpression had no effect on contact inhibition at all. All cell 
lines grew to confluence after cultivation for up to 96 h (Figure 33 A+C), but the p-YAP/YAP ratio did 
not rise with increasing cell density in any of the diffuse infiltrative E0771-LG (breast) or CT26 (colon) 
E-cadherin-overexpression cell lines (Figure 33 B+D). This demonstrates that the E-cadherin 
overexpression could not restore contact inhibition. Instead, the cells continued to show a tonic YAP 
signaling without functional contact inhibition. 
RESULTS  96 
 
 
Figure 33: Effects of E-cadherin overexpression on contact inhibition mechanisms in vitro. 
Characterization of (A–B) E0771-LG and (C–D) CT26 control (CTL) and E-cadherin-overexpression (OE) 
breast and colon cancer cells concerning contact inhibition mechanisms in vitro. (A+C) Confluence 
assay. (A1+C1) Level of cellular confluence during cultivation is displayed in percent and (A2+C2) 
representative images at low and high confluence are shown. Scale bars represent 200 µm. 
(B+D) Western blot analysis of phospho-YAP (p-YAP) and YAP over time as measurement for functional 
contact inhibition. Protein band intensities of p-YAP and YAP were normalized to corresponding 
loading controls (ACTIN) and the ratio was calculated. Quantification of p-YAP/YAP expression is 
displayed as fold change over 24 h. Representative bands for all indicated proteins and one 
representative loading control are shown (mean + SD, n = 3; two-way ANOVA followed by Dunnett’s 
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3.3.3.2. Impaired contact inhibition after E-cadherin knockdown 
In contrast, the situation was different after downregulation of E-cadherin. Although control as well as 
knockdown cell lines grew to confluence after cultivation for up to 96 h (Figure 34 A+C), I saw 
noticeable differences in the ratio of p-YAP and YAP. In both epithelial infiltrative 410.4 (breast) and 
CMT93Var (colon) control cell lines the p-YAP/YAP ratio rose with increasing cell density pointing to 
intact contact inhibition mechanisms. However, the knockdown abolished the increase of the 
p-YAP/YAP ratio by confluence as expected. This demonstrates that the E-cadherin knockdown led to 
loss of contact inhibition (Figure 34 B+D). It further emphasizes that epithelial infiltrative cell lines 
seem to depend on E-cadherin levels for maintenance of functional contact inhibition. 
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Figure 34: Effects of E-cadherin knockdown on contact inhibition mechanisms in vitro. 
Characterization of (A–B) 410.4 and (C–D) CMT93Var control (CTL) and E-cadherin-knockdown (sh) 
breast and colon cancer cells concerning contact inhibition mechanisms in vitro. (A+C) Confluence 
assay. (A1+C1) Level of cellular confluence during cultivation is displayed in percent and (A2+C2) 
representative images at low and high confluence are shown. Scale bars represent 200 µm. 
(B+D) Western blot analysis of phospho-YAP (p-YAP) and YAP over time as measurement for functional 
contact inhibition. Protein band intensities of p-YAP and YAP were normalized to corresponding 
loading controls (ACTIN) and the ratio was calculated. Quantification of p-YAP/YAP expression is 
displayed as fold change over 24 h. Representative bands for all indicated proteins and one 
representative loading control are shown (mean + SD, n = 3; two-way ANOVA followed by Dunnett’s 
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3.3.4. Summary of in vitro characterization results 
In summary, the modifications of the cell adhesion receptor E-cadherin in diffuse and epithelial 
infiltrative murine brain metastasis model cell lines had major implications on their morphology and 
migratory and invasive behavior in vitro (Figure 35). Although both approaches provoked profound 
phenotypic changes, with a switch from diffuse to more epithelial-like morphology in case of 
E-cadherin upregulation and the other way around in case of downregulation, all modified lines 
maintained their original cell character with mesenchymal or epithelial equipment. Furthermore, the 
modifications of E-cadherin did not result in a switch of their gene expression signature including cell 
adhesion markers, ECM binding integrins, EMT markers, cytoskeletal components and metabolic 
genes. While the overexpression of E-cadherin reduced migration behavior and invasive capacity in 
breast and colon cancer cells, the knockdown led to an increase in both aspects. Consistently, spheroid 
outgrowth was reduced after overexpression. However, all modified cells maintained their ability to 
form colonies under anchorage-independent conditions in 3D models. Although contact inhibition 
could not be restored by E-cadherin overexpression, it was actually lost in the knockdown cells. 
These data demonstrated the different dependencies of diffuse and epithelial infiltrative models on 
the cell adhesion receptor E-cadherin in vitro and reinforced the theory of different molecular 
mechanisms supporting both types of breast and colon cancer infiltration. 
 
Figure 35: Summary of E-cadherin modification effects in murine brain metastasis model cell lines
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3.4. E-cadherin modifications in brain metastasis mouse models 
After the promising results in different cellular assays, the next step was to clarify if the findings could 
be applied to the situation in the living animal. In the following part of this thesis, I put emphasis on 
the detailed characterization of effects of E-cadherin modifications in both diffuse and epithelial 
infiltrative brain metastasis mouse models. To this end, I used our well-established late brain 
colonization model and injected control and modified cell lines stereotactically into the cortex of 
syngeneic mice. The resulting brain metastases were perfectly suited for the study of the role of 
E-cadherin in metastatic brain colonization to reveal underlying mechanisms and outcomes on various 
levels. First on a descriptive basis by comparing the survival curves of mice. Next, on a morphological 
basis by investigating the growth patterns, especially at the MMPI, and quantifying the infiltration 
grade into the surrounding brain parenchyma. The characterization of the surrounding metastatic 
microenvironment was also included in this context. Finally, on a molecular basis by analyzing the 
expression of previously identified DEGs in the metastatic tissue compared to the situation in the 
healthy brain.  
The modified groups were pooled to one cohort in the following analyses if not stated otherwise. 
3.4.1. Effects of E-cadherin modifications on overall survival 
The first aim was to compare the colonization potential of control and modified cell lines in vivo by 
analyzing the overall survival of the groups and comparing the survival curves. For this purpose, 
I stereotactically injected 1000 cells of the respective line into the right hemisphere of syngeneic mice 
as described in the methods section (see 2.2.3). The required numbers of injected cells needed to 
obtain brain metastases within a reasonable time had been previously established for each wild-type 
cell line in our lab. Therefore, I chose the lowest possible number that had led to successful organ 
colonization in all models and used it for all control and modified cell lines. Equal numbers of injected 
cells enabled better comparability between diffuse and epithelial infiltrative brain metastasis models. 
3.4.1.1. Prolonged survival after E-cadherin overexpression 
In diffuse infiltrative E0771-LG, metastases appeared very early within approximately 2 weeks in all 
mice and E-cadherin overexpression had no effect on overall survival (median OS = 15.5 days in CTL 
and 14 days in OE) (Figure 36 A). The increased level of E-cadherin in the overexpression group was 
only detectable by quantitative RT-PCR analysis of the metastatic brain tissue (Figure 36 B) but not 
visible in IHC stainings (Figure 36 C). In comparison to that, the diffuse infiltrative CT26 needed almost 
the double amount of time until metastases occurred. Nevertheless, they were still quite aggressive 
with metastases appearing within 3 to 4 weeks and E-cadherin overexpression significantly prolonged 
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survival (median OS = 23 days in CTL and 26.5 days in OE, P = 0.0055) (Figure 36 D). Furthermore, the 
increased level of E-cadherin was detectable by quantitative RT-PCR analysis of the metastatic brain 
tissue (Figure 36 E) and visible in IHC stainings (Figure 36 F). 
 
Figure 36: Effects of E-cadherin overexpression in diffuse infiltrative brain metastasis mouse models 
on survival. Effects of E-cadherin overexpression in (A–C) E0771-LG and (D–F) CT26 breast and colon 
cancer brain metastases. (A+D) Kaplan-Meier survival curves of mice injected with control (CTL; n = 10) 
and E-cadherin-overexpression cells (OE; n = 18; log-rank test; **P < 0.01, n.s. = not significant). (B+E) 
Quantitative RT-PCR analysis of E-cadherin (Cdh1) expression in brain metastases of control (CTL Met) 
and E-cadherin-overexpression (OE Met) cells as well as only ECM injected brains of control mice 
(Brain; C57BL/6 for E0771-LG, BALB/c for CT26). Gapdh and Pgk1 were used as housekeeping genes 
(HK; mean and individual values; n ≥ 4; one-way ANOVA followed by Tukey’s multiple comparisons; 
****P < 0.0001). (C+F) IHC staining of E-cadherin (ECAD) in tissue sections of CTL and OE brain 
metastases. (C1+F1) Representative images of coronal brain sections and images of the MMPI at higher 
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magnifications are shown. (C2+F2) Quantification of E-cadherin staining is indicated as the percentage 
of stained area in whole brain slices (mean + SD, n = 3; unpaired t-test; *P < 0.05, n.s. = not significant). 
 
3.4.1.2. Shortened survival after E-cadherin knockdown 
As expected based on the in vitro findings, E-cadherin knockdown in epithelial infiltrative models had 
the opposite effect. In epithelial infiltrative 410.4, it took approximately 4 months until metastases 
appeared in all mice in the control group. Compared to that, E-cadherin knockdown had a severe 
impact on overall survival as metastases occurred already after 2 months in all mice (median OS = 
114 days in CTL and 64 days in sh, P < 0.0001) (Figure 37 A). I saw a similar trend in epithelial infiltrative 
CMT93Var, where 6 of 10 mice of the control group also developed metastases after approximately 
4 months. E-cadherin knockdown again shortened the overall survival with metastases occurring after 
3.5 months in 13 of 17 mice (median OS = 118.5 days in CTL and 101 days in sh), although the effect 
was not as prominent as in 410.4 (Figure 37 D). Mice remaining symptom-free until the end of the 
experiments were sacrificed at day 200. Subsequent IHC stainings confirmed the absence of any brain 
metastases in these mice (data not shown). The reduced level of E-cadherin was detectable by 
quantitative RT-PCR analysis of the metastatic brain tissue (Figure 37 B+E) and visible in IHC stainings 
(Figure 37 C+F) for both 410.4 and CMT93Var models. 
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Figure 37: Effects of E-cadherin knockdown in epithelial infiltrative brain metastasis mouse models 
on survival. Effects of E-cadherin knockdown in (A–C) 410.4 and (D–F) CMT93Var breast and colon 
cancer brain metastases. (A+D) Kaplan-Meier survival curves of mice injected with control (CTL; n = 10) 
and E-cadherin-knockdown cells (sh; n = 17; log-rank test; ****P < 0.0001, n.s. = not significant). 
(B+E) Quantitative RT-PCR analysis of E-cadherin (Cdh1) expression in brain metastases of control 
(CTL Met) and E-cadherin-knockdown (sh Met) cells as well as only ECM injected brains of control mice 
(Brain; BALB/c for 410.4, C57BL/6 for CMT93Var). Gapdh and Pgk1 were used as housekeeping genes 
(HK; mean and individual values; n ≥ 4; one-way ANOVA followed by Tukey’s multiple comparisons; 
**P < 0.01, ****P < 0.0001). (C+F) IHC staining of E-cadherin (ECAD) in tissue sections of CTL and sh 
brain metastases. (C1+F1) Representative images of coronal brain sections and images of the MMPI at 
higher magnifications are shown. (C2+F2) Quantification of E-cadherin staining is indicated as the 
percentage of stained area in whole brain slices (mean + SD, n = 3; unpaired t-test; *P < 0.05, 
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3.4.1.3. Impact on colonization index 
The colonization index (CI) is an easy and accurate method to compare different metastatic brain 
colonization models and findings from survival studies across entities. It was previously established in 
our lab as a precise and useful tool to quantify the aggressiveness of different cancer cell lines in vivo. 
This mathematical formula includes three parameters to calculate the colonization capacity: (i) the 
rate of mice with successful brain colonization (in percent), (ii) the number of injected cells and (iii) the 
median overall survival of the mice (in days) (Figure 38 A). First, I compared the colonization capacities 
of all control cell lines. While the diffuse infiltrative E0771-LG and CT26 displayed a highly aggressive 
colonization potential, it was low in the case of the epithelial infiltrative 410.4 and CMT93Var 
(Figure 38 B). The effects of E-cadherin modifications on colonization capacities are summarized in a 
table and overall effects (increase (+) or decrease (−) compared to control group) are depicted 
(Figure 38 C). The overexpression resulted in a less aggressive colonization potential in CT26, while the 
knockdown had the opposite effect in 410.4 and CMT93Var. 
 
Figure 38: Effects of E-cadherin modifications in diffuse and epithelial infiltrative brain metastasis 
mouse models on colonization index. (A) The colonization index (CI) is a mathematical formula used 
to compare the colonization potential of different cancer cell lines in vivo. Cell lines with high CI are 
considered more aggressive than cell lines with low CI. (B) CI comparison of diffuse (E0771-LG (E0) and 
CT26) and epithelial (410.4 and CMT93Var (CMT)) infiltrative breast and colon control cancer cell lines. 
(C) Effect of E-cadherin modification on CI. Respective control (CTL) is compared to E-cadherin-
overexpression (OE) or E-cadherin-knockdown (sh) group and the difference (increase (+) or decrease 
(−)) is displayed. 
  
E-cadherin Overexpression E-cadherin Knockdown
Entity Cell line CTL vs. OE Cell line CTL vs. sh
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Colon CT26 - CMT93Var +
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Breast [E0771-LG] 1000 100 15.5 0.65
Colon [CT26] 1000 100 23.0 0.43
Epithelial
Breast [410.4] 1000 100 114.0 0.09
Colon [CMT93Var] 1000 60 118.5 0.05
E-cadherin overexpression
MMPI Cell line CTL OE Δ
Diffuse
Breast [E0771-LG] 0.65 0.71 +
Colon [CT26] 0.43 0.38 −
E-cadherin knockdown
MMPI Cell line CTL sh Δ
Epithelial
Breast [410.4] 0.09 0.16 +
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3.4.1.4. Correlation of overall survival and vimentin level 
In an additional step, I split the pooled survival curves of the E-cadherin modification groups and 
compared them separately. In both diffuse models, as well as the epithelial 410.4, the separate groups 
(OE#1 and OE#2, sh#1 and sh#2) showed the same effects in general (Figure 39 A1+B1+C1). However, 
in epithelial infiltrative CMT93Var I observed contradictory effects for sh#1 and sh#2. Compared to the 
control group, where metastases appeared after 4 months in 60 percent of mice (median OS = 
118.5 days), E-cadherin knockdown shortened overall survival in mice injected with sh#1 to 3 months 
(median OS = 87 days) but even prolonged it in the sh#2 cohort to almost 6 months (median OS = 
161.5 days) (Figure 39 D1). Interestingly, colonization was successful in all mice injected with sh#1, but 
only in fifty percent of the sh#2 animals. The colonization index reflected the increased colonization 
capacity of sh#1 (0.11) compared to the control line (0.05) and even showed the decrease in case of 
sh#2 (0.03) (data not shown). This difference in aggressiveness could not be explained by the level of 
E-cadherin, which was reduced in both knockdown groups (data not shown). Hence, other factors had 
to be responsible for the observation.  
In the search for possible candidates, I could identify the mesenchymal marker vimentin to be 
differentially expressed in the CMT93Var cell lines. Along with the intended knockdown of E-cadherin, 
the CMT93Var sh#2 cells had lost most of their vimentin expression. This difference was present on 
RNA level in the gene cluster analysis data and on protein level in Western blots. For better 
visualization, I calculated the protein expression ratios of vimentin and E-cadherin and noticed that 
prolonged survival correlated with decreasing ratios in overexpression lines (Figure 39 A2+B2) while 
shortened survival correlated with increasing ratios in knockdown lines (Figure 39 C2+D2). CMT93Var 
sh#2 represented the only exception of the knockdown lines showing a decreased ratio instead. 
This pointed out the altered vimentin level as the underlying factor for the prolonged survival of this 
group. Additionally, the protein expression ratios of cytokeratin-8 and E-cadherin are displayed to 
confirm that this effect was specific for vimentin. Although this epithelial marker showed similar 
correlations of ratio and survival in general, it was not differentially expressed in CMT93Var sh#1 and 
sh#2 and consequently not involved in their opposing survival rates. An overview of all correlations is 
also shown below (Figure 39 E). In summary, the mesenchymal factor vimentin seemed to play a 
crucial role in long-term survival. 
Due to these findings, the CMT93Var sh#2 group was not included in further analyses. 
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Figure 39: Correlation of overall survival and vimentin level in diffuse and epithelial infiltrative brain 
metastasis mouse models. Comparison of (A) E0771-LG, (B) CT26, (C) 410.4 and (D) CMT93Var breast 
and colon cancer brain metastases. (A1+B1+C1+D1) Kaplan-Meier survival curves of mice injected with 
control (CTL; n = 10) and E-cadherin-overexpression (OE; n = 9) or E-cadherin-knockdown (sh; n = 8–9) 
cells displayed as separate groups (#1 and #2; log-rank test for overall effect; *P < 0.05, **P < 0.01, 
***P < 0.001). (A2+B2+C2+D2) Quantification of E-cadherin (ECAD), vimentin (VIM) and cytokeratin-8 
(CK8) protein expression in murine brain metastasis model cell lines after E-cadherin modifications 
(CTL: control, OE: E-cadherin-overexpression, sh: E-cadherin-knockdown). Protein expression was 
normalized to corresponding loading controls and the ratios of VIM/ECAD and CK8/ECAD are displayed. 
(E) Summary table relating overall survival of separate groups to protein ratios of VIM/ECAD and 
CK8/ECAD. Respective control (CTL) is compared to E-cadherin-overexpression (OE) or E-cadherin-
knockdown (sh) group and the difference (increase (+) or decrease (−)) is displayed (log-rank test; 
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3.4.2. Effects of E-cadherin modifications on MMPI pattern and infiltration 
In the next parts of this work, I focused on morphological features of the brain metastases and 
investigated whether E-cadherin modifications affected the brain colonization and outgrowth pattern 
of breast and colon cancer cells. For this purpose, I compared the MMPI patterns resulting from control 
and modified cell lines and quantified the infiltration grade into the surrounding brain parenchyma by 
analyzing IHC stainings of coronal brain sections.  
3.4.2.1. Reduced infiltration at the MMPI after E-cadherin overexpression 
Metastatic growth in the diffuse infiltrative brain metastasis mouse models resulting from the highly 
metastatic E0771-LG and CT26 was visualized again by vimentin stainings. As already described, it is 
used for carcinomas without noticeable expression of epithelial markers. VIM stainings displayed the 
diffuse infiltrative patterns with metastatic cells deeply infiltrating the adjacent brain tissue. However, 
compared to the control group, where numerous single metastatic cells invaded hundreds of µm far 
into the brain parenchyma, infiltration was less pronounced after E-cadherin overexpression in 
E0771-LG and manifested in a more compact diffuse infiltrative MMPI. Furthermore, metastatic cells 
were stuck together as clusters of several single cells and invaded mainly in those small cohorts 
(Figure 40 A). The phenotype thus became more similar to the epithelial infiltrative pattern 
characterized by clusters of tumor cells collectively infiltrating the adjacent tissue. I could observe the 
same phenomenon in the colon CT26 models, although infiltration is generally less pronounced 
compared to the breast E0771-LG (Figure 40 C).  
The overexpression of E-cadherin definitely had a strong influence on the metastatic growth pattern 
of both breast and colon cancer cells. In order to emphasize this phenotypic switch and express it in 
numbers, I analyzed all metastases in a systematic approach. I quantified the extent of infiltrative 
growth into the brain parenchyma along the MMPI and classified the metastatic growth pattern as 
highly infiltrative (>2/3), moderately infiltrative (2/3–1/3), or low infiltrative (<1/3). In contrast to the 
highly infiltrative growth of the control group (CTL, 89%), the E-cadherin-overexpression cohort 
revealed a predominantly moderate infiltration pattern (OE, 75%) in E0771-LG (Figure 40 B). In the 
CT26 models, the infiltrative growth accordingly switched from moderate in control mice (CTL, 86%) 
to low in mice injected with E-cadherin-overexpression cells (OE, 63%) (Figure 40 D). In both cases, the 
difference was significant (P = 0.002 for E0771-LG, P = 0.033 for CT26). 
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Figure 40: Effects of E-cadherin overexpression in diffuse infiltrative brain metastasis mouse models 
on MMPI pattern and infiltration. Effects of E-cadherin overexpression in (A–B) E0771-LG and (C–D) 
CT26 breast and colon cancer brain metastases. Comparison of MMPI patterns and infiltration grade 
in control (CTL) and E-cadherin-overexpression (OE) mice. (A+C) IHC staining of vimentin (VIM) in tissue 
sections of brain metastases. Representative images of coronal brain sections and images of the MMPI 
at higher magnifications are shown. (B+D) Infiltration grade of brain metastases. 
(B1+D1) Representative images of high (>2/3), moderate (2/3–1/3), and low (<1/3) infiltration are 
shown. Brain metastases were stained against VIM. The black solid line indicates no infiltration, while 
the red dotted line marks zones of infiltration within the brain metastases. Scale bars represent 1 mm. 
(B2+D2) Quantification of the metastatic infiltration pattern is displayed as percentage of infiltration 
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3.4.2.2. Increased infiltration at the MMPI after E-cadherin knockdown 
Metastatic growth in the epithelial infiltrative brain metastasis mouse models resulting from the 
moderately to low metastatic 410.4 and CMT93Var was visualized again by cytokeratin-8 stainings. 
As described previously, it is widely used by pathologists to recognize growth patterns of 
adenocarcinomas. In both control cohorts, CK8 stainings displayed the typical epithelial infiltrative 
patterns characterized by clusters of metastatic cells collectively infiltrating the adjacent brain 
parenchyma. However, while only some bulks of metastatic cells invaded into the brain parenchyma 
as cohorts in the 410.4 control group, infiltration was more pronounced after E-cadherin knockdown. 
Metastatic cells invaded farer into the surrounding tissue and were predominantly isolated from each 
other or in small groups (Figure 41 A). The phenotype was thus becoming more similar to the diffuse 
infiltrative pattern characterized by numerous single metastatic cells infiltrating the adjacent tissue on 
their own. I could observe a comparable effect in the colon CMT93Var models. Here, the phenotype 
switched from metastases showing almost no infiltrative growth with glandular appearance in the 
control cohort to higher infiltration displayed by small clusters with inner lumen or even individual 
cells invading further away from the metastatic border (Figure 41 C).  
Thus, the knockdown of E-cadherin had an even stronger influence on the metastatic growth pattern 
of both breast and colon cancer cells than the overexpression depicted above. Again, I analyzed all 
metastases systematically and classified them as high, moderate or low infiltrative as described before. 
In contrast to the predominantly low infiltrative growth of the control group (CTL, 78%), the 
E-cadherin-knockdown cohort displayed significantly increased infiltration rates with moderate 
growth (sh, 64%) in 410.4 (P = 0.0301, Figure 41 B). In the CMT93Var models, I observed the most 
drastic effect of E-cadherin modification among all investigated brain metastasis models. 
The infiltrative growth switched from exclusively low in control mice (CTL, 100%) to entirely high in 
mice injected with E-cadherin-knockdown cells (sh, 100%) (P = 0.0005, Figure 41 D) and the infiltration 
depth often exceeded 1 mm. 
Interestingly, the infiltration pattern in the previously featured CMT93Var sh#2 cohort was similar to 
the respective control group showing only low infiltrative growth (data not shown). This reflected the 
results of prolonged survival in vivo and confirmed its exclusion from further analyses.  
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Figure 41: Effects of E-cadherin knockdown in epithelial infiltrative brain metastasis mouse models 
on MMPI pattern and infiltration. Effects of E-cadherin knockdown in (A–B) 410.4 and (C–D) 
CMT93Var breast and colon cancer brain metastases. Comparison of MMPI patterns and infiltration 
grade in control (CTL) and E-cadherin-knockdown (sh) mice. (A+C) IHC staining of cytokeratin-8 (CK8) 
in tissue sections of brain metastases. Representative images of coronal brain sections and images of 
the MMPI at higher magnifications are shown. (B+D) Infiltration grade of brain metastases. 
(B1+D1) Representative images of high (>2/3), moderate (2/3–1/3), and low (<1/3) infiltration are 
shown. Brain metastases were stained against CK8. The black solid line indicates no infiltration, while 
the red dotted line marks zones of infiltration within the brain metastases. Scale bars represent 1 mm. 
(B2+D2) Quantification of the metastatic infiltration pattern is displayed as percentage of infiltration 
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3.4.3. Effects of E-cadherin modifications on angiogenesis in brain 
metastases 
Besides the uncontrolled growth and the capability to invade into surrounding tissues, another 
hallmark of cancer is the induction of angiogenesis for the growth of new blood vessels (Hanahan et 
al., 2000). They ensure the optimal supply with oxygen and nutrients for invading cancer cells. 
Angiotropic infiltration is thereby defined as tumor cells growing as sheaths around blood vessels and 
protruding far into the adjacent tissue by this way. The sheaths either consist of groups of cancer cells 
or single cells (Blazquez et al., 2020b). Diffuse and epithelial infiltrative models often show mixed 
patterns including angiotropic growth (see 1.1.3). The inner surface of blood vessels is covered by 
endothelial cells that can be visualized in histological stainings by detecting the platelet endothelial 
cell adhesion molecule, also known as CD31. After staining for this endothelial marker, I analyzed brain 
metastases of all models for vessel number and density as described in the methods section 
(see 2.2.6.2.3.2).  
First, I compared the total amount of endothelial cells in the control cohorts of the diffuse and 
epithelial infiltrative models and found an overall effect of the MMPI pattern (P = 0.026). In both 
diffuse models, the metastatic tissue exhibited a lower vessel density in comparison to the number of 
vessels in the equivalent epithelial models (data not shown).  
Next, I characterized the effects of E-cadherin modifications and their resulting altered growth 
patterns on endothelial cells and vessel density in metastatic and brain tissue. In general, I observed 
significantly higher number of vessels with larger diameters after overexpression (P = 0.038) 
(Figure 42 A+B) and lower numbers and decreased size after knockdown of E-cadherin (P = 0.021) 
(Figure 42 D+E) in metastatic tissues of breast cancer models. I saw no difference in brain tissues, 
except for a slight decrease after overexpression probably due to less angiotropic growth because of 
less infiltration. Effects of E-cadherin modifications were not as demarcated in colon lines as they 
displayed lower numbers of vessels in general, although the same tendencies were present (data not 
shown). 
High magnifications of stainings for metastatic (VIM/CK8) and endothelial cells (CD31) in consecutive 
brain slices of control cohorts displayed typical angiotropic growth patterns of metastatic cells as 
sheets of many cells around long vessels in diffuse E0771-LG (Figure 42 C) or surrounding small vessels 
in epithelial 410.4 breast cancer models (Figure 42 F).  
Taken together, vessel number, size and density in the metastatic tissue seemed to depend on the 
growth pattern as they were increased in more compact metastases after E-cadherin overexpression 
and decreased in looser metastases after knockdown (Figure 42 G). 
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Figure 42: Characterization of endothelial cells in the metastatic brain tissue after E-cadherin 
modifications. IHC staining of endothelial cells (CD31) in tissue sections of mice with breast cancer 
brain metastasis of (A–C) E0771-LG control (CTL) and E-cadherin-overexpression (OE) cells and (D–F) 
410.4 control (CTL) and E-cadherin-knockdown (sh) cells. (A+D) Representative images of coronal brain 
sections and images of metastatic tissue and brain tissue at higher magnification are shown. Unlabeled 
scale bars represent 100 µm. (B+E) Quantification of CD31 staining. (B1+E1) The black dotted line 
indicates the MMPI. CD31 counts are displayed as masks in different colors (orange: metastatic tissue 
counts, black: brain tissue counts) and (B2+E2) microvessel density (MVD) is indicated as counts per 
mm² in respective brain region (mean + SD). (C+F) Representative images of endothelial cells (CD31) 
and angiotropic growth of metastatic cells in (C) diffuse E0771-LG CTL (VIM) or (F) epithelial 410.4 CTL 
(CK8) in consecutive brain slices at high magnification are shown. Scale bars represent 100 µm. 
(G) Comparison of endothelial cells (MVD) in the metastatic brain tissue after E-cadherin 
modifications. Respective control (CTL) is compared to E-cadherin-overexpression (OE) or E-cadherin-
knockdown (sh) group and the difference (increase (+) or decrease (−)) is displayed (n = 3; two-way 
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3.4.4. Effects of E-cadherin modifications on metastatic microenvironment 
As described earlier, initial histological stainings of the metastatic brain tissue of diffuse and epithelial 
infiltrative breast cancer models had revealed profound morphological differences in the MME 
between MMPI types (see 3.1.3). This required a systematic investigation and quantification of 
microenvironment components in all available animal models via immunohistological and 
morphometric analyses. In the following, I addressed the question whether the modification of 
E-cadherin could influence the interaction of breast and colon cancer cell lines with the immune cells 
and their infiltration pattern and distribution within the metastatic tissue. The MMPI had already been 
assessed in stainings of the metastatic tissue for VIM (E0771-LG and CT26) or CK8 (410.4 and 
CMT93Var), which facilitated the selection of specific ROIs. After staining for respective markers of the 
previously established immune panel in consecutive coronal brain slices, I analyzed the 
microglia/macrophage response, astrocytic reaction and T cell response in separated brain regions 
(metastatic core, metastatic margin, MMPI and adjacent brain tissue) compared to contralateral brain 
tissue representing the healthy control situation as described in the methods section (see 2.2.6.2.3.3). 
3.4.4.1. Characterization of microglia/macrophages in the metastatic brain 
tissue after E-cadherin modifications 
Microglia are the resident macrophage cells in the brain. In their activated state, they can be quantified 
in IHC stainings for IBA1. At first, I had a look at their general distribution within the brain. Overall, I 
found activated microglia/macrophages in the adjacent brain tissue and even higher levels inside the 
metastatic lesions in all brain colonization models. However, I only saw very low levels in the 
contralateral hemispheres representing the situation in the healthy brain parenchyma were microglia 
are not activated and rather widely distributed. This situation was not changed by any of the E-cadherin 
modifications in contrast to the other regions. 
In the diffuse infiltrative models, the distribution of activated microglia/macrophages did not 
significantly change after overexpression of E-cadherin in any of the selected regions. Although I 
noticed a slight decreasing trend at the MMPI and adjacent brain parenchyma in E0771-LG (breast) 
(Figure 43 A), the situation was not changed at all in CT26 (colon) (data not shown).  
In contrast, the knockdown of E-cadherin had an enormous impact on the density of activated 
microglia/macrophage at the MMPI and adjacent brain tissue in epithelial infiltrative models. I found 
significantly increased microglia/macrophage levels in the knockdown groups of both 410.4 (breast) 
(P = 0.0294) (data not shown) and CMT93Var (colon) (P < 0.0001) compared to the respective controls 
in the adjacent brain tissue and at the MMPI of CMT93Var (P = 0.0001) (Figure 43 B). 
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Figure 43: Characterization of microglia/macrophages in the metastatic brain tissue after E-cadherin 
modifications. IHC staining of activated microglia/macrophages (IBA1) in tissue sections of mice with 
(A) breast cancer brain metastasis of E0771-LG control (CTL) and E-cadherin-overexpression (OE) cells 
and (B) colon cancer brain metastasis of CMT93Var control (CTL) and E-cadherin-knockdown (sh) cells. 
(A1+B1) Representative images of coronal brain sections and images of metastatic margin, MMPI and 
adjacent brain tissue at higher magnification are shown. The black dotted line indicates the MMPI. 
Unlabeled scale bars represent 75 µm. (A2+B2) Quantification of IBA1 staining is indicated as the 
percentage of stained area in respective brain region (mean + SD, n = 3; two-way ANOVA followed by 
Sidak’s multiple comparisons; ***P < 0.001, n.s. = not significant). 
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3.4.4.2. Characterization of astrocytes in the metastatic brain tissue after 
E-cadherin modifications 
Astrocytes are the most abundant glial cells of the CNS. In their activated state, they can be quantified 
in IHC stainings for GFAP. At first, I had a look at the general distribution of astrocytes within the brain. 
Overall, I found high levels of activated astrocytes in the adjacent brain tissue and at the MMPI similar 
to the microglia situation. In contrast, no activated astrocytes appeared inside the metastatic lesions 
in all brain colonization models apart from a few exceptions. Activated astrocytes were also absent in 
the contralateral hemisphere representing the situation in the healthy brain parenchyma, where these 
glial cells only maintain the BBB in an inactivated state. Again, none of the E-cadherin modifications 
had an influence on the levels in this region. When I compared the amount of activated astrocytes in 
the control cohorts of the diffuse and epithelial infiltrative models, I found an overall effect of MMPI 
pattern (P < 0.05 for metastatic core, MMPI and adjacent brain tissue, P = 0.058 for metastatic margin) 
with epithelial models showing higher levels of astrocyte density compared to their respective diffuse 
counterparts (data not shown).  
In the diffuse infiltrative models, the overexpression of E-cadherin significantly decreased the amount 
of activated astrocytes in the adjacent brain tissue in E0771-LG (breast) (P < 0.0001) (Figure 44 A). 
Interestingly, astrocytes formed an even thicker surrounding capsule at the MMPI in CT26 (colon) (data 
not shown).  
The knockdown of E-cadherin also had an enormous impact on the astrocytic reaction at the MMPI 
and adjacent brain tissue in epithelial infiltrative models. Although effects were not as pronounced in 
410.4 (breast) (data not shown), I found significantly increased levels of activated astrocytes in the 
knockdown group of CMT93Var (colon) compared to the respective control (P = 0.0221 at MMPI, 
P < 0.0001 in adjacent brain tissue) (Figure 44 B). Here, the phenotype switched from an encapsulated 
state to an expanded activation far reaching into the surrounding brain tissue. 
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Figure 44: Characterization of astrocytes in the metastatic brain tissue after E-cadherin 
modifications. IHC staining of activated astrocytes (GFAP) in tissue sections of mice with (A) breast 
cancer brain metastasis of E0771-LG control (CTL) and E-cadherin-overexpression (OE) cells and 
(B) colon cancer brain metastasis of CMT93Var control (CTL) and E-cadherin-knockdown (sh) cells. 
(A1+B1) Representative images of coronal brain sections and images of metastatic margin, MMPI and 
adjacent brain tissue at higher magnification are shown. The black dotted line indicates the MMPI. 
Unlabeled scale bars represent 75 µm. (A2+B2) Quantification of GFAP staining is indicated as the 
percentage of stained area in respective brain region (mean + SD, n = 3; two-way ANOVA followed by 
Sidak’s multiple comparisons; *P < 0.05, ****P < 0.0001, n.s. = not significant). 
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3.4.4.3. Characterization of T cells in the metastatic brain tissue after 
E-cadherin modifications 
T cells are the main adaptive immune system effector cells and were quantified in IHC stainings for 
CD3. At first, I had a look at the general distribution of T cells within the brain. Overall, I found 
infiltrating T cells mainly in the metastatic tissue in all brain colonization models. They were rare in the 
adjacent brain tissue and completely absent in the contralateral hemisphere representing the situation 
in the healthy CNS. The latter case was not changed by any of the E-cadherin modifications.  
In the diffuse infiltrative models, the number of T cells did not significantly change after overexpression 
of E-cadherin in any of the metastatic regions. Nevertheless, I noticed a slight decreasing trend in both 
E0771-LG (breast) (Figure 45 A) and CT26 (colon) (data not shown). 
The knockdown of E-cadherin in epithelial infiltrative models also had a negative effect on T cell 
number in both metastatic regions (metastatic core and margin). I found significantly decreased levels 
in the knockdown group of 410.4 (breast) (P = 0.0043 for metastatic core, P = 0.0339 for metastatic 
margin) (Figure 45 B) and slightly reduced ones in CMT93Var (colon) (data not shown) compared to 
the respective controls. However, at the MMPI and adjacent brain tissue I found contradictory results 
for T cell density in breast and colon models. A decrease in 410.4 (P = 0.048 at MMPI) compares with 
an increasing trend in CMT93Var. 
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Figure 45: Characterization of T cells in the metastatic brain tissue after E-cadherin modifications. 
IHC staining of T cells (CD3) in tissue sections of mice with breast cancer brain metastasis of 
(A) E0771-LG control (CTL) and E-cadherin-overexpression (OE) cells and (B) 410.4 control (CTL) and 
E-cadherin-knockdown (sh) cells. (A1+B1) Representative images of coronal brain sections and images 
of metastatic margin, MMPI and adjacent brain tissue at higher magnification are shown. The black 
dotted line indicates the MMPI. Unlabeled scale bars represent 75 µm. (A2+B2) Quantification of CD3 
staining is indicated as counts per mm² in respective brain region (mean + SD, n = 3; two-way ANOVA 
followed by Sidak’s multiple comparisons; *P < 0.05, **P < 0.01, n.s. = not significant). 
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3.4.4.4. Overview of changes in the metastatic microenvironment 
Across models and entities, the differences in the immune response observed after E-cadherin 
modifications were most striking in the areas MMPI and adjacent brain tissue. These regions include 
direct contact between metastatic cells and brain tissue and the MME is thus very reactive there. 
I summarized both regions in a comparative overview showing the overall changes in the metastatic 
microenvironment (Figure 46). The reduced infiltration due to E-cadherin overexpression in diffuse 
infiltrative models led to a decrease of immune reaction, while the increased infiltration after 
E-cadherin knockdown in epithelial infiltrative models resulted in a stronger immune response.  
 
Figure 46: Overview of changes in the metastatic microenvironment after E-cadherin modifications. 
Summary of IHC staining quantifications of different immune response components in the metastatic 
brain tissue of mice after E-cadherin modifications. Results for activated microglia/macrophages (MΦ) 
(IBA1), activated astrocytes (GFAP) and T cells (CD3) are included. Respective control (CTL) is compared 
to E-cadherin-overexpression (OE) or E-cadherin-knockdown (sh) group and the difference (increase 
(+) or decrease (−)) is displayed for selected regions (MMPI and adjacent brain tissue; grey arrow: 
increase/gain, black arrow: decrease/loss; n = 3; two-way ANOVA followed by Sidak’s multiple 
comparisons; *P < 0.05, ***P < 0.001, ****P < 0.0001, n.s. = not significant). 
  
Microglia/MΦ Astrocytes T cells
E-cadherin overexpression
Region Cell line
IBA1 GFAP CD3 Overall
effectCTL vs. OE P CTL vs. OE P CTL vs. OE P
MMPI
Breast [E0771-LG] − n.s. − n.s. − n.s.
Colon [CT26] − n.s. + + + * − n.s.
Adjacent
brain tissue
Breast [E0771-LG] − − n.s. − − **** − − n.s.
Colon [CT26] − n.s. + n.s. − n.s.
E-cadherin knockdown
Region Cell line
IBA1 GFAP CD3 Overall
effectCTL vs. sh P CTL vs. sh P CTL vs. sh P
MMPI
Breast [410.4] + n.s. + n.s. − − − *
Colon [CMT93Var] + + + *** + + + * + n.s.
Adjacent
brain tissue
Breast [410.4] + + * + + n.s. − n.s.
Colon [CMT93Var] + + + **** + + + **** + + n.s.
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3.4.5. Impact of entity on angiogenesis and metastatic microenvironment 
The quantifications of microvessel density and different metastatic microenvironment components 
across all models revealed additional interesting findings concerning the impact of the entity of the 
metastatic cells. 
The comparison of the control cohorts of the diffuse and epithelial infiltrative models showed an 
overall effect of entity for the total amount of endothelial cells in the brain slices (P = 0.0019) with 
both breast models showing higher number of vessels compared to their respective colon counterparts 
(Figure 47 A).  
In addition, I found an overall effect of entity concerning the general microglia/macrophage response 
(P = 0.0125) and T cell response (P = 0.0233) in the brain slices (Figure 47 B+D). Both breast models 
showed higher levels of activated microglia/macrophages and higher numbers of T cells compared to 
their respective colon counterparts. Although the entity had no direct effect on the intensity of the 
astrocytic reaction (Figure 47 C), it seemed to influence the distribution of activated astrocytes in the 
metastatic microenvironment. In both colon models, they accumulated around the MMPI in a more 
encapsulated state compared to their respective breast counterparts (data not shown). 
This difference in the immune response between breast and colon cancer models might be interesting 
for clinical applications. 
 
Figure 47: Impact of entity on angiogenesis and metastatic microenvironment. IHC staining 
quantifications for endothelial cells (CD31), activated microglia/macrophages (MΦ) (IBA1), activated 
astrocytes (GFAP) and T cells (CD3) in the metastatic brain tissue of mice with breast cancer brain 
metastasis of diffuse infiltrative E0771-LG (E0) and epithelial infiltrative 410.4 and colon cancer brain 
metastasis of diffuse infiltrative CT26 and epithelial infiltrative CMT93Var (CMT). CD31 staining is 
indicated as counts per mm² in whole tissue. Quantification of IBA1 and GFAP staining is indicated as 
the percentage of stained area and quantification of CD3 staining is indicated as counts per mm² 
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3.4.6. Summary of in vivo characterization results 
In summary, the modifications of the cell adhesion receptor E-cadherin did not impair the colonization 
capacity of the cells but had an enormous impact on MMPI pattern and infiltration grade in murine 
brain metastases in vivo, which in turn resulted in pronounced changes in overall survival rates and 
immune response (Figure 48). Both approaches resulted in profound morphological changes at the 
MMPI, with a switch from diffuse infiltrative to more epithelial-like infiltrative pattern in case of 
E-cadherin upregulation and the other way around in case of downregulation. Consistently, the 
infiltration grade was decreased after overexpression and increased after knockdown. The altered 
infiltration was reflected in the survival data with partly prolonged survival of mice after the 
overexpression of E-cadherin and significantly shortened survival after its knockdown in breast and 
colon models. In addition, higher levels of E-cadherin and the resulting growth in a more compact way 
correlated with more angiogenesis in the metastatic tissue. Remarkably, the infiltration grade also 
directly affected the immune response of the metastatic microenvironment. Higher infiltration rates 
correlated with an increased immune reaction at the MMPI. Interestingly, the entity of the metastatic 
cells itself also had an impact on angiogenesis and immune response as higher levels were observed in 
breast cancer models in both cases. These data demonstrated the different dependencies of diffuse 
and epithelial infiltrative models on the cell adhesion receptor E-cadherin in vivo and further 
emphasized the concept of different molecular mechanisms supporting both types of breast and colon 
cancer infiltration. 
 
Figure 48: Summary of E-cadherin modification effects in brain metastasis mouse models  
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3.5. Verification of the prognostic value of the gene expression signature 
As demonstrated before, the identified gene expression signature (see 3.2.4) still differentiated diffuse 
and epithelial-like infiltrative cells with mesenchymal character from epithelial and diffuse-like 
infiltrative cells with epithelial character independent of E-cadherin modification (see 3.3.2.1). Thus, 
the last part of this work addressed the question of its prognostic impact in vivo across species. 
The signature was first validated in all different brain metastasis mouse models and afterwards tested 
in a data set of human metastases. 
3.5.1. Validation of gene expression signature in mouse models 
First, I validated selected targets of the gene expression signature in all brain metastasis mouse models 
by quantitative RT-PCR analysis of genes from the previously identified gene clusters in control brains 
of mice injected only with ECM and brain metastases of mice after E-cadherin modifications of diffuse 
and epithelial infiltrative breast and colon cancer cell lines. I could confirm that the gene expression 
profiles reliably separated mice with brain metastases from control mice that were injected only with 
ECM representing the healthy situation. Furthermore, the signature distinguished metastases formed 
by diffuse and epithelial-like infiltrative cells with mesenchymal character (E0771-LG and CT26 
metastases) from metastases caused by epithelial and diffuse-like infiltrative cells with epithelial 
character (410.4 and CMT93Var metastases) independent of E-cadherin modifications (Figure 49 A). 
Two representative genes are shown in detail and demonstrate the exclusive significant upregulation 
in brain metastasis mouse models of diffuse and epithelial-like infiltrative cells with mesenchymal 
character or epithelial and diffuse-like infiltrative cells with epithelial character compared to brains of 
control mice (Figure 49 B). In addition, they once again illustrate that the E-cadherin modifications did 
not change the expression of other signature components. The prognostic impact of the signature was 
emphasized by the comparison of survival curves of all mice with brain metastases showing the 
significantly shorter survival of cohorts with diffuse and epithelial-like infiltrative MMPI pattern and 
mesenchymal character of metastatic cells (Figure 49 C). Furthermore, there was still a large gap 
between the most aggressive knockdown cohort (410.4 sh) and the least aggressive overexpression 
cohort (CT26 OE). Although the overexpression of E-cadherin had prolonged survival and the 
knockdown had shortened it due to a switch of the infiltration patterns, this effect alone was not 
sufficient to completely change the aggressiveness of the cells and adapt the overall survival to the 
opposite state in vivo.  
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Figure 49: Validation of gene expression signature in brain metastasis mouse models. 
(A+B) Quantitative RT-PCR analysis of selected genes from previously identified gene clusters in brain 
metastases of mice after E-cadherin modifications of diffuse and epithelial infiltrative breast (B) and 
colon (C) cancer cell lines (CTL: control, OE: E-cadherin-overexpression, sh: E-cadherin-knockdown) as 
well as only ECM injected brains of control mice (Brain; C57BL/6 for E0771-LG and CMT93Var, BALB/c 
for CT26 and 410.4). Gapdh and Pgk1 were used as housekeeping genes (HK). (A) Heatmap displaying 
log2 transformed z-scores. Unsupervised hierarchical clustering clearly separates diffuse infiltrative 
brain metastases with mesenchymal character, epithelial infiltrative brain metastases with epithelial 
character as well as control brains from each other. (B) Representative prognostic candidate genes for 
(B1) shorter survival and (B2) longer survival (circles: C57BL/6, rhombs: BALB/c; mean and individual 
values; n ≥ 4; one-way ANOVA followed by Sidak’s multiple comparisons; ****P < 0.0001). (C) Kaplan-
Meier survival curves of mice injected with diffuse and epithelial infiltrative control and E-cadherin-
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3.5.2. Application of gene expression signature on human metastases 
In a final step, we had the opportunity to examine the prognostic value of the final gene expression 
signature (Figure 50 A) in a data set of human metastases in collaboration with the department of 
medical bioinformatics at the University Medicine Göttingen. This data set contained gene expression 
values of brain and liver metastases from patients with breast, colorectal or lung cancer. Metastases 
were assigned to two groups based on their signature score values (HIGH: > median; LOW: ≤ median) 
and a survival curve was created for the resulting patient cohorts (Figure 50 B). Indeed, the signature 
also had a prognostic impact in human metastases. Patients with high signature score values (median 
OS = 26.33 months) demonstrated significantly prolonged survival rates compared to the patient 
cohort with low values (median OS = 8.58 months, P = 0.0002). This gene expression signature could 
therefore represent an important prognostic tool for clinical practice.  
 
Figure 50: Application of gene expression signature on human metastases. (A) Final gene expression 
signature including cell adhesion and cytoskeletal components, ECM binding integrins, EMT markers, 
metabolic genes and others. (B) Kaplan-Meier survival curves of patients with brain or liver metastases 
assigned to cohorts based on their signature score values (high: > median; low: ≤ median; n = 61; 
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4. Discussion 
Although metastasis of primary tumors is a major clinical problem for cancer patients, research for the 
underlying mechanisms is still underrepresented in oncological studies. In the frame of this thesis, 
I aimed to shed more light on the mechanisms underlying metastatic infiltration of tumor cells in the 
brain parenchyma, especially in context of innate and modified E-cadherin levels, and thus contribute 
to our understanding of colonization mechanisms in the brain. 
4.1. Selection of mouse models for the study of the MMPI in brain 
metastases 
The existence of different MMPI patterns is widely accepted and has been confirmed across entities 
(Shiono et al., 2005; Siam et al., 2015; van Dam et al., 2017). The fact that the MMPI has a prognostic 
impact for the patient emphasizes the existence of different underlying mechanisms and a changed 
pathophysiology. It is necessary to understand these differences on a molecular level to be able to 
identify potential treatment targets as a prerequisite for the effective development of targeted 
therapies. As infiltrative MMPIs correlate with worst survival rates, they were the focus of this study. 
For the detailed study of the MMPI in brain metastases, adequate mouse models are needed that 
represent the different infiltrative MMPI patterns observed in human brain metastases.  
4.1.1. Comparison of murine and human brain metastases 
In our lab, we have established a wide variety of murine cancer cell lines in a late brain colonization 
model, which ensures the reliable and reproducible outgrowth of metastases within short periods. 
The resulting brain metastasis mouse models cover a wide range of aggressiveness and infiltration 
level and realistically reflect the diversity observed in oncological diagnostics.  
In both human breast cancer brain metastases as well as the resembling murine models, infiltrative 
growth patterns displayed visible macroscopic metastases and tumor cells that were physically 
separated from the metastatic border. A closer examination of the MMPI revealed that diffuse 
infiltrative patterns were characterized by several single tumor cells with mesenchymal morphological 
features that deeply infiltrated the adjacent tissue, while epithelial infiltration manifested in clusters 
of tumor cells that collectively infiltrated into the adjacent brain parenchyma as cohorts or clusters 
with an inner lumen (Blazquez et al., 2020b). 
The highly aggressive diffuse infiltrative models E0771-LG and CT26 and the moderate to low 
aggressive epithelial infiltrative models 410.4 and CMT93Var of breast and colon origin, respectively, 
were perfectly suited for this study. Nevertheless, one has to keep in mind that the terms high and low 
aggressive are relative concepts, as all those infiltrative models led to the occurrence of metastases 
DISCUSSION  126 
 
and the death of the animals within a few months. The usage of different entities should ensure that 
any identified effects were robust between entities and not a random phenomenon. Findings of this 
study therefore have a bigger chance to be generally valid for all brain metastases. The selection of 
breast and colon cancer was motivated by the fact that they are commonly involved in brain 
metastases and comprise some of the highest risk of brain metastasis formation (Neagu et al., 2015). 
In future experiments, one could include more risky entities including melanoma or lung cancer cell 
lines, which we partially already have established in our in vivo model. 
In previous studies, our group came across interesting observations concerning the expression of 
E-cadherin, which contradicted the common knowledge of this cell adhesion receptor to be solely 
regulated by EMT mechanisms. In detail, we noticed an upregulation of E-cadherin at the border of 
metastatic tissue and adjacent brain parenchyma and even found E-cadherin positive cell clusters 
within blood vessels in human and murine samples (Blazquez et al., 2020a), although one would not 
have expected any expression in this location according to the EMT theory. However, EMT is no longer 
seen as the key reason, but more as a side effect, and the role of E-cadherin is currently undergoing a 
structural change (Petrova et al., 2016; Romeo et al., 2019). Indeed, E-cadherin has been shown to play 
an essential role in the metastatic process in recent studies (Bajrami et al., 2018; Gall et al., 2013; Li et 
al., 2017; Padmanaban et al., 2019; Wong et al., 2018). 
Histological stainings of the selected mouse models could confirm the innate level of E-cadherin as one 
of the key differences between diffuse and epithelial infiltrative MMPI models, as it was the case in 
human brain metastasis samples. In both cases, human breast cancer brain metastases as well as the 
resembling murine models, E-cadherin was almost absent in the metastatic tissue of diffuse infiltrative 
models and highly expressed in epithelial infiltrative counterparts. These observations highlighted the 
importance of E-cadherin as an interesting candidate for more detailed studies of the underlying 
mechanisms in context of different infiltrative MMPI patterns.  
4.1.2. Characterization of respective murine cancer cell lines 
After the selection of suitable mouse models, the next logical step was the detailed in vitro 
characterization of the respective murine cancer cell lines to assess the initial situation and create a 
basis for subsequent genetic modifications of E-cadherin. Diffuse and epithelial infiltrative cell lines 
were also compared to identify MMPI pattern- or entity-specific effects.  
All cell lines were adherent and easy to cultivate in cell culture. They showed a MMPI pattern-specific 
morphology that resembled their outgrowth pattern in vivo. Diffuse infiltrative E0771-LG breast and 
CT26 colon cell lines displayed a mesenchymal phenotype with fibroblast-like morphology and mainly 
remained as single cells even at high confluence levels, while epithelial infiltrative 410.4 breast and 
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CMT93Var colon cell lines presented a cobblestone-like morphology and pronounced cell-cell contacts. 
However, since no MMPI pattern-specific differences concerning cell proliferation and survival rates 
were present, the striking contrast in infiltration grade in brain metastases could not be simply 
explained based on differences in their proliferative behavior.  
Furthermore, all cell lines behaved according to expectations in the broad spectrum of functional 
assays that have been established and refined in our lab over the years. They showed their 
characteristic migration behavior and invasive capacity in 2D in vitro assays and MMPI pattern-specific 
differences were clearly visible. Compared to the slower and less aggressive epithelial lines, both 
diffuse lines migrated faster, were accompanied by a larger number of single spreading cells and had 
a higher invasive capacity. This represented the situation in the brain metastasis mouse models very 
well, with the diffuse infiltrative cell lines being more aggressive and displaying a high number of single 
tumor cells invading into the brain parenchyma. The situation was similar in 3D in vitro assays that 
mimic the formation of micro-metastases and metastatic outgrowth in the brain. Diffuse cell lines 
formed spheroids with larger outgrowth area and a higher number of colonies compared to epithelial 
counterparts. The CMT93Var cell line even displayed the lowest colony formation rate and did not 
form quantifiable spheroids at all. This fact resembled their outgrowth ability and speed in the in vivo 
brain colonization model, where they show the slowest occurrence of brain metastases among all 
selected models.  
Due to the fact that low levels of E-cadherin correlated with higher migration and invasiveness across 
entities, the specific opposing genetic modification of E-cadherin in the metastatic outgrowth models 
appeared to be a promising target to switch the pattern of the MMPIs. 
4.2. Role of E-cadherin in metastatic brain colonization 
Several methods are available for the genetic modification of specific targets. Among other factors, 
the strategies differ in terms of complexity, practicability, cost, and reproducibility. For this study, the 
method of lentiviral transduction was used to create stable cell lines either overexpressing or 
suppressing E-cadherin levels of diffuse and epithelial infiltrative cell lines, respectively. This method 
is relatively easy to handle and comes with several advantages. For example, there is no need for 
repeated introduction of genetic material into the cells, as the produced lentiviral vectors integrate 
into the nucleus of the target cells and can regulate gene expression at the translational level. 
The resulting overexpression and knockdown cell lines are stable and perfectly suited for long-term 
studies in culture and in the animal model. Furthermore, this method has a high efficiency and results 
are reproducible. In order to avoid effects of selection antibiotics on the tumor or other stromal or 
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immune cells in following in vivo experiments, selected constructs did not require inducing treatments 
and mice received no systemic therapy at any time.  
For epithelial cell lines with high innate E-cadherin levels, a knockdown was chosen instead of a 
complete knockout. The shRNA only reduced the gene expression at the mRNA level instead of 
completely silencing the gene at the DNA level, as it would have been the case using CRISPR 
techniques. The knockdown approach better reflects the real biological situation, since mice with a 
complete knockout of E-cadherin are embryonic lethal (Larue et al., 1994) and those with a conditional 
knockout fail to survive upon activation (Bondow et al., 2012).  
In order to exclude random effects in the following studies, two different modified cell lines with the 
most pronounced changes in E-cadherin levels and one control were chosen for each parental cell line. 
Interestingly, the artificially added E-cadherin did not show the typical cellular distribution as expected 
from the epithelial wild-type situation. It rather accumulated within the cytoplasm and did not appear 
at regions of cell-cell contacts. The established stable overexpression and knockdown cell lines now 
enabled the comparative study of the role of E-cadherin levels in metastatic brain colonization. 
4.2.1. Impact of E-cadherin modifications in murine cancer cell lines 
The first part focused on the direct impact of E-cadherin modifications on the cells in vitro since these 
data can give a first hint on the outcome in the animal model. 
As expected, both modifications provoked profound changes in cell morphology. Across entities, the 
overexpression of E-cadherin clearly switched the diffuse and mesenchymal phenotype with 
fibroblast-like morphology towards a more epithelial-like phenotype with some cobblestone-like 
features and increased cell-cell contacts, while the knockdown had the opposite effect. These findings 
are in accordance with previous observations and the EMT theory. However, besides the 
morphological changes these modifications did not substantially affect the original cell character. 
Contrary to the current concept of EMT, the protein levels of other epithelial and mesenchymal 
markers, including cytokeratin-8 and vimentin, remained stable and did not change in relation to the 
altered level of E-cadherin. Although diffuse cells acquired a more epithelial-like morphology, they 
retained their mesenchymal equipment. Moreover, epithelial cells that had switched to a more diffuse-
like phenotype still kept their epithelial character and structure. Gene expression studies of a variety 
of cell adhesion and cytoskeletal components, ECM binding integrins, EMT markers, metabolic genes 
and other factors reinforced that the modification of E-cadherin only resulted in a morphological EMT 
phenotype by changing the cell-cell adhesion, but did not change the cellular equipment or 
metabolism. Interestingly, the level of β-catenin showed a positive correlation to the altered levels of 
E-cadherin. Instead of its previously postulated predominant role as an intracellular signaling molecule, 
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its main function in the investigated cells seemed to be the cell adhesion as a binding partner in the 
α-catenin/β-catenin/E-cadherin complex.  
Since none of the modifications had major effects on cell proliferation or survival rates of the cell lines, 
proliferation-induced effects of E-cadherin modification on migration and invasion efficacy could be 
excluded. Across entities, the gain of E-cadherin significantly decreased migration speed and invasive 
capacity in diffuse cell lines, while the artificial loss of E-cadherin made epithelial lines faster and even 
more invasive. In other words, there was a negative correlation between the level of E-cadherin and 
the invasive capacity. As already demonstrated on a morphological basis, lowered levels of E-cadherin 
resulted in less cell-cell contacts by adherens junctions. Cells were predominantly in a single-mode and 
could infiltrate farer into the surrounding area. Conversely, increased levels of E-cadherin enabled 
more cell-cell contacts through adherens junctions. Cells stuck together, preferably grew as a wall 
connected to each other and infiltrated less far and often as clusters. These results were in accordance 
with previous experimental in vitro studies that could partially suppress the tumorigenicity of cancer 
cells without detectable E-cadherin expression by the re-expression of this cell adhesion molecule 
(Navarro et al., 1991). 
Furthermore, anchorage-independent growth in soft agar was not significantly affected in any of the 
diffuse lines with increased E-cadherin levels while they showed significantly reduced outgrowth speed 
compared to controls in the 3D culture spheroid model. As these assays mimic the formation of micro-
metastases and metastatic outgrowth in vivo, it pointed to a slowed outgrowth of brain metastases 
after injection of E-cadherin-overexpressing cells but no impairment of the general colonization ability. 
Contrary to expectations from diffuse lines with low E-cadherin expression showing increased spheroid 
outgrowth, the suppression of E-cadherin in epithelial breast cancer 410.4 disabled their ability to form 
spheroids in 3D culture models. This observation suggested that they might depend on E-cadherin for 
efficient micro-metastasis formation and outgrowth and would maybe not be able to settle down in 
the in vivo setting. None of the CMT93Var colon cancer lines was able to recover the ability to form 
quantifiable spheroids after E-cadherin knockdown, but this was not a surprise, as already the wild-
type cell line had shown no spheroid formation ability compared to the other diffuse and epithelial 
infiltrative cell lines. However, since all knockdown lines were able to form colonies in soft agar assays, 
we still expected the formation of brain metastases after injection of E-cadherin-knockdown cells. 
Taken together, the in vitro results emphasized that the impact of E-cadherin on colonization is 
context-dependent and affirmed the need for further investigations of the in vivo situation. 
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4.2.2. Impact of E-cadherin modifications in brain metastasis mouse models 
Indeed, previous in vitro data could be directly transferred from cell culture to the situation in the living 
animal. Intracortical injections of control and modified cell lines into syngeneic mice resulted in brain 
metastases in all models and revealed interesting findings concerning the impact of E-cadherin level 
on MMPI pattern and infiltration grade of brain metastases and its correlation with overall survival and 
the interplay with immune system components of the metastatic microenvironment at the MMPI.  
4.2.2.1. Impact of E-cadherin level on infiltration grade at the MMPI 
Based on the similar behavior of both modified cell lines in initial experiments, the modified cohorts 
had been pooled to one group in the following in vivo survival analyses. As expected from 3D in vitro 
assays, none of the modifications of E-cadherin had an effect on the general colonization capacity of 
the cell lines since all models resulted in quantifiable brain metastases after intracortical injections. 
However, all genetic modifications resulted in profound morphological changes at the MMPI across 
entities. The level of E-cadherin directly correlated with the morphology of infiltrating cells that were 
physically separated from the metastatic border. Along with an increasing level of E-cadherin, the 
MMPI of diffuse infiltrative E0771-LG and CT26 overexpression lines was dominated by clusters of 
tumor cells that collectively infiltrated into the adjacent brain parenchyma as cohorts. Nevertheless, 
they still protruded far into the surrounding brain parenchyma and maintained their generally high 
infiltrative character. In epithelial infiltrative 410.4 and CMT93Var mouse models, infiltration was more 
pronounced after knockdown. Decreased levels of E-cadherin resulted in an increased number of single 
metastatic cells predominantly isolated from each other that invaded much farer into the surrounding 
tissue comared to the control situation. However, the infiltration depth of most knockdown 
metastases did not reach the level of the highly infiltrative diffuse models. The modification of 
E-cadherin thus resulted in a clear switch from diffuse to more epithelial-like infiltrative pattern in case 
of E-cadherin upregulation and the other way around in case of downregulation.  
These morphological changes in the infiltration grade were even quantifiable in a systematic approach 
by analyzing the extent of infiltrative growth into the brain parenchyma along the MMPI in all brain 
metastases. Consequently, changes in infiltration grade were directly correlated with altered overall 
survival rates of mice.  
DISCUSSION  131 
 
4.2.2.2. Prolonged survival due to reduced infiltration at the MMPI after 
E-cadherin overexpression 
In both diffuse infiltrative models, metastases appeared within short periods from only 2 weeks in 
E0771-LG to 4 weeks in CT26. This demonstrated their high aggressiveness, especially in comparison 
with the epithelial infiltrative models, where symptom-free survival ranged from 2 to 4 months.  
While the overexpression of E-cadherin significantly prolonged survival of mice in the diffuse 
infiltrative CT26 colon cancer model, this effect was not observable in the corresponding variant of 
E0771-LG of breast origin. Taking into account that all metastases developed within 3 weeks in this 
model, also the modified cell lines were probably still so aggressive that possible differences had no 
time to become apparent. Another reason could have been the relatively low level of E-cadherin in the 
overexpression group, which was only detectable by quantitative RT-PCR analysis of the metastatic 
brain tissue but not visible in IHC stainings. In contrast, E-cadherin overexpression clearly reached 
higher levels in the CT26 colon model, as confirmed by immunohistological stainings of brain slices. 
Furthermore, there was more time for differences to became apparent and E-cadherin could thus 
significantly prolong survival in this model.  
Taken together, the reduced infiltration at the MMPI after E-cadherin overexpression resulted in 
prolonged survival. These results are in accordance with clinical studies reporting lower incidence of 
metastases in cancer patients with increased E-cadherin expression (Li et al., 2017). With increasing 
expression of E-cadherin, less cells detach from the primary tumor, enter the circulation and have the 
potential to form critical metastases. 
4.2.2.3. Shortened survival due to increased infiltration at the MMPI after 
E-cadherin knockdown 
Contrary to considerations from 3D in vitro assay observations, where 410.4 knockdown cells were not 
able to form quantifiable spheroids, they were not impaired at all in the real in vivo setting in the brain. 
They even became much more aggressive and showed the most prominent effects of all survival 
analyses. The knockdown of E-cadherin reduced the symptom-free survival of experimental animals to 
about one-half of the original timespan in the 410.4 breast cancer model.  
For reasons of comparability, the number of injected cells had been equalized to 1000 in all mouse 
models. As the control line of the CMT93Var colon cancer model did not successfully colonize in all 
animals, probably an initially higher number of injected cells would have been necessary to result in 
brain metastases in all animals. As already mentioned earlier, CMT93Var cells have the lowest 
metastatic potential of all selected model cell lines. At first glance, no significant differences were 
present between cohorts except for a negative trend in the knockdown group.  
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Originally, the modified cohorts had been pooled to one group for the analyses due to similar effects 
in initial experiments. However, in later analyses it became apparent that this procedure was not 
capable of depicting the actual situation in CMT93Var. The re-analysis of all survival curves in separate 
groups justified the previous pooling for all models except CMT93Var. Here, substantial differences in 
overall survival were revealed between the two knockdown cell lines. One of the CMT93Var 
knockdown lines (sh#1) showed shortened survival and remarkably higher success rates resulting in 
metastases in all injected animals. In contrast, the second knockdown line (sh#2) even prolonged the 
survival and was only successful in half of the cases. The increased colonization capacity of sh#1 and 
the decreased value for sh#2 were also reflected by the previously explained colonization index. 
Interestingly, the growth pattern of the sh#2 cohort in histological stainings was similar to the control 
situation and did not resemble the sh#1 knockdown cohort at all. Since the level of E-cadherin was 
reduced in both knockdown groups to a similar extend, this difference in aggressiveness had to be 
explained by another factor. We assumed a random variation or deregulation had taken place in the 
divergent second knockdown line and could indeed identify the mesenchymal marker vimentin to be 
differentially expressed in the two CMT93Var knockdown cell lines. Prolonged survival rates of mice 
correlated with decreasing ratios of vimentin and E-cadherin across models and entities and this effect 
was specific for vimentin across all investigated targets. Since the CMT93Var sh#2 cell line showed 
reduced levels of vimentin and consequently a decreased vimentin/E-cadherin ratio, this offered an 
explanation for their prolonged survival rates. The positive correlation between vimentin level and 
aggressiveness emphasizes that this mesenchymal factor seems to play a crucial role in long-term 
survival and should be further examined in following studies. 
As in all probability an unintended mutation or deregulation had occurred in the second CMT93Var 
knockdown line, which resulted in reduced levels of the mesenchymal marker vimentin, it was thus 
not indicative for the assessment of the sole impact of E-cadherin knockdown in the mouse models. 
Although these animals were thus excluded from further in vivo analyses in this thesis, the two 
different CMT93Var knockdown cell lines represent an interesting model system to further study the 
interplay of E-cadherin and vimentin.  
Taken together, the increased infiltration at the MMPI after E-cadherin knockdown resulted in 
shortened survival. These findings are in accordance with data from clinical studies that associate 
functional loss of E-cadherin with poor prognosis and survival (Wong et al., 2018). 
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4.2.2.4. Correlation of growth pattern and angiogenesis in metastatic tissue 
Cancer cells ensure themselves the optimal supply with oxygen and nutrients for further metastatic 
outgrowth by angiogenesis, the growth of new blood vessels (Hanahan et al., 2000). Tumors rely on 
this vascularization and can not enlarge beyond 1 to 2 mm in diameter without it probably due to 
hypoxia-induced apoptosis (Erdogan et al., 2010). Angiotropic growth occurs in both diffuse and 
epithelial infiltrative MMPI patterns and is characterized by metastatic cells that grow as sheaths 
around new vessels to protrude even farer into the surrounding parenchyma (Blazquez et al., 2020b). 
Angiogenesis within the metastatic tissue can be quantified in immunohistochemical stainings using 
antibodies that are specific for vascular endothelial cells (for example, CD31) and is usually expressed 
as microvessel density (Sener et al., 2016).  
In primary tumors, MVD has been associated with poor outcome and advanced pathologic stage in 
several types of cancer including breast, lung, and colon as well as malignant melanoma (Sener et al., 
2016). As all those types involve major risks for brain metastasis formation, MVD is also likely to be a 
prognostic factor in brain metastases. 
In primary brain tumors, MVD has been proved as a prognostic factor for the grade of astrocytomas, a 
type of glioma that originates in astrocytes. Astrocytomas can be classified based on their infiltration 
grade into non-invasive (WHO grade I) with clear outlines on diagnostic images and invasive (WHO 
grade II–IV) with diffuse zones of infiltration. In several studies, the highest MVD rates were found in 
the most infiltrative forms (Leon et al., 1996; Mahzouni et al., 2010). However, to our knowledge no 
one has focused on a direct comparison of angiogenesis rates in different infiltrative MMPI patterns in 
brain metastases. 
Within the brain tissue itself, only few small vessels were present throughout conditions and entities 
and any observed effects were most evident in the metastatic tissue. Interestingly, the growth pattern 
had a direct effect on microvessel density since both originally epithelial infiltrative models exhibited 
higher vessel density in comparison to corresponding diffuse infiltrative models. Metastases of the 
epithelial type grew in a very compact manner without much space between single metastatic cells 
and thus required a higher vascularization to avoid hypoxia-induced apoptosis compared to diffuse 
metastases that grew less dense in a looser manner with larger areas between cells. In accordance, 
diffuse infiltrative metastases showed a more pronounced angiotropic growth with many vessels in 
the adjacent brain parenchyma being surrounded by invading metastatic cells. 
Consistent with that, the overexpression of E-cadherin, which changed the morphology from diffuse 
infiltrative to epithelial-like infiltrative, resulted in a higher number of vessels with additionally larger 
diameter in breast cancer E0771-LG. Furthermore, the knockdown of E-cadherin had the opposite 
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effect, causing a phenotypic switch from epithelial infiltrative to diffuse-like infiltrative features and 
accordingly led to a lower number of vessels with even decreased size in breast cancer 410.4. 
Differences between colon lines showed the same tendencies, but were not as demarcated and did 
not reach significance. This could be partially explained by the fact that colon models showed lower 
vessel numbers in general compared to their respective breast counterparts.  
Taken together, the altered growth pattern of brain metastases due to the modification of E-cadherin 
levels had a clear impact on angiogenesis and resulted in a switch from low to high angiogenic-active 
state in more compact diffuse infiltrative metastases after overexpression and the other way around 
after knockdown. These results indicate the prognostic value of microvessel density for the metastatic 
growth pattern and infiltration grade and thus overall survival in infiltrative brain metastases. 
4.2.2.5. Impact of infiltration grade on the metastatic microenvironment 
The metastatic microenvironment plays an essential role in the metastatic process. Apart from their 
actual task of defending the organ from potentially harmful intruders, immune cells can also be 
hijacked by invading cancer cells causing a shift in their behavior (Chuang et al., 2013; Pukrop et al., 
2010). As a result, the MME can facilitate initial survival of disseminated cancer cells and promote their 
further proliferation resulting in even more efficient colonization of the target organ (Fidler, 2011; 
Quail et al., 2013). It is therefore of particular importance to understand the underlying mechanisms 
that cause this change of the brain immune system from a defensive into an advertising attitude 
towards metastatic cells. Previous observations of our group suggested that the MMPI pattern could 
influence immune infiltration and thus may affect the response to specific therapies. In this case, future 
therapeutic decisions for cancer patients with brain metastases could depend on prior assessment of 
the present MMPI pattern. To address this question, a detailed morphological analysis of the present 
immune response situation in the established mouse models with different infiltrative MMPI patterns 
before and after modification of E-cadherin levels was carried out. 
As described in the introduction, the immune reaction in the brain mainly consists of macrophage 
response, astrocytic reaction and T cell response. The first region of interest would naturally be the 
MMPI, as it usually entails the largest contact area for an interaction of metastatic cells and common 
immune players of the surrounding microenvironment. However, as diffuse infiltrative MMPI patterns 
are characterized by metastatic cells that infiltrate way farer into the adjacent tissue compared to the 
epithelial infiltrative type, they thus offer more possible interaction sites. In fact, the distribution of 
immune response components was altered even within the metastatic and brain tissue across models 
and therefore analyzed in a region-dependent manner. 
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Activated microglia, the resident macrophage cells in the brain (Berghoff et al., 2015) were quantified 
in stainings for IBA1. However, it has been taken into account that IBA1 detects activated microglia (Ito 
et al., 2001) as well as activated macrophages that immigrated from the blood stream (Ohsawa et al., 
2004). It is thus not possible to differentiate between tissue-resident microglia and infiltrating 
monocyte-derived macrophage populations in the brain tissue with this antibody. Nevertheless, the 
staining gives a good impression of microglia/macrophage reaction and is well established in our lab. 
Activated astrocytes, the most abundant glial cells of the CNS, were quantified in stainings for GFAP 
(Xing et al., 2013) and CD3 was used as a marker for the response of T cells, the main adaptive immune 
system effector cells (Berghoff et al., 2015).  
The general distribution of immune cells within the brain was mainly restricted to the metastatic tissue 
regions and adjacent brain parenchyma independent of the infiltration pattern at the MMPI. Activated 
microglia and astrocytes and T cells were almost absent in the contralateral hemispheres which 
perfectly represented the situation in the healthy brain parenchyma. All three key players were found 
at the MMPI, but otherwise showed area-specific distributions. T cells mainly operated inside the 
metastasis, astrocytes predominantly stayed outside in the adjacent brain tissue, and 
microglia/macrophages were equally active on both sides. 
The origin of metastatic cells also seems to play a decisive role. In general, entity-specific differences 
were present with breast cancer-derived models showing higher levels of microglia/macrophage 
response and T cell number compared to the milder reactions in colon cancer-derived models. The 
lower microglia and T cell infiltration in metastatic tissues of colon origin could partially explain the 
fact that to date checkpoint blockade has only been reported to be effective in patients with breast 
cancer but not in cohorts with colon cancer. Recent clinical studies showed that therapies with 
checkpoint inhibitors, which trigger a defense reaction of the immune system against the tumor tissue, 
were effective in early and advanced triple-negative breast cancer and significantly increased the 
percentage of patients with a pathological complete response when administered in combination with 
neoadjuvant chemotherapy (Schmid et al., 2018; Schmid et al., 2020). Future experiments should 
investigate these differences in MME composition between entities in more detail to reveal the 
underlying molecular mechanisms and potentially identify promising therapeutic targets. 
Furthermore, the pattern of activated astrocytes in breast cancer-derived models was distributed over 
a wider area compared to the characteristic dense accumulation around the MMPI in colon entities. 
A detailed look at the growth pattern might explain this observation. Colon-derived cancer cells 
generally infiltrate in a more encapsulated state and thus may allow immune cells to form something 
like a shield by accumulating predominantly at the MMPI.  
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According to our theory, a difference in immune infiltration, or in other words the presence of immune 
cells in the metastasis, between control and modified diffuse and epithelial infiltrative MMPI models 
was to be expected. Indeed, this could be especially observed for activated microglia/macrophages 
and T cells. When metastatic cells grew less compact, as it was the case in diffuse infiltrative models 
or formerly epithelial infiltrative models after knockdown of E-cadherin, more immune cells could 
enter the metastatic region by passing the MMPI barrier and fight against the foreign intruders inside 
the metastatic lesion. Due to the loss of E-cadherin, those formerly epithelial infiltrative metastatic 
cells also adapted their tissue-destructive mechanism to the situation present in diffuse infiltrative 
metastases and expanded the infiltration zone over a larger area. Subsequently, the immune reaction 
of the MME was increased and showed an altered distribution pattern. In epithelial infiltrative models 
or formerly diffuse infiltrative models after overexpression of E-cadherin, a barrier was formed and 
provided a defined area for immune cells to attack. Consequently, they could not easily cross the 
barrier and were thus found only in smaller quantities inside the metastasis, while the majority 
accumulated outside in the surrounding parenchyma and predominantly at the MMPI. The switch from 
a diffuse infiltrative to a more compact epithelial-like infiltrative MMPI pattern due to the E-cadherin 
overexpression thus seemed to force an immune exclusion phenotype of the metastatic cells because 
of the newly forming epithelial barrier.  
Furthermore, astrocytes and microglia, which represent the first line of defense in the MME in the 
brain, seemed to effectively shield compact epithelial infiltrative metastases from healthy brain 
parenchyma. In widely spread diffuse infiltrative metastases and less compact growing diffuse-like 
epithelial infiltrative ones due to the loss of E-cadherin, this demarcated shielding was not possible as 
immune cells had to spread over a larger area in the brain tissue to fight all infiltrating single metastatic 
cells. Such a shielding mechanism, characterized by activated microglia and astrocytes that form a 
cellular barrier at the MMPI to encapsulate the metastatic cells and thus potentially prevent 
inflammation and induce a local immune suppression, was also previously observed in our lab. It was 
present in different model systems, ranging from ex vivo organotypic brain slice cocultures to in vivo 
mouse models for late brain colonization and also found in samples of human brain metastases 
(Blazquez et al., 2018; Chuang et al., 2013; Pukrop et al., 2010).  
Taken together, these findings reinforce the importance of the MMPI pattern for the composition of 
the metastatic microenvironment and the immune infiltrate. A switch of the infiltration pattern, as it 
was caused by modifications of the cell adhesion receptor E-cadherin, results in an altered reaction of 
the surrounding tissue and has an enormous impact on the metastatic microenvironment and organ 
defense. Further studies should focus on the underlying molecular mechanisms of these shielding 
immune cells to investigate their therapeutic potential for a targeted prevention or inhibition of 
metastatic colonization in the brain.  
DISCUSSION  137 
 
4.2.3. Contact inhibition as potential therapeutic target mechanism 
The metastatic growth pattern not only correlates with the overall prognosis for the patient, but also 
seems to influence the efficacy of therapeutic concepts (Kienast et al., 2010). As a consequence, a 
therapy should to be chosen according to the present MMPI pattern. Massague and colleagues have 
already demonstrated that YAP-TAZ signaling is essential for colonization (Er et al., 2018). For many of 
their experiments they used brain metastatic cancer cell lines of the diffuse infiltrative type. It thus has 
to be clarified if this only accounts for diffuse infiltrative models or also for epithelial infiltrative ones. 
The general assessment of the situation in wild-type cell lines could identify contact inhibition as a 
further mechanism that clearly differed between diffuse and epithelial MMPI model cell lines. These 
observations reinforced the theory of different molecular mechanisms supporting both types of breast 
and colon cancer infiltration. On the one hand, the epithelial infiltrating 410.4 and CMT93Var cells 
retained the expression of E-cadherin and showed intact contact inhibition. On the other hand, the 
diffuse infiltrating E0771-LG and CT26 lost the expression of this adhesion molecule and seemed to 
have no functional contact inhibition.  
Since the E-cadherin receptor in the cell membrane is a key player in contact inhibition of proliferation, 
we were interested whether any of the E-cadherin modifications had an influence on the basic 
situation. Contrary to expectations, the overexpression of E-cadherin could not restore contact 
inhibition in diffuse cell lines that continued to show a tonic YAP signaling. Taking into account that the 
artificial expression of E-cadherin did not lead to the accumulation and localization of this adhesion 
protein at the cell membranes, this non-existing effect might be partially explained. If the increased 
E-cadherin level is not present at the membranes, it can not contribute to contact inhibition of 
proliferation via adherens junctions as described in the introduction. In contrast, the knockdown of 
E-cadherin clearly led to a loss of contact inhibition. The cells had lost most of their E-cadherin 
expression and the remaining protein was mainly localized in the cytoplasm and not at the membranes 
any more. This emphasized that epithelial infiltrative cells strongly depend on E-cadherin levels for 
maintenance of functional contact inhibition.  
Hence, this mechanism might be a feasible target for treatment of brain metastases. The blockade of 
contact inhibition can be achieved by the inhibition of the Hippo pathway and YAP inhibitors are one 
promising therapeutic target currently under investigation. Preliminary in vitro experiments in our lab 
showed that diffuse infiltrative cell lines without functional contact inhibition but tonic YAP signaling 
seem to be more sensitive to treatment with YAP inhibitors compared to epithelial infiltrative cell lines. 
This now has to be studied in detail in future experiments. First in various in vitro and ex vivo assays, 
and later in vivo in our brain metastasis mouse models. According to our theory, the epithelial 
infiltrative cell lines, which have intact contact inhibition and upregulate YAP during colonization, are 
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not accessible for a YAP therapy as soon as they have reached the status of micro-metastases, because 
the concentrations needed for a visible effect would be excessively high. In contrast, the diffuse 
infiltrative cell lines, which show a constant YAP signaling independent of cell-cell contacts, could offer 
an excellent target for an anti-YAP therapy. A further option would be that both MMPI types are 
vulnerable through YAP inhibition during early colonization. In this case, YAP inhibition would 
represent a general therapy option for infiltrative metastases. 
4.3. Prognostic value of established gene expression signature 
With all of these profound differences between diffuse and epithelial infiltrative MMPI models in mind, 
one should expect that the metastatic growth pattern influences the expression of certain genes. Since 
the MMPI pattern has been shown to correlate with survival rates in humans and mice, it was an 
additional aim of this thesis to find gene targets that could represent a prognostic tool to classify the 
outcome of patients with metastases based on the analysis of their tumor gene expression signature. 
Based on previous proteomics analyses and microarray data of different mouse cancer cell lines in our 
lab, we selected a set of interesting candidate genes with the most pronounced differences. Initially, 
their expression levels were assessed in RNA samples collected from all parental murine brain 
metastasis model cell lines in a qRT-PCR screening and indeed several differentially expressed genes 
could be identified. Hierarchical clustering of these data in a heatmap resulted in one cluster of genes 
that were exclusively highly expressed in diffuse cells and a second cluster with high expression only 
in epithelial cells. This gene signature included a variety of cell adhesion and cytoskeletal components, 
ECM binding integrins, EMT markers, metabolic genes, and other factors. Therefore, it was a surprise 
that the E-cadherin modifications did not alter this gene expression signature to any substantial extent. 
Contrary to the current concept of EMT, the loss of E-cadherin did not switch the epithelial character 
of the cells into a mesenchymal state and had no influence on their metabolism. Consistently, 
mesenchymal cells maintained their cellular equipment and did not aquire epithelial characteristics 
even after the artificial overexpression of this cell adhesion receptor. Although the altered level of 
E-cadherin was clearly visible in the heatmap, it was not reflected in the rest of the signature and the 
previously identified clusters were still present.  
Hence, this gene expression signature seemed to be not only determined by the infiltrative growth 
pattern but also by the original character of the cells, which did not change after the modification of 
E-cadherin in contrast to the phenotype. It rather differentiated diffuse and epithelial-like infiltrative 
cells with mesenchymal character from epithelial and diffuse-like infiltrative cells with epithelial 
character. Since cells of the first group were generally more aggressive compared to the second group 
in our animal experiments, we assumed that the signature could also have a prognostic impact in vivo.  
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Selected targets from the previously identified gene clusters were tested in brains with metastases 
arising from the different diffuse and epithelial infiltrative models as well as control brains. Indeed, the 
gene expression profile reliably separated mice with pathological conditions from healthy animals. 
Furthermore, it distinguished metastases associated with short survival rates from metastases with 
significantly increased survival of the animals and thus clearly had a prognostic impact on overall 
survival in our brain metastasis mouse models. 
Finally, the signature was tested in a data set of human brain and liver metastases from patients with 
breast, colorectal or lung cancer in collaboration with the department of medical bioinformatics at the 
University Medicine Göttingen. Again, it could demonstrate its prognostic impact since it reliably 
splitted the patient cohort into two groups with significantly different survival rates. It might thus really 
represent a potential diagnostic tool for clinical practice in the future and strongly requires follow-up 
studies in larger patient cohorts. 
4.4. Future research perspectives 
In addition to possible future experiments resulting directly from previous findings described above, 
the following approaches could be of particular interest in the future. 
As explained earlier, the profound survival differences between the two E-cadherin knockdown models 
of CMT93Var seemed to be caused by an unintended mutation or deregulation of the innate vimentin 
expression. The positive correlation between vimentin level and aggressiveness suggests that this 
mesenchymal factor might also play a crucial role in long-term survival. Although the affected animals 
bearing the vimentin variation were excluded from further in vivo analyses in this thesis, the two 
different CMT93Var knockdown cell lines represent an interesting model system to further study the 
interplay of E-cadherin and vimentin. A detailed comparison of both knockdown cell lines on RNA level 
by RNA-sequencing methods could potentially identify further candidates responsible for their 
different survival rates. Subsequent experiments could involve the targeted genetic modification of 
innate vimentin levels and investigate if an intentional downregulation of this mesenchymal marker 
also results in prolonged survival.  
The promising results concerning a prognostic impact of the MMPI pattern in the experiments 
described in this study emphasize the further investigation of this concept. Future animal experiments 
could test if it is possible to recognize known MMPI patterns in mice after tumor cell injection using 
small animal magnetic resonance imaging (MRI), a non-invasive imaging technique commonly used in 
radiology. In the future, an early recognition of MMPI pattern via MRI could help to visualize and 
predict patient survival and choose adequate therapy concepts without the need for an invasive 
surgical procedure. 
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5. Summary and Conclusions 
The prognostic impact of the metastatic infiltration pattern in brain metastases makes the MMPI an 
interesting and promising area of oncologic research. This study was designed to contribute to our 
understanding of colonization processes of tumor cells in the brain and shed more light on the 
mechanisms underlying metastatic infiltration in different MMPI patterns to potentially support the 
development of targeted therapies in the future.  
The variety of brain metastasis mouse models in our lab enabled the detailed morphological and 
molecular characterization of different infiltrative MMPI patterns. Since they cover a wide range of 
aggressiveness and infiltration level, they realistically reflected the diversity observed in oncological 
diagnostics. In both species, human and mouse, one of the key differences between diffuse and 
epithelial infiltrative MMPI models was their innate level of E-cadherin. Since low levels of E-cadherin 
were associated with higher migration and invasiveness across entities, this cell adhesion receptor 
seemed to be not only a marker for the infiltration type, but was also a promising factor to play an 
important functional role in the metastatic process. The specific genetic modification of E-cadherin in 
the metastatic outgrowth models thus appeared to be a suitable target to switch the MMPI pattern of 
breast and colon cancer cells in the brain and study the outcome on the metastatic microenvironment. 
Indeed, the amount of E-cadherin directly affected the morphology of the cells. Artificially increased 
levels caused a phenotypic switch from a diffuse and mesenchymal-like to epithelial-like morphology 
with more cell contacts, while the loss of this cell adhesion receptor caused cells to adapt 
mesenchymal-like features. However, only the morphology was affected while the cells maintained 
their original mesenchymal or epithelial character. Nevertheless, the altered cell adhesion alone was 
sufficient to change the migratory and invasive capacity of the cell lines in vitro.  
In the animal model, both genetic approaches resulted in profound phenotypic changes at the MMPI. 
Diffuse infiltrative models switched to more epithelial-like infiltrative characteristics after the gain of 
E-cadherin and displayed less infiltration into the adjacent brain parenchyma. In accordance, its loss in 
epithelial infiltrative models resulted in increased infiltration rates and the cells even gained diffuse-
like infiltrative features at the MMPI. In both cases, the switch of the original infiltration pattern had a 
direct impact on the overall survival of animals. However, this effect alone was not sufficient to 
completely change the aggressiveness of the cells into the opposite state. Animals with a mesenchymal 
character of metastatic cells displayed a generally shorter survival and a large gap was still present in 
relation to the most aggressive knockdown cohort. Although those metastatic cells with epithelial 
cellular equipment acquired an additional destructive character due to the altered infiltration pattern, 
they did not gain the special defense mechanisms and metabolic plasticity that are characteristic for 
the highly aggressive diffuse infiltrative models with mesenchymal character. 
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The altered infiltration pattern in turn had an enormous impact on the immune cell composition and 
reaction of the metastatic microenvironment. In compact growing epithelial infiltrative metastases, 
activated astrocytes and microglia formed a barrier to shield the metastatic cells from the surrounding 
healthy brain parenchyma and prevent further damage. In addition, the general immune response was 
lower compared to diffuse infiltrative models. The loss of E-cadherin resulted in a looser metastatic 
outgrowth that broadened the infiltration zone and impaired such a demarcated shielding mechanism. 
Consequently, immune cells had to spread over a larger area to fight the infiltrating metastatic cells 
and the immune reaction was notably increased. Due to the work with metastatic cells from breast 
and colon origin, entity-specific differences in the immune cell composition and reaction at the MME 
became apparent, which might explain the (non-) response to checkpoint blockade in clinical studies. 
In addition, there was a positive correlation between compact metastatic outgrowth and angiogenesis. 
The number of blood vessels in metastatic tissues might thus represent a further potential prognostic 
factor for the anticipated metastatic outgrowth and associated prognosis. 
Furthermore, we established a characteristic gene expression signature that seemed to be determined 
by the infiltrative growth pattern and the original character of the metastatic cells. It clearly separated 
highly aggressive metastases with mesenchymal character from cohorts with epithelial characteristics 
and prolonged survival in our animal models and even demonstrated its prognostic impact in a data 
set of human metastases. Such prognostic gene targets could represent an important diagnostic tool 
in clinical practice to classify the outcome of patients with metastases based on the analysis of their 
tumor gene expression signature. In summary, the findings of this study might contribute to MMPI 
pattern-based therapeutic decisions for cancer patients with brain metastases in the future.  
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